PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
29845270-10	2018	In addition, according to the results of the WB and qRT-PCR analyses, the expression of the E3 ubiquitin ligase muscle RING finger-containing protein 1 (MuRF1) was downregulated in skeletal muscle and cardiac muscle, whereas atrogin-1 was downregulated only in skeletal muscle in the luteolin treatment group vs. the model group.	Luteolin	284-292	tripartite motif-containing 63	Mus musculus	153-158
30083786-4	2018	Luteolin (3",4",5,7-tetrahydroxyflavone, LUT) is a widespread flavone known to have antioxidant and cytoprotective properties related to nuclear factor erythroid 2-related factor 2-(Nrf2) pathway.	Luteolin	0-8	NFE2 like bZIP transcription factor 2	Homo sapiens	137-180
30083786-4	2018	Luteolin (3",4",5,7-tetrahydroxyflavone, LUT) is a widespread flavone known to have antioxidant and cytoprotective properties related to nuclear factor erythroid 2-related factor 2-(Nrf2) pathway.	Luteolin	0-8	NFE2 like bZIP transcription factor 2	Homo sapiens	182-186
30083786-4	2018	Luteolin (3",4",5,7-tetrahydroxyflavone, LUT) is a widespread flavone known to have antioxidant and cytoprotective properties related to nuclear factor erythroid 2-related factor 2-(Nrf2) pathway.	Luteolin	10-39	NFE2 like bZIP transcription factor 2	Homo sapiens	137-180
30083786-4	2018	Luteolin (3",4",5,7-tetrahydroxyflavone, LUT) is a widespread flavone known to have antioxidant and cytoprotective properties related to nuclear factor erythroid 2-related factor 2-(Nrf2) pathway.	Luteolin	10-39	NFE2 like bZIP transcription factor 2	Homo sapiens	182-186
29976410-0	2018	Flavonoids Luteolin and Quercetin Inhibit RPS19 and contributes to metastasis of cancer cells through c-Myc reduction.	Luteolin	11-19	ribosomal protein S19	Homo sapiens	42-47
29976410-0	2018	Flavonoids Luteolin and Quercetin Inhibit RPS19 and contributes to metastasis of cancer cells through c-Myc reduction.	Luteolin	11-19	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	102-107
29336809-7	2018	By taking the advantage of the screening method, luteolin and epicatechin gallate were discovered as the new BCR-ABL inhibitors.	Luteolin	49-57	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	109-116
29867083-0	2018	Luteolin attenuates Wnt signaling via upregulation of FZD6 to suppress prostate cancer stemness revealed by comparative proteomics.	Luteolin	0-8	frizzled class receptor 6	Homo sapiens	54-58
29277460-13	2018	Luteolin, a potent inhibitor of Nrf2, markedly prevented MRP2 and BCRP expression from being induced by the three Aconitum alkaloids.	Luteolin	0-8	NFE2 like bZIP transcription factor 2	Homo sapiens	32-36
29277460-13	2018	Luteolin, a potent inhibitor of Nrf2, markedly prevented MRP2 and BCRP expression from being induced by the three Aconitum alkaloids.	Luteolin	0-8	ATP binding cassette subfamily C member 2	Homo sapiens	57-61
29277460-13	2018	Luteolin, a potent inhibitor of Nrf2, markedly prevented MRP2 and BCRP expression from being induced by the three Aconitum alkaloids.	Luteolin	0-8	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	66-70
29654773-3	2018	PSP-2 was the most effective fraction, which was identified as procyanidin B3 mainly and procyanidin dimer [(E)C-luteolin or keampferol] secondarily.	Luteolin	113-121	regenerating family member 1 beta	Homo sapiens	0-5
29519319-10	2018	Further investigation implied that luteolin and luteolin-4"-O-glucoside improved the symptoms of inflammation by decreasing the levels of IL-1beta and TNF-alpha.	Luteolin	35-43	interleukin 1 beta	Mus musculus	138-146
29519319-10	2018	Further investigation implied that luteolin and luteolin-4"-O-glucoside improved the symptoms of inflammation by decreasing the levels of IL-1beta and TNF-alpha.	Luteolin	35-43	tumor necrosis factor	Mus musculus	151-160
28884178-6	2017	C/ebpbeta was significantly reduced by genistein and kaempferol, ppargamma by genistein and pterostilbene, srebp1c by luteolin, genistein, hesperidin, kaempferol, pterostilbene and vanillic acid, and lpl by kaempferol.	Luteolin	118-126	CCAAT/enhancer binding protein (C/EBP), beta	Mus musculus	0-9
29115570-9	2018	In addition, 20 microM luteolin had a significant inhibitory effect on multi-heavy metal mixture-induced cleavage of caspase-9, caspase-3 and poly(adenosine diphosphate-ribose) polymerase-1 protein.	Luteolin	23-31	caspase 9	Homo sapiens	117-126
29115570-9	2018	In addition, 20 microM luteolin had a significant inhibitory effect on multi-heavy metal mixture-induced cleavage of caspase-9, caspase-3 and poly(adenosine diphosphate-ribose) polymerase-1 protein.	Luteolin	23-31	caspase 3	Homo sapiens	128-137
28872689-5	2017	METHODS: Two flavonoids, luteolin and quercetin, were evaluated as potential inhibitors of eight human CYP isoforms, of six UDP-glucuronosyltransferase (UGT) isoforms and of APAP glucuronidation and sulfation.	Luteolin	25-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	103-106
28872689-5	2017	METHODS: Two flavonoids, luteolin and quercetin, were evaluated as potential inhibitors of eight human CYP isoforms, of six UDP-glucuronosyltransferase (UGT) isoforms and of APAP glucuronidation and sulfation.	Luteolin	25-33	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	124-151
28872689-5	2017	METHODS: Two flavonoids, luteolin and quercetin, were evaluated as potential inhibitors of eight human CYP isoforms, of six UDP-glucuronosyltransferase (UGT) isoforms and of APAP glucuronidation and sulfation.	Luteolin	25-33	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	153-156
28884178-6	2017	C/ebpbeta was significantly reduced by genistein and kaempferol, ppargamma by genistein and pterostilbene, srebp1c by luteolin, genistein, hesperidin, kaempferol, pterostilbene and vanillic acid, and lpl by kaempferol.	Luteolin	118-126	sterol regulatory element binding transcription factor 1	Mus musculus	107-114
28800542-0	2017	Digitoflavone (DG) attenuates LPS-induced acute lung injury through reducing oxidative stress and inflammatory response dependent on the suppression of TXNIP/NLRP3 and NF-kappaB.	Luteolin	0-13	thioredoxin interacting protein	Mus musculus	152-157
28800542-0	2017	Digitoflavone (DG) attenuates LPS-induced acute lung injury through reducing oxidative stress and inflammatory response dependent on the suppression of TXNIP/NLRP3 and NF-kappaB.	Luteolin	0-13	NLR family, pyrin domain containing 3	Mus musculus	158-163
28800542-0	2017	Digitoflavone (DG) attenuates LPS-induced acute lung injury through reducing oxidative stress and inflammatory response dependent on the suppression of TXNIP/NLRP3 and NF-kappaB.	Luteolin	0-13	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	168-177
28789432-3	2017	The aim of the present study was to investigate the mechanism by which the mitogen-activated protein kinase (MAPK) and phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) signaling pathways regulate the apoptosis in vitro of BGC-823 cells following treatment with luteolin.	Luteolin	266-274	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	119-165
31966836-0	2017	Luteolin suppresses tumor progression through lncRNA BANCR and its downstream TSHR/CCND1 signaling in thyroid carcinoma.	Luteolin	0-8	BRAF-activated non-protein coding RNA	Homo sapiens	53-58
31966836-0	2017	Luteolin suppresses tumor progression through lncRNA BANCR and its downstream TSHR/CCND1 signaling in thyroid carcinoma.	Luteolin	0-8	thyroid stimulating hormone receptor	Homo sapiens	78-82
31966836-0	2017	Luteolin suppresses tumor progression through lncRNA BANCR and its downstream TSHR/CCND1 signaling in thyroid carcinoma.	Luteolin	0-8	cyclin D1	Homo sapiens	83-88
31966836-6	2017	We found that luteolin decreased the expression of BRAF-activated long noncoding RNA (BANCR), which further led to downregulation of TSHR and downstream oncogenic signaling.	Luteolin	14-22	BRAF-activated non-protein coding RNA	Homo sapiens	51-84
31966836-6	2017	We found that luteolin decreased the expression of BRAF-activated long noncoding RNA (BANCR), which further led to downregulation of TSHR and downstream oncogenic signaling.	Luteolin	14-22	BRAF-activated non-protein coding RNA	Homo sapiens	86-91
31966836-6	2017	We found that luteolin decreased the expression of BRAF-activated long noncoding RNA (BANCR), which further led to downregulation of TSHR and downstream oncogenic signaling.	Luteolin	14-22	thyroid stimulating hormone receptor	Homo sapiens	133-137
31966836-7	2017	Moreover, overexpression of BANCR/TSHR signaling can largely abolish the anti-tumor effects of luteolin on thyroid carcinoma in vitro and in vivo.	Luteolin	95-103	BRAF-activated non-protein coding RNA	Homo sapiens	28-33
31966836-7	2017	Moreover, overexpression of BANCR/TSHR signaling can largely abolish the anti-tumor effects of luteolin on thyroid carcinoma in vitro and in vivo.	Luteolin	95-103	thyroid stimulating hormone receptor	Homo sapiens	34-38
31966836-8	2017	In conclusion, luteolin may serve as a potential important anticancer agent for thyroid carcinoma by blocking the BANCR/TSHR signaling.	Luteolin	15-23	BRAF-activated non-protein coding RNA	Homo sapiens	114-119
31966836-8	2017	In conclusion, luteolin may serve as a potential important anticancer agent for thyroid carcinoma by blocking the BANCR/TSHR signaling.	Luteolin	15-23	thyroid stimulating hormone receptor	Homo sapiens	120-124
28791416-5	2017	Luteolin-induced apoptosis was accompanied by the activation of intracellular and mitochondrial reactive oxygen species scavenging through the activation of antioxidant enzymes, such as superoxide dismutase and catalase in HT-29 cells.	Luteolin	0-8	catalase	Homo sapiens	211-219
28583009-7	2017	Taken together, these results demonstrate that the ameliorative effects of luteolin against arsenite in the dopaminergic cell may be modulated by alpha-Syn, and indicating that luteolin may be developed as a chemopreventive supplementary agent to ameliorate dopaminergic cell apoptosis resulting from arsenite exposure.	Luteolin	75-83	synuclein alpha	Rattus norvegicus	146-155
28875706-2	2017	The IC50 values for baicalein, (+)-catechin, quercetin, and luteolin were 74.1 +- 5.6, 175.1 +- 9.1, 281.2 +- 19.2, and 339.4 +- 16.3 muM, respectively, against alpha-glucosidase.	Luteolin	60-68	latexin	Homo sapiens	134-137
28875706-2	2017	The IC50 values for baicalein, (+)-catechin, quercetin, and luteolin were 74.1 +- 5.6, 175.1 +- 9.1, 281.2 +- 19.2, and 339.4 +- 16.3 muM, respectively, against alpha-glucosidase.	Luteolin	60-68	sucrase-isomaltase	Homo sapiens	161-178
28939905-8	2017	Co-ultramicronized palmitoylethanolamide/luteolin, an established anti-inflammatory/ neuroprotective agent, reduced Saa1 expression in OPCs subjected to TNF-alpha treatment.	Luteolin	41-49	serum amyloid A1	Homo sapiens	116-120
28939905-8	2017	Co-ultramicronized palmitoylethanolamide/luteolin, an established anti-inflammatory/ neuroprotective agent, reduced Saa1 expression in OPCs subjected to TNF-alpha treatment.	Luteolin	41-49	tumor necrosis factor	Homo sapiens	153-162
28277581-0	2017	Dietary flavonoids, luteolin and quercetin, inhibit invasion of cervical cancer by reduction of UBE2S through epithelial-mesenchymal transition signaling.	Luteolin	20-28	ubiquitin conjugating enzyme E2 S	Homo sapiens	96-101
28620169-3	2017	In present study, we have performed detailed biophysical studies for the interaction of human c-myc G-quadruplex DNA with nine representative flavonoids: Luteolin, Quercetin, Rutin, Genistein, Kaempferol, Puerarin, Hesperidin, Myricetin and Daidzein.	Luteolin	154-162	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	94-99
26569039-4	2016	Meanwhile, quercetin (7), diosmetin (9) and luteolin (10) inhibited TNF-alpha-induced NF-kappaB reporter gene expression on HeLa cells up to 30 and 100 muM.	Luteolin	44-52	tumor necrosis factor	Homo sapiens	68-77
29052401-5	2017	And buddleoside combined with luteolin could also significantly increase p-Akt and p-eNOS protein expressions.The results suggested that the combination of buddleoside and luteolin could effectively relax the blood vessel, and the mechanism may be to increase the synthesis and release of NO and reach the role of relaxing blood vessel by activating PI3K/Akt/NO signaling pathway and enhancing the activity of eNOS.	Luteolin	30-38	AKT serine/threonine kinase 1	Rattus norvegicus	75-78
29052401-5	2017	And buddleoside combined with luteolin could also significantly increase p-Akt and p-eNOS protein expressions.The results suggested that the combination of buddleoside and luteolin could effectively relax the blood vessel, and the mechanism may be to increase the synthesis and release of NO and reach the role of relaxing blood vessel by activating PI3K/Akt/NO signaling pathway and enhancing the activity of eNOS.	Luteolin	30-38	AKT serine/threonine kinase 1	Rattus norvegicus	355-358
29052401-5	2017	And buddleoside combined with luteolin could also significantly increase p-Akt and p-eNOS protein expressions.The results suggested that the combination of buddleoside and luteolin could effectively relax the blood vessel, and the mechanism may be to increase the synthesis and release of NO and reach the role of relaxing blood vessel by activating PI3K/Akt/NO signaling pathway and enhancing the activity of eNOS.	Luteolin	172-180	AKT serine/threonine kinase 1	Rattus norvegicus	75-78
29052401-5	2017	And buddleoside combined with luteolin could also significantly increase p-Akt and p-eNOS protein expressions.The results suggested that the combination of buddleoside and luteolin could effectively relax the blood vessel, and the mechanism may be to increase the synthesis and release of NO and reach the role of relaxing blood vessel by activating PI3K/Akt/NO signaling pathway and enhancing the activity of eNOS.	Luteolin	172-180	AKT serine/threonine kinase 1	Rattus norvegicus	355-358
28035396-2	2017	In the present study, we demonstrated the effect of luteolin, a flavonoid with antioxidant, anti-inflammatory and anticancer activities, on the expression and activation of TAM RTKs and the association with its cytotoxicity in non-small cell lung cancer (NSCLC) cells.	Luteolin	52-60	Myeloproliferative syndrome, transient (transient abnormal myelopoiesis)	Homo sapiens	173-176
27221336-5	2016	Pretreatment with luteolin prior to MG exposure reduced MG-induced mitochondrial dysfunction and increased the peroxisome proliferator-activated receptor gamma co-activator 1alpha (PGC-1alpha) and nitric oxide levels, suggesting that luteolin may induce mitochondrial biogenesis.	Luteolin	18-26	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	111-179
27221336-5	2016	Pretreatment with luteolin prior to MG exposure reduced MG-induced mitochondrial dysfunction and increased the peroxisome proliferator-activated receptor gamma co-activator 1alpha (PGC-1alpha) and nitric oxide levels, suggesting that luteolin may induce mitochondrial biogenesis.	Luteolin	18-26	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	181-191
27853236-7	2016	Luteolin enhanced antioxidant defense system based on Keap1, Nrf2, HO-1, NQO1, and KLF9.	Luteolin	0-8	kelch like ECH associated protein 1	Homo sapiens	54-59
27853236-7	2016	Luteolin enhanced antioxidant defense system based on Keap1, Nrf2, HO-1, NQO1, and KLF9.	Luteolin	0-8	NFE2 like bZIP transcription factor 2	Homo sapiens	61-65
27853236-7	2016	Luteolin enhanced antioxidant defense system based on Keap1, Nrf2, HO-1, NQO1, and KLF9.	Luteolin	0-8	heme oxygenase 1	Homo sapiens	67-71
27853236-7	2016	Luteolin enhanced antioxidant defense system based on Keap1, Nrf2, HO-1, NQO1, and KLF9.	Luteolin	0-8	NAD(P)H quinone dehydrogenase 1	Homo sapiens	73-77
27853236-7	2016	Luteolin enhanced antioxidant defense system based on Keap1, Nrf2, HO-1, NQO1, and KLF9.	Luteolin	0-8	Kruppel like factor 9	Homo sapiens	83-87
26569039-4	2016	Meanwhile, quercetin (7), diosmetin (9) and luteolin (10) inhibited TNF-alpha-induced NF-kappaB reporter gene expression on HeLa cells up to 30 and 100 muM.	Luteolin	44-52	latexin	Homo sapiens	152-155
27088891-6	2016	Among them, luteolin (2), eriodictyol (5), ethyl rosmarinate (13), and clinopodic acids B (14) were proved to be potent alpha-glucosidase inhibitors with IC50 value ranging from 0.6 to 2.0 mum.	Luteolin	12-20	sucrase-isomaltase	Homo sapiens	120-137
25851346-6	2015	The celecoxib and luteolin combination treatment induced synergistic effects via Akt inactivation and extracellular signal-regulated kinase (ERK) signaling inhibition in MCF-7 and MCF7/HER18 cells and via Akt inactivation and ERK signaling activation in MDA-MB-231 and SkBr3 cells.	Luteolin	18-26	AKT serine/threonine kinase 1	Homo sapiens	81-84
26573275-0	2016	Anti-tumor activities of luteolin and silibinin in glioblastoma cells: overexpression of miR-7-1-3p augmented luteolin and silibinin to inhibit autophagy and induce apoptosis in glioblastoma in vivo.	Luteolin	25-33	microRNA 7-1	Homo sapiens	89-96
26800359-18	2016	Various vegetable polyphenols (luteolin, quercetin, apigenin) inhibited the hyperosmotic expression of bFGF, HB-EGF, and NFAT5 genes.	Luteolin	31-39	fibroblast growth factor 2	Homo sapiens	103-107
26800359-18	2016	Various vegetable polyphenols (luteolin, quercetin, apigenin) inhibited the hyperosmotic expression of bFGF, HB-EGF, and NFAT5 genes.	Luteolin	31-39	heparin binding EGF like growth factor	Homo sapiens	109-115
26800359-18	2016	Various vegetable polyphenols (luteolin, quercetin, apigenin) inhibited the hyperosmotic expression of bFGF, HB-EGF, and NFAT5 genes.	Luteolin	31-39	nuclear factor of activated T cells 5	Homo sapiens	121-126
27002403-8	2016	RESULTS: In ECE, luteolin and rosmarinic acid were relatively abundant among the other flavonoids and phenolic acids.	Luteolin	17-25	endothelin converting enzyme 1	Rattus norvegicus	12-15
26607666-4	2016	In this study, we investigated whether a series of N-acylethanolamines (NAEs), quercetin, and luteolin could regulate SIRT6 activity.	Luteolin	94-102	sirtuin 6	Homo sapiens	118-123
25851346-6	2015	The celecoxib and luteolin combination treatment induced synergistic effects via Akt inactivation and extracellular signal-regulated kinase (ERK) signaling inhibition in MCF-7 and MCF7/HER18 cells and via Akt inactivation and ERK signaling activation in MDA-MB-231 and SkBr3 cells.	Luteolin	18-26	mitogen-activated protein kinase 1	Homo sapiens	102-139
25851346-6	2015	The celecoxib and luteolin combination treatment induced synergistic effects via Akt inactivation and extracellular signal-regulated kinase (ERK) signaling inhibition in MCF-7 and MCF7/HER18 cells and via Akt inactivation and ERK signaling activation in MDA-MB-231 and SkBr3 cells.	Luteolin	18-26	mitogen-activated protein kinase 1	Homo sapiens	141-144
25851346-6	2015	The celecoxib and luteolin combination treatment induced synergistic effects via Akt inactivation and extracellular signal-regulated kinase (ERK) signaling inhibition in MCF-7 and MCF7/HER18 cells and via Akt inactivation and ERK signaling activation in MDA-MB-231 and SkBr3 cells.	Luteolin	18-26	AKT serine/threonine kinase 1	Homo sapiens	205-208
25851346-6	2015	The celecoxib and luteolin combination treatment induced synergistic effects via Akt inactivation and extracellular signal-regulated kinase (ERK) signaling inhibition in MCF-7 and MCF7/HER18 cells and via Akt inactivation and ERK signaling activation in MDA-MB-231 and SkBr3 cells.	Luteolin	18-26	mitogen-activated protein kinase 1	Homo sapiens	226-229
26002582-10	2015	Luteolin administration significantly decreased acetaminophen-induced serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), tumor necrosis factor alpha (TNF-alpha), interleukin 6 (IL-6), malondialdehyde (MDA) levels, as well as glutathione (GSH) depletion and decrease of superoxide dismutase (SOD).	Luteolin	0-8	glutamic pyruvic transaminase, soluble	Mus musculus	102-105
26205695-0	2015	Therapeutic potential of digitoflavone on diabetic nephropathy: nuclear factor erythroid 2-related factor 2-dependent anti-oxidant and anti-inflammatory effect.	Luteolin	25-38	nuclear factor, erythroid derived 2, like 2	Mus musculus	64-107
26205695-4	2015	In the present study, we evaluated the Nrf2-dependent anti-oxidative and anti-inflammatory effects of digitoflavone in streptozotocin-induced diabetic nephropathy.	Luteolin	102-115	nuclear factor, erythroid derived 2, like 2	Mus musculus	39-43
26205695-7	2015	Digitoflavone induced Nrf2 activation and decreased oxidative damage, inflammation, TGF-beta1 expression, extracellular matrix protein expression, and mesangial cell hyperplasia in SV40-Mes13 cells.	Luteolin	0-13	nuclear factor, erythroid derived 2, like 2	Mus musculus	22-26
26205695-7	2015	Digitoflavone induced Nrf2 activation and decreased oxidative damage, inflammation, TGF-beta1 expression, extracellular matrix protein expression, and mesangial cell hyperplasia in SV40-Mes13 cells.	Luteolin	0-13	transforming growth factor, beta 1	Mus musculus	84-93
26205695-8	2015	Digitoflavone-treated Nrf2+/+ mice, but not Nrf2-/- mice, showed attenuated common metabolic disorder symptoms, improved renal performance, minimized pathological alterations, and decreased oxidative damage, inflammatory gene expression, inflammatory cell infiltration, TGF-beta1 expression, and extracellular matrix protein expression.	Luteolin	0-13	nuclear factor, erythroid derived 2, like 2	Mus musculus	22-26
26205695-8	2015	Digitoflavone-treated Nrf2+/+ mice, but not Nrf2-/- mice, showed attenuated common metabolic disorder symptoms, improved renal performance, minimized pathological alterations, and decreased oxidative damage, inflammatory gene expression, inflammatory cell infiltration, TGF-beta1 expression, and extracellular matrix protein expression.	Luteolin	0-13	transforming growth factor, beta 1	Mus musculus	270-279
26205695-9	2015	Our results show that the anti-oxidative and anti-inflammatory effects of digitoflavone are mediated by Nrf2 activation and that digitoflavone can be used therapeutically to improve metabolic disorders and relieve renal damage induced by diabetes.	Luteolin	74-87	nuclear factor, erythroid derived 2, like 2	Mus musculus	104-108
26002582-10	2015	Luteolin administration significantly decreased acetaminophen-induced serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), tumor necrosis factor alpha (TNF-alpha), interleukin 6 (IL-6), malondialdehyde (MDA) levels, as well as glutathione (GSH) depletion and decrease of superoxide dismutase (SOD).	Luteolin	0-8	glutamic pyruvic transaminase, soluble	Mus musculus	76-100
26002582-10	2015	Luteolin administration significantly decreased acetaminophen-induced serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), tumor necrosis factor alpha (TNF-alpha), interleukin 6 (IL-6), malondialdehyde (MDA) levels, as well as glutathione (GSH) depletion and decrease of superoxide dismutase (SOD).	Luteolin	0-8	solute carrier family 17 (anion/sugar transporter), member 5	Mus musculus	108-134
26002582-10	2015	Luteolin administration significantly decreased acetaminophen-induced serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), tumor necrosis factor alpha (TNF-alpha), interleukin 6 (IL-6), malondialdehyde (MDA) levels, as well as glutathione (GSH) depletion and decrease of superoxide dismutase (SOD).	Luteolin	0-8	solute carrier family 17 (anion/sugar transporter), member 5	Mus musculus	136-139
26002582-10	2015	Luteolin administration significantly decreased acetaminophen-induced serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), tumor necrosis factor alpha (TNF-alpha), interleukin 6 (IL-6), malondialdehyde (MDA) levels, as well as glutathione (GSH) depletion and decrease of superoxide dismutase (SOD).	Luteolin	0-8	tumor necrosis factor	Mus musculus	142-169
26002582-10	2015	Luteolin administration significantly decreased acetaminophen-induced serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), tumor necrosis factor alpha (TNF-alpha), interleukin 6 (IL-6), malondialdehyde (MDA) levels, as well as glutathione (GSH) depletion and decrease of superoxide dismutase (SOD).	Luteolin	0-8	tumor necrosis factor	Mus musculus	171-180
26002582-10	2015	Luteolin administration significantly decreased acetaminophen-induced serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), tumor necrosis factor alpha (TNF-alpha), interleukin 6 (IL-6), malondialdehyde (MDA) levels, as well as glutathione (GSH) depletion and decrease of superoxide dismutase (SOD).	Luteolin	0-8	interleukin 6	Mus musculus	183-196
26002582-10	2015	Luteolin administration significantly decreased acetaminophen-induced serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), tumor necrosis factor alpha (TNF-alpha), interleukin 6 (IL-6), malondialdehyde (MDA) levels, as well as glutathione (GSH) depletion and decrease of superoxide dismutase (SOD).	Luteolin	0-8	interleukin 6	Mus musculus	198-202
25577468-7	2015	In an animal study, C57BL/6 mice were fed a diet containing 0% or 0.6% luteolin for 3 weeks, and luteolin supplementation greatly suppressed TNF-alpha-induced increase in circulating levels of MCP-1/JE, CXCL1/KC and sICAM-1 in C57BL/6 mice.	Luteolin	71-79	tumor necrosis factor	Mus musculus	141-150
25549925-5	2015	Among them, luteolin (2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4H-1-benzopyran-4-one) showed the most potent inhibition (IC5095nM), which is also more potent compared to all known classes of CBR1 inhibitors.	Luteolin	12-20	carbonyl reductase 1	Homo sapiens	188-192
25549925-5	2015	Among them, luteolin (2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4H-1-benzopyran-4-one) showed the most potent inhibition (IC5095nM), which is also more potent compared to all known classes of CBR1 inhibitors.	Luteolin	22-81	carbonyl reductase 1	Homo sapiens	188-192
26005679-9	2015	There was no difference on hepatic protein levels of sirtuin 1 (SIRT1) among all groups; however, luteolin supplementation significantly reversed alcohol-reduced SIRT1 activity assessed by the ratio of acetylated and total forkhead box protein O1 (FoXO1) and SIRT1 target proliferator-activated receptor gamma, coactivator 1 alpha (PGC1alpha).	Luteolin	98-106	sirtuin 1	Mus musculus	162-167
26005679-9	2015	There was no difference on hepatic protein levels of sirtuin 1 (SIRT1) among all groups; however, luteolin supplementation significantly reversed alcohol-reduced SIRT1 activity assessed by the ratio of acetylated and total forkhead box protein O1 (FoXO1) and SIRT1 target proliferator-activated receptor gamma, coactivator 1 alpha (PGC1alpha).	Luteolin	98-106	forkhead box O1	Mus musculus	223-246
26005679-9	2015	There was no difference on hepatic protein levels of sirtuin 1 (SIRT1) among all groups; however, luteolin supplementation significantly reversed alcohol-reduced SIRT1 activity assessed by the ratio of acetylated and total forkhead box protein O1 (FoXO1) and SIRT1 target proliferator-activated receptor gamma, coactivator 1 alpha (PGC1alpha).	Luteolin	98-106	forkhead box O1	Mus musculus	248-253
26005679-9	2015	There was no difference on hepatic protein levels of sirtuin 1 (SIRT1) among all groups; however, luteolin supplementation significantly reversed alcohol-reduced SIRT1 activity assessed by the ratio of acetylated and total forkhead box protein O1 (FoXO1) and SIRT1 target proliferator-activated receptor gamma, coactivator 1 alpha (PGC1alpha).	Luteolin	98-106	sirtuin 1	Mus musculus	162-167
26005679-9	2015	There was no difference on hepatic protein levels of sirtuin 1 (SIRT1) among all groups; however, luteolin supplementation significantly reversed alcohol-reduced SIRT1 activity assessed by the ratio of acetylated and total forkhead box protein O1 (FoXO1) and SIRT1 target proliferator-activated receptor gamma, coactivator 1 alpha (PGC1alpha).	Luteolin	98-106	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	332-341
26415702-8	2015	Some polyphenols (e.g. luteolin, apigenin and curcumin) have been shown to be very potent CBR1 inhibitors.	Luteolin	23-31	carbonyl reductase 1	Homo sapiens	90-94
25409926-4	2015	We explored whether luteolin, a common flavonoid in many types of plants, may inhibit interleukin (IL)-1beta function induction of the inflammation biomarker cyclooxygenase (COX)-2.	Luteolin	20-28	interleukin 1 beta	Homo sapiens	86-108
25409926-4	2015	We explored whether luteolin, a common flavonoid in many types of plants, may inhibit interleukin (IL)-1beta function induction of the inflammation biomarker cyclooxygenase (COX)-2.	Luteolin	20-28	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	158-180
26471424-0	2015	Chlorogenic acid and luteolin synergistically inhibit the proliferation of interleukin-1beta-induced fibroblast-like synoviocytes through regulating the activation of NF-kappaB and JAK/STAT-signaling pathways.	Luteolin	21-29	interleukin 1 beta	Homo sapiens	75-92
25383596-9	2015	Furthermore, luteolin, luteolin 7-O-glucoside, and luteolin 7-O-glucuronide suppressed the expression of iNOS and COX-2, and t-BHP-induced ROS generation in LPS-stimulated RAW 264.7 cells.	Luteolin	13-21	nitric oxide synthase 2, inducible	Mus musculus	105-109
25383596-9	2015	Furthermore, luteolin, luteolin 7-O-glucoside, and luteolin 7-O-glucuronide suppressed the expression of iNOS and COX-2, and t-BHP-induced ROS generation in LPS-stimulated RAW 264.7 cells.	Luteolin	13-21	cytochrome c oxidase II, mitochondrial	Mus musculus	114-119
28962277-8	2014	Luteolin and quercetin were incorporated into mitochondria fractions within 1-h incubation and attenuated MAO-A activity slightly but significantly.	Luteolin	0-8	monoamine oxidase A	Homo sapiens	106-111
25446924-9	2014	In conclusion, quercetin, luteolin and EGCG inhibited ER stress-associated TXNIP and NLRP3 inflammasome activation, and thereby protected endothelial cells from inflammatory and apoptotic damage.	Luteolin	26-34	thioredoxin interacting protein	Homo sapiens	75-80
25446924-9	2014	In conclusion, quercetin, luteolin and EGCG inhibited ER stress-associated TXNIP and NLRP3 inflammasome activation, and thereby protected endothelial cells from inflammatory and apoptotic damage.	Luteolin	26-34	NLR family pyrin domain containing 3	Homo sapiens	85-90
25856707-7	2015	The antioxidant capacity of digitoflavone was also determined by measuring reduced glutathione (GSH) level and catalase (CAT) activity quantification.	Luteolin	28-41	catalase	Rattus norvegicus	111-119
25856707-7	2015	The antioxidant capacity of digitoflavone was also determined by measuring reduced glutathione (GSH) level and catalase (CAT) activity quantification.	Luteolin	28-41	catalase	Rattus norvegicus	121-124
25856707-12	2015	Antioxidant ability of digitoflavone was indicated by the elevation of GSH level and CAT activity.	Luteolin	23-36	catalase	Rattus norvegicus	85-88
25446924-0	2014	Quercetin, luteolin and epigallocatechin gallate alleviate TXNIP and NLRP3-mediated inflammation and apoptosis with regulation of AMPK in endothelial cells.	Luteolin	11-19	thioredoxin interacting protein	Homo sapiens	59-64
25446924-0	2014	Quercetin, luteolin and epigallocatechin gallate alleviate TXNIP and NLRP3-mediated inflammation and apoptosis with regulation of AMPK in endothelial cells.	Luteolin	11-19	NLR family pyrin domain containing 3	Homo sapiens	69-74
25446924-0	2014	Quercetin, luteolin and epigallocatechin gallate alleviate TXNIP and NLRP3-mediated inflammation and apoptosis with regulation of AMPK in endothelial cells.	Luteolin	11-19	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	130-134
25446924-5	2014	Quercetin, luteolin and EGCG reduced reactive oxygen species production and inhibited TXNIP and NLRP3 inflammasome activation, lead to the downregulation of IL-1beta expression.	Luteolin	11-19	thioredoxin interacting protein	Homo sapiens	86-91
25446924-5	2014	Quercetin, luteolin and EGCG reduced reactive oxygen species production and inhibited TXNIP and NLRP3 inflammasome activation, lead to the downregulation of IL-1beta expression.	Luteolin	11-19	NLR family pyrin domain containing 3	Homo sapiens	96-101
25446924-5	2014	Quercetin, luteolin and EGCG reduced reactive oxygen species production and inhibited TXNIP and NLRP3 inflammasome activation, lead to the downregulation of IL-1beta expression.	Luteolin	11-19	interleukin 1 beta	Homo sapiens	157-165
25229015-9	2014	These results demonstrated that oxidative stress was involved in Abeta-induced neuronal death, and antioxidative flavonoid compounds, especially epicatechin, EGCG, luteolin, and myricetin, could inhibit neuronal death.	Luteolin	164-172	amyloid beta (A4) precursor protein	Mus musculus	65-70
24914470-3	2014	Previous our result demonstrated that luteolin, a natural flavonoid existing in vegetables and herbs, competed the binding of TCDD to AhR.	Luteolin	38-46	aryl hydrocarbon receptor	Homo sapiens	134-137
24914470-4	2014	In the present study, we investigated the effect of luteolin on the expression of drug-metabolizing enzymes through the AhR and Nrf2 pathways.	Luteolin	52-60	aryl hydrocarbon receptor	Homo sapiens	120-123
24914470-4	2014	In the present study, we investigated the effect of luteolin on the expression of drug-metabolizing enzymes through the AhR and Nrf2 pathways.	Luteolin	52-60	NFE2 like bZIP transcription factor 2	Homo sapiens	128-132
24914470-6	2014	Luteolin suppressed TCDD- and tert-butylhydroquinone-induced Nrf2 protein by decreasing its stability in HepG2 cells.	Luteolin	0-8	NFE2 like bZIP transcription factor 2	Homo sapiens	61-65
24642087-7	2014	Moreover, luteolin enhanced the translocation of Nrf2 to the nucleus both in vivo and in vitro, which was proved by the results of Western blot, immunohistochemistry, and electrophoretic mobility shift assay (EMSA).	Luteolin	10-18	nuclear factor, erythroid derived 2, like 2	Mus musculus	49-53
25187683-4	2014	Therefore, the predicted structure of HBx using threading in LOMET was used for docking against plant derived natural compounds (curcumin, oleanolic acid, resveratrol, bilobetin, luteoline, ellagic acid, betulinic acid and rutin) by Molegro Virtual Docker.	Luteolin	179-188	X protein	Hepatitis B virus	38-41
25057854-0	2014	Quercetin, luteolin, and epigallocatechin gallate promote glucose disposal in adipocytes with regulation of AMP-activated kinase and/or sirtuin 1 activity.	Luteolin	11-19	sirtuin 1	Homo sapiens	136-145
25057854-5	2014	Quercetin, luteolin, and epigallocatechin gallate suppressed nuclear factor-kappaB activation by inhibition of p65 phosphorylation with beneficial regulation of adipokine expression, whereas these actions were diminished by coincubation with compound C. The sirtuin 1 inhibitor nicotinamide attenuated the effects of luteolin and EGCG on p65 phosphorylation and adipokine expression without any influence on the activity of quercetin.	Luteolin	11-19	RELA proto-oncogene, NF-kB subunit	Homo sapiens	111-114
25057854-5	2014	Quercetin, luteolin, and epigallocatechin gallate suppressed nuclear factor-kappaB activation by inhibition of p65 phosphorylation with beneficial regulation of adipokine expression, whereas these actions were diminished by coincubation with compound C. The sirtuin 1 inhibitor nicotinamide attenuated the effects of luteolin and EGCG on p65 phosphorylation and adipokine expression without any influence on the activity of quercetin.	Luteolin	11-19	sirtuin 1	Homo sapiens	258-267
25057854-5	2014	Quercetin, luteolin, and epigallocatechin gallate suppressed nuclear factor-kappaB activation by inhibition of p65 phosphorylation with beneficial regulation of adipokine expression, whereas these actions were diminished by coincubation with compound C. The sirtuin 1 inhibitor nicotinamide attenuated the effects of luteolin and EGCG on p65 phosphorylation and adipokine expression without any influence on the activity of quercetin.	Luteolin	11-19	RELA proto-oncogene, NF-kB subunit	Homo sapiens	338-341
25057854-5	2014	Quercetin, luteolin, and epigallocatechin gallate suppressed nuclear factor-kappaB activation by inhibition of p65 phosphorylation with beneficial regulation of adipokine expression, whereas these actions were diminished by coincubation with compound C. The sirtuin 1 inhibitor nicotinamide attenuated the effects of luteolin and EGCG on p65 phosphorylation and adipokine expression without any influence on the activity of quercetin.	Luteolin	317-325	sirtuin 1	Homo sapiens	258-267
25057854-6	2014	Results of Western blot and fluorescence microscopy also showed that quercetin, luteolin, and epigallocatechin gallate increased Akt substrate of 160 kDa phosphorylation and promoted 2-deoxy-D-glucose uptake by adipocytes under basal and inflammatory conditions.	Luteolin	80-88	AKT serine/threonine kinase 1	Homo sapiens	129-132
25057854-7	2014	These findings suggested that quercetin, luteolin, and epigallocatechin gallate inhibited inflammation and promoted glucose disposal in adipocytes with the regulation of AMP-activated kinase and/or sirtuin 1.	Luteolin	41-49	sirtuin 1	Homo sapiens	198-207
24971999-0	2014	Gefitinib and luteolin cause growth arrest of human prostate cancer PC-3 cells via inhibition of cyclin G-associated kinase and induction of miR-630.	Luteolin	14-22	cyclin G associated kinase	Homo sapiens	97-123
24971999-0	2014	Gefitinib and luteolin cause growth arrest of human prostate cancer PC-3 cells via inhibition of cyclin G-associated kinase and induction of miR-630.	Luteolin	14-22	microRNA 630	Homo sapiens	141-148
24859282-0	2014	Luteolin and quercetin affect the cholesterol absorption mediated by epithelial cholesterol transporter niemann-pick c1-like 1 in caco-2 cells and rats.	Luteolin	0-8	NPC1 like intracellular cholesterol transporter 1	Homo sapiens	104-126
24859282-8	2014	Luteolin and quercetin inhibited cholesterol absorption by Caco-2 cells and human embryonic kidney 293T cells expressing NPC1L1.	Luteolin	0-8	NPC1 like intracellular cholesterol transporter 1	Homo sapiens	121-127
24361407-0	2014	Luteolin and luteolin-7-O-glucoside strengthen antioxidative potential through the modulation of Nrf2/MAPK mediated HO-1 signaling cascade in RAW 264.7 cells.	Luteolin	0-8	nuclear factor, erythroid derived 2, like 2	Mus musculus	97-101
24846311-4	2014	The results showed that when PC12 cells were pre-treated with luteolin (20 microM) 30 min prior to 6-OHDA (100 microM) exposure, 6-OHDA-induced ROS overproduction, cytotoxicity, caspase-3 activation, and mRNA expression of BIM, TRB3 and GADD34 were significantly attenuated.	Luteolin	62-70	caspase 3	Rattus norvegicus	178-187
24846311-4	2014	The results showed that when PC12 cells were pre-treated with luteolin (20 microM) 30 min prior to 6-OHDA (100 microM) exposure, 6-OHDA-induced ROS overproduction, cytotoxicity, caspase-3 activation, and mRNA expression of BIM, TRB3 and GADD34 were significantly attenuated.	Luteolin	62-70	Bcl2-like 11	Rattus norvegicus	223-226
24846311-4	2014	The results showed that when PC12 cells were pre-treated with luteolin (20 microM) 30 min prior to 6-OHDA (100 microM) exposure, 6-OHDA-induced ROS overproduction, cytotoxicity, caspase-3 activation, and mRNA expression of BIM, TRB3 and GADD34 were significantly attenuated.	Luteolin	62-70	tribbles pseudokinase 3	Rattus norvegicus	228-232
24846311-4	2014	The results showed that when PC12 cells were pre-treated with luteolin (20 microM) 30 min prior to 6-OHDA (100 microM) exposure, 6-OHDA-induced ROS overproduction, cytotoxicity, caspase-3 activation, and mRNA expression of BIM, TRB3 and GADD34 were significantly attenuated.	Luteolin	62-70	protein phosphatase 1, regulatory subunit 15A	Rattus norvegicus	237-243
24786236-6	2014	Among the 63 phytochemicals screened, 6 compounds, including coptisine sulfate, bilobalide, schizandrin B, luteolin, schizandrin A and puerarin, at 100 mumol/L inhibited CYP2D6(*)1- and CYP2D6(*)10-mediated O-demethylation of a coumarin compound AMMC by more than 50%.	Luteolin	107-115	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	170-176
24525192-6	2014	Co-administration of luteolin and paclitaxel resulted in an increase in apoptosis compared with the treatment of paclitaxel alone as evidenced by the results of a diamidino-2-phenylindole (DAPI) stain and Annexin-V-based assay.	Luteolin	21-29	annexin A5	Homo sapiens	205-214
24991108-0	2014	Luteolin, a bioflavonoid inhibits azoxymethane-induced colon carcinogenesis: Involvement of iNOS and COX-2.	Luteolin	0-8	nitric oxide synthase 2, inducible	Mus musculus	92-96
24991108-0	2014	Luteolin, a bioflavonoid inhibits azoxymethane-induced colon carcinogenesis: Involvement of iNOS and COX-2.	Luteolin	0-8	cytochrome c oxidase II, mitochondrial	Mus musculus	101-106
24602443-0	2014	Chemoprevention of dietary digitoflavone on colitis-associated colon tumorigenesis through inducing Nrf2 signaling pathway and inhibition of inflammation.	Luteolin	27-40	NFE2 like bZIP transcription factor 2	Homo sapiens	100-104
24602443-5	2014	Activation of Nrf2 by digitoflavone was confirmed through mRNA, protein and GSH level assay in Caco-2 cell line.	Luteolin	22-35	NFE2 like bZIP transcription factor 2	Homo sapiens	14-18
24602443-6	2014	The cytoprotective effect of digitoflavone was evaluated in H2O2-induced oxidative stress model and further signaling pathways analysis was used to determine the target of digitoflavone induced Nrf2 activation.	Luteolin	172-185	NFE2 like bZIP transcription factor 2	Homo sapiens	194-198
24602443-8	2014	RESULT: Micromolarity (10 muM) level of digitoflavone increased Nrf2 expressing, nuclear translocation and expression of downstream phase II antioxidant enzymes.	Luteolin	40-53	latexin	Homo sapiens	26-29
24602443-8	2014	RESULT: Micromolarity (10 muM) level of digitoflavone increased Nrf2 expressing, nuclear translocation and expression of downstream phase II antioxidant enzymes.	Luteolin	40-53	NFE2 like bZIP transcription factor 2	Homo sapiens	64-68
24602443-9	2014	Furthermore, digitoflavone decreased H2O2-induced oxidative stress and cell death via p38 MAPK-Nrf2/ARE pathway.	Luteolin	13-26	mitogen-activated protein kinase 14	Homo sapiens	86-89
24602443-9	2014	Furthermore, digitoflavone decreased H2O2-induced oxidative stress and cell death via p38 MAPK-Nrf2/ARE pathway.	Luteolin	13-26	NFE2 like bZIP transcription factor 2	Homo sapiens	95-99
24602443-11	2014	CONCLUSION: These observations suggest that digitoflavone is a novel Nrf2 pathway activator, and protects against oxidative stress-induced cell injury.	Luteolin	44-57	NFE2 like bZIP transcription factor 2	Homo sapiens	69-73
24361407-0	2014	Luteolin and luteolin-7-O-glucoside strengthen antioxidative potential through the modulation of Nrf2/MAPK mediated HO-1 signaling cascade in RAW 264.7 cells.	Luteolin	0-8	heme oxygenase 1	Mus musculus	116-120
24361407-4	2014	Heme oxygenase-1 (HO-1), one of the phase II enzymes showing an antioxidative activity, was potently induced by luteolin and luteolin-7-O-glucoside treatment, which was in accordance with the translocated nuclear factor-erythroid 2 p45-related factor 2 (Nrf2) into nucleus.	Luteolin	112-120	heme oxygenase 1	Mus musculus	0-16
24361407-4	2014	Heme oxygenase-1 (HO-1), one of the phase II enzymes showing an antioxidative activity, was potently induced by luteolin and luteolin-7-O-glucoside treatment, which was in accordance with the translocated nuclear factor-erythroid 2 p45-related factor 2 (Nrf2) into nucleus.	Luteolin	112-120	heme oxygenase 1	Mus musculus	18-22
24361407-4	2014	Heme oxygenase-1 (HO-1), one of the phase II enzymes showing an antioxidative activity, was potently induced by luteolin and luteolin-7-O-glucoside treatment, which was in accordance with the translocated nuclear factor-erythroid 2 p45-related factor 2 (Nrf2) into nucleus.	Luteolin	112-120	nuclear factor, erythroid derived 2, like 2	Mus musculus	254-258
24361407-7	2014	Consequently, luteolin and luteolin-7-O-glucoside potently strengthen the HO-1-mediated antioxidative potential through the modulation of the Nrf2/MAPK signaling pathways.	Luteolin	14-22	heme oxygenase 1	Mus musculus	74-78
24361407-7	2014	Consequently, luteolin and luteolin-7-O-glucoside potently strengthen the HO-1-mediated antioxidative potential through the modulation of the Nrf2/MAPK signaling pathways.	Luteolin	14-22	nuclear factor, erythroid derived 2, like 2	Mus musculus	142-146
25040994-3	2014	At physiological concentrations, luteolin as a flavonoid compound can inhibit Nrf2 and sensitize cancer cells to chemotherapeutic agents.	Luteolin	33-41	NFE2 like bZIP transcription factor 2	Homo sapiens	78-82
24146961-0	2013	Digitoflavone inhibits IkappaBalpha kinase and enhances apoptosis induced by TNFalpha through downregulation of expression of nuclear factor kappaB-regulated gene products in human pancreatic cancer cells.	Luteolin	0-13	NFKB inhibitor alpha	Homo sapiens	23-35
24998588-11	2014	The results showed that interleukin-6 (IL-6)-induced JAK/STAT3 activation in KKU-M156 cells was suppressed by treatment with luteolin.	Luteolin	125-133	interleukin 6	Homo sapiens	24-37
24998588-11	2014	The results showed that interleukin-6 (IL-6)-induced JAK/STAT3 activation in KKU-M156 cells was suppressed by treatment with luteolin.	Luteolin	125-133	interleukin 6	Homo sapiens	39-43
24998588-11	2014	The results showed that interleukin-6 (IL-6)-induced JAK/STAT3 activation in KKU-M156 cells was suppressed by treatment with luteolin.	Luteolin	125-133	signal transducer and activator of transcription 3	Homo sapiens	57-62
24353826-0	2013	Luteolin and luteolin-7-O-glucoside inhibit lipopolysaccharide-induced inflammatory responses through modulation of NF-kappaB/AP-1/PI3K-Akt signaling cascades in RAW 264.7 cells.	Luteolin	0-8	jun proto-oncogene	Mus musculus	126-130
25338981-8	2014	We summarize recent updates on piperlongumine, phenethyl isothiocyanate and luteolin induced activation of TRAIL mediated apoptosis.	Luteolin	76-84	TNF superfamily member 10	Homo sapiens	107-112
24024667-0	2014	Luteolin, a bioflavonoid inhibits Azoxymethane-induced colorectal cancer through activation of Nrf2 signaling.	Luteolin	0-8	nuclear factor, erythroid derived 2, like 2	Mus musculus	95-99
24146961-0	2013	Digitoflavone inhibits IkappaBalpha kinase and enhances apoptosis induced by TNFalpha through downregulation of expression of nuclear factor kappaB-regulated gene products in human pancreatic cancer cells.	Luteolin	0-13	tumor necrosis factor	Homo sapiens	77-85
24146961-3	2013	We found that pretreatment with digitoflavone, a plant flavonoid, greatly sensitized TNFalpha-induced apoptotic cell death in several human pancreatic cancer cells.	Luteolin	32-45	tumor necrosis factor	Homo sapiens	85-93
24146961-4	2013	In search of the molecular basis of the sensitization effect of digitoflavone, digitoflavone was found to inhibit TNFalpha-induced activation of nuclear transcription factor-kappa B (NF-kappaB) which is the main survival factor in TNFalpha signaling.	Luteolin	64-77	tumor necrosis factor	Homo sapiens	114-122
24146961-4	2013	In search of the molecular basis of the sensitization effect of digitoflavone, digitoflavone was found to inhibit TNFalpha-induced activation of nuclear transcription factor-kappa B (NF-kappaB) which is the main survival factor in TNFalpha signaling.	Luteolin	64-77	tumor necrosis factor	Homo sapiens	231-239
24146961-4	2013	In search of the molecular basis of the sensitization effect of digitoflavone, digitoflavone was found to inhibit TNFalpha-induced activation of nuclear transcription factor-kappa B (NF-kappaB) which is the main survival factor in TNFalpha signaling.	Luteolin	79-92	tumor necrosis factor	Homo sapiens	114-122
24146961-4	2013	In search of the molecular basis of the sensitization effect of digitoflavone, digitoflavone was found to inhibit TNFalpha-induced activation of nuclear transcription factor-kappa B (NF-kappaB) which is the main survival factor in TNFalpha signaling.	Luteolin	79-92	tumor necrosis factor	Homo sapiens	231-239
24146961-7	2013	In addition, digitoflavone can activate JNK through inhibition of NF-kappaB signaling, provide a continuous blockade of the feed-back inhibitory mechanism by JNK-induced NF-kappaB activation.	Luteolin	13-26	mitogen-activated protein kinase 8	Homo sapiens	40-43
24146961-7	2013	In addition, digitoflavone can activate JNK through inhibition of NF-kappaB signaling, provide a continuous blockade of the feed-back inhibitory mechanism by JNK-induced NF-kappaB activation.	Luteolin	13-26	mitogen-activated protein kinase 8	Homo sapiens	158-161
23085339-3	2013	In our previous study, we demonstrated that R. officinalis and its active compounds, luteolin (Lut), carnosic acid (CA), and rosmarinic acid (RA), exhibited neurotrophic effects and improved cholinergic functions in PC12 cells in correlation with mitogen-activated protein kinase (MAPK), ERK1/2 signaling pathway.	Luteolin	85-93	mitogen activated protein kinase 3	Rattus norvegicus	281-285
23534413-5	2013	Myricetin and luteolin were found to be the potential dual inhibitors of xanthine oxidase and cyclooxygenase-2 as demonstrated by IC(50): 62.7 and 3.29 mug/mL (xanthine oxidase)/70.8 and 16.38 mug/mL (cyclooxygenase-2), respectively.	Luteolin	14-22	prostaglandin-endoperoxide synthase 2	Homo sapiens	94-110
23534413-5	2013	Myricetin and luteolin were found to be the potential dual inhibitors of xanthine oxidase and cyclooxygenase-2 as demonstrated by IC(50): 62.7 and 3.29 mug/mL (xanthine oxidase)/70.8 and 16.38 mug/mL (cyclooxygenase-2), respectively.	Luteolin	14-22	prostaglandin-endoperoxide synthase 2	Homo sapiens	201-217
23085339-3	2013	In our previous study, we demonstrated that R. officinalis and its active compounds, luteolin (Lut), carnosic acid (CA), and rosmarinic acid (RA), exhibited neurotrophic effects and improved cholinergic functions in PC12 cells in correlation with mitogen-activated protein kinase (MAPK), ERK1/2 signaling pathway.	Luteolin	95-98	mitogen activated protein kinase 3	Rattus norvegicus	281-285
23085339-3	2013	In our previous study, we demonstrated that R. officinalis and its active compounds, luteolin (Lut), carnosic acid (CA), and rosmarinic acid (RA), exhibited neurotrophic effects and improved cholinergic functions in PC12 cells in correlation with mitogen-activated protein kinase (MAPK), ERK1/2 signaling pathway.	Luteolin	85-93	mitogen activated protein kinase 3	Rattus norvegicus	288-294
23085339-3	2013	In our previous study, we demonstrated that R. officinalis and its active compounds, luteolin (Lut), carnosic acid (CA), and rosmarinic acid (RA), exhibited neurotrophic effects and improved cholinergic functions in PC12 cells in correlation with mitogen-activated protein kinase (MAPK), ERK1/2 signaling pathway.	Luteolin	95-98	mitogen activated protein kinase 3	Rattus norvegicus	288-294
22843013-8	2013	Quercetin, luteolin, and EGCG inhibited inflammation-evoked IKKbeta activation and IRS-1 serine phosphorylation in adipose tissue, and thereby effectively restored glucose load-stimulated IRS-1 tyrosine and Akt phosphorylation, leading to an increase in insulin-mediated glucose uptake in adipocytes.	Luteolin	11-19	inhibitor of kappaB kinase beta	Mus musculus	60-67
22843013-8	2013	Quercetin, luteolin, and EGCG inhibited inflammation-evoked IKKbeta activation and IRS-1 serine phosphorylation in adipose tissue, and thereby effectively restored glucose load-stimulated IRS-1 tyrosine and Akt phosphorylation, leading to an increase in insulin-mediated glucose uptake in adipocytes.	Luteolin	11-19	insulin receptor substrate 1	Mus musculus	83-88
22843013-5	2013	Luteolin and EGCG, but not quercetin, inhibited glucose load-induced insulin receptor substrate-1(IRS-1) tyrosine and Akt phosphorylation in adipose tissue.	Luteolin	0-8	insulin receptor substrate 1	Mus musculus	98-103
22843013-8	2013	Quercetin, luteolin, and EGCG inhibited inflammation-evoked IKKbeta activation and IRS-1 serine phosphorylation in adipose tissue, and thereby effectively restored glucose load-stimulated IRS-1 tyrosine and Akt phosphorylation, leading to an increase in insulin-mediated glucose uptake in adipocytes.	Luteolin	11-19	insulin receptor substrate 1	Mus musculus	188-193
22843013-8	2013	Quercetin, luteolin, and EGCG inhibited inflammation-evoked IKKbeta activation and IRS-1 serine phosphorylation in adipose tissue, and thereby effectively restored glucose load-stimulated IRS-1 tyrosine and Akt phosphorylation, leading to an increase in insulin-mediated glucose uptake in adipocytes.	Luteolin	11-19	thymoma viral proto-oncogene 1	Mus musculus	207-210
22843013-5	2013	Luteolin and EGCG, but not quercetin, inhibited glucose load-induced insulin receptor substrate-1(IRS-1) tyrosine and Akt phosphorylation in adipose tissue.	Luteolin	0-8	thymoma viral proto-oncogene 1	Mus musculus	118-121
22626874-7	2012	Luteolin treatment induced a significant decrease in serum TG, TC, LDL, MDA, CK, LDH, and myocardial CTGF and a significant increase in HDL, SOD and Akt phosphorylation levels in comparison with the diabetic group.	Luteolin	0-8	cellular communication network factor 2	Rattus norvegicus	101-105
22637477-5	2012	Similar suppression also results from genetic deletion of 12/15-lipoxygenase or inhibiting its activity with nordihydroguaiaretic acid or luteolin.	Luteolin	138-146	arachidonate 15-lipoxygenase	Mus musculus	58-76
22749133-0	2013	The flavonoids diosmetin and luteolin exert synergistic cytostatic effects in human hepatoma HepG2 cells via CYP1A-catalyzed metabolism, activation of JNK and ERK and P53/P21 up-regulation.	Luteolin	29-37	mitogen-activated protein kinase 8	Homo sapiens	151-154
22749133-0	2013	The flavonoids diosmetin and luteolin exert synergistic cytostatic effects in human hepatoma HepG2 cells via CYP1A-catalyzed metabolism, activation of JNK and ERK and P53/P21 up-regulation.	Luteolin	29-37	mitogen-activated protein kinase 1	Homo sapiens	159-162
22749133-0	2013	The flavonoids diosmetin and luteolin exert synergistic cytostatic effects in human hepatoma HepG2 cells via CYP1A-catalyzed metabolism, activation of JNK and ERK and P53/P21 up-regulation.	Luteolin	29-37	tumor protein p53	Homo sapiens	167-174
22626874-7	2012	Luteolin treatment induced a significant decrease in serum TG, TC, LDL, MDA, CK, LDH, and myocardial CTGF and a significant increase in HDL, SOD and Akt phosphorylation levels in comparison with the diabetic group.	Luteolin	0-8	AKT serine/threonine kinase 1	Rattus norvegicus	149-152
22107990-12	2012	The phytochemical study of Ba-CAE showed the presence of flavones as luteolin and acacetin, caffeoylquinic acids as chlorogenic acid, and tannins.	Luteolin	69-77	gap junction protein alpha 8	Homo sapiens	30-33
22420665-8	2012	The activation of Src, PDK1, Akt (308), Akt (473) in the luteolin-treated group was significantly lower than that seen in the H(2) O(2) group.	Luteolin	57-65	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	18-21
22420665-8	2012	The activation of Src, PDK1, Akt (308), Akt (473) in the luteolin-treated group was significantly lower than that seen in the H(2) O(2) group.	Luteolin	57-65	pyruvate dehydrogenase kinase 1	Homo sapiens	23-27
22420665-8	2012	The activation of Src, PDK1, Akt (308), Akt (473) in the luteolin-treated group was significantly lower than that seen in the H(2) O(2) group.	Luteolin	57-65	AKT serine/threonine kinase 1	Homo sapiens	29-32
22420665-8	2012	The activation of Src, PDK1, Akt (308), Akt (473) in the luteolin-treated group was significantly lower than that seen in the H(2) O(2) group.	Luteolin	57-65	AKT serine/threonine kinase 1	Homo sapiens	40-43
22284780-11	2012	Specifically, apiegenin, baicalein, curcumin, EGCG, genistein, luteolin, oridonin, quercetin, and wogonin repress NF-kappaB (NF-kappaB, a proinflammatory transcription factor) and inhibit proinflammatory cytokines such as TNF-alpha and IL-6.	Luteolin	63-71	nuclear factor kappa B subunit 1	Homo sapiens	114-123
22284780-11	2012	Specifically, apiegenin, baicalein, curcumin, EGCG, genistein, luteolin, oridonin, quercetin, and wogonin repress NF-kappaB (NF-kappaB, a proinflammatory transcription factor) and inhibit proinflammatory cytokines such as TNF-alpha and IL-6.	Luteolin	63-71	nuclear factor kappa B subunit 1	Homo sapiens	125-134
22284780-11	2012	Specifically, apiegenin, baicalein, curcumin, EGCG, genistein, luteolin, oridonin, quercetin, and wogonin repress NF-kappaB (NF-kappaB, a proinflammatory transcription factor) and inhibit proinflammatory cytokines such as TNF-alpha and IL-6.	Luteolin	63-71	tumor necrosis factor	Homo sapiens	222-231
22284780-11	2012	Specifically, apiegenin, baicalein, curcumin, EGCG, genistein, luteolin, oridonin, quercetin, and wogonin repress NF-kappaB (NF-kappaB, a proinflammatory transcription factor) and inhibit proinflammatory cytokines such as TNF-alpha and IL-6.	Luteolin	63-71	interleukin 6	Homo sapiens	236-240
22284780-13	2012	Recent studies further indicate that apigenin, genistein, kaempferol, luteolin, and quercetin potently inhibit VEGF production and suppress ovarian cancer cell metastasis in vitro.	Luteolin	70-78	vascular endothelial growth factor A	Homo sapiens	111-115
22916239-5	2012	Moreover, luteolin-induced CREB activation, miR-132 expression and neurite outgrowth were inhibited by adenylate cyclase, protein kinase A (PKA) and MAPK/ERK kinase 1/2 (MEK1/2) inhibitors but not by protein kinase C (PKC) or calcium/calmodulin-dependent protein kinase II (CaMK II) inhibitors.	Luteolin	10-18	Eph receptor B1	Rattus norvegicus	154-157
22916239-5	2012	Moreover, luteolin-induced CREB activation, miR-132 expression and neurite outgrowth were inhibited by adenylate cyclase, protein kinase A (PKA) and MAPK/ERK kinase 1/2 (MEK1/2) inhibitors but not by protein kinase C (PKC) or calcium/calmodulin-dependent protein kinase II (CaMK II) inhibitors.	Luteolin	10-18	mitogen activated protein kinase kinase 1	Rattus norvegicus	170-176
22916239-5	2012	Moreover, luteolin-induced CREB activation, miR-132 expression and neurite outgrowth were inhibited by adenylate cyclase, protein kinase A (PKA) and MAPK/ERK kinase 1/2 (MEK1/2) inhibitors but not by protein kinase C (PKC) or calcium/calmodulin-dependent protein kinase II (CaMK II) inhibitors.	Luteolin	10-18	cAMP responsive element binding protein 1	Rattus norvegicus	27-31
22916239-5	2012	Moreover, luteolin-induced CREB activation, miR-132 expression and neurite outgrowth were inhibited by adenylate cyclase, protein kinase A (PKA) and MAPK/ERK kinase 1/2 (MEK1/2) inhibitors but not by protein kinase C (PKC) or calcium/calmodulin-dependent protein kinase II (CaMK II) inhibitors.	Luteolin	10-18	microRNA 132	Rattus norvegicus	44-51
21605053-7	2011	Indeed, polyphenols including resveratrol, EGCG and luteolin significantly inhibit the activation of the key apoptotic executioner, caspase-3 and are able to modulate mitogen-activated protein kinases known to play an important role in neuronal apoptosis.	Luteolin	52-60	caspase 3	Homo sapiens	132-141
22916239-5	2012	Moreover, luteolin-induced CREB activation, miR-132 expression and neurite outgrowth were inhibited by adenylate cyclase, protein kinase A (PKA) and MAPK/ERK kinase 1/2 (MEK1/2) inhibitors but not by protein kinase C (PKC) or calcium/calmodulin-dependent protein kinase II (CaMK II) inhibitors.	Luteolin	10-18	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	122-138
22916239-5	2012	Moreover, luteolin-induced CREB activation, miR-132 expression and neurite outgrowth were inhibited by adenylate cyclase, protein kinase A (PKA) and MAPK/ERK kinase 1/2 (MEK1/2) inhibitors but not by protein kinase C (PKC) or calcium/calmodulin-dependent protein kinase II (CaMK II) inhibitors.	Luteolin	10-18	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	140-143
21752154-6	2011	Overexpression of MMP-9 resulted in induction of the EMT in A431-P cells and this could be reversed by treating with luteolin or quercetin.	Luteolin	117-125	matrix metallopeptidase 9	Homo sapiens	18-23
21036586-4	2011	In the present study, we report the inhibitory effect of luteolin on lipopolysaccharide (LPS)/interferon gamma (IFN-gamma)-induced NO and proinflammatory cytokine production in rat primary microglia and BV-2 microglial cells.	Luteolin	57-65	toll-like receptor 4	Mus musculus	89-92
21036586-4	2011	In the present study, we report the inhibitory effect of luteolin on lipopolysaccharide (LPS)/interferon gamma (IFN-gamma)-induced NO and proinflammatory cytokine production in rat primary microglia and BV-2 microglial cells.	Luteolin	57-65	interferon gamma	Rattus norvegicus	94-121
21513709-0	2011	Luteolin and chicoric acid synergistically inhibited inflammatory responses via inactivation of PI3K-Akt pathway and impairment of NF-kappaB translocation in LPS stimulated RAW 264.7 cells.	Luteolin	0-8	thymoma viral proto-oncogene 1	Mus musculus	101-104
21513709-0	2011	Luteolin and chicoric acid synergistically inhibited inflammatory responses via inactivation of PI3K-Akt pathway and impairment of NF-kappaB translocation in LPS stimulated RAW 264.7 cells.	Luteolin	0-8	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	131-140
21513709-5	2011	Luteolin and chicoric acid co-treatment inhibited phosphorylation of NF-kappaB and Akt, but had no effect on extracellular signal-regulated kinase (ERK), c-Jun NH2-terminal kinase (JNK), and p38.	Luteolin	0-8	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	69-78
21513709-2	2011	Co-treatment with luteolin and chicoric acid synergistically reduced cellular concentrations of nitric oxide (NO) and prostaglandin E2 (PGE2) and also inhibited expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2).	Luteolin	18-26	nitric oxide synthase 2, inducible	Mus musculus	175-206
21513709-5	2011	Luteolin and chicoric acid co-treatment inhibited phosphorylation of NF-kappaB and Akt, but had no effect on extracellular signal-regulated kinase (ERK), c-Jun NH2-terminal kinase (JNK), and p38.	Luteolin	0-8	thymoma viral proto-oncogene 1	Mus musculus	83-86
21513709-2	2011	Co-treatment with luteolin and chicoric acid synergistically reduced cellular concentrations of nitric oxide (NO) and prostaglandin E2 (PGE2) and also inhibited expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2).	Luteolin	18-26	nitric oxide synthase 2, inducible	Mus musculus	208-212
21513709-5	2011	Luteolin and chicoric acid co-treatment inhibited phosphorylation of NF-kappaB and Akt, but had no effect on extracellular signal-regulated kinase (ERK), c-Jun NH2-terminal kinase (JNK), and p38.	Luteolin	0-8	mitogen-activated protein kinase 14	Mus musculus	191-194
21513709-2	2011	Co-treatment with luteolin and chicoric acid synergistically reduced cellular concentrations of nitric oxide (NO) and prostaglandin E2 (PGE2) and also inhibited expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2).	Luteolin	18-26	prostaglandin-endoperoxide synthase 2	Mus musculus	218-234
21513709-2	2011	Co-treatment with luteolin and chicoric acid synergistically reduced cellular concentrations of nitric oxide (NO) and prostaglandin E2 (PGE2) and also inhibited expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2).	Luteolin	18-26	prostaglandin-endoperoxide synthase 2	Mus musculus	236-241
20971650-1	2010	Luteolin, 5,7-dihydroxy-2-(3,4-dihydroxyphenyl)-4H-chromen-4-one, has been proposed and proved to be a novel dopamine transporter (DAT) activator.	Luteolin	0-8	solute carrier family 6 member 3	Rattus norvegicus	131-134
21488180-9	2011	TBK1 kinase can be a target for certain flavonoids such as EGCG, luteolin, quercetin, chrysin, and eriodictyol to regulate TRIF-dependent TLR pathways.	Luteolin	65-73	TANK binding kinase 1	Homo sapiens	0-4
21488180-9	2011	TBK1 kinase can be a target for certain flavonoids such as EGCG, luteolin, quercetin, chrysin, and eriodictyol to regulate TRIF-dependent TLR pathways.	Luteolin	65-73	TIR domain containing adaptor molecule 1	Homo sapiens	123-127
21443429-0	2011	Citrus flavonoids luteolin, apigenin, and quercetin inhibit glycogen synthase kinase-3beta enzymatic activity by lowering the interaction energy within the binding cavity.	Luteolin	18-26	glycogen synthase kinase 3 beta	Homo sapiens	60-90
21443429-3	2011	Of the 22 citrus compounds tested, the flavonoids luteolin, apigenin, and quercetin had the highest inhibitory effects on GSK-3beta, with 50% inhibitory values of 1.5, 1.9, and 2.0 muM, respectively.	Luteolin	50-58	glycogen synthase kinase 3 beta	Homo sapiens	122-131
21443429-3	2011	Of the 22 citrus compounds tested, the flavonoids luteolin, apigenin, and quercetin had the highest inhibitory effects on GSK-3beta, with 50% inhibitory values of 1.5, 1.9, and 2.0 muM, respectively.	Luteolin	50-58	latexin	Homo sapiens	181-184
20958047-5	2010	We found that oral administration of luteolin (10 mg/kg) efficiently suppressed the neutrophil infiltration as well as TNF-alpha and IL-6 elevation in the bronchoalveolar lavage fluid in bleomycin-instilled C57BL/6J mice.	Luteolin	37-45	tumor necrosis factor	Mus musculus	119-128
20958047-5	2010	We found that oral administration of luteolin (10 mg/kg) efficiently suppressed the neutrophil infiltration as well as TNF-alpha and IL-6 elevation in the bronchoalveolar lavage fluid in bleomycin-instilled C57BL/6J mice.	Luteolin	37-45	interleukin 6	Mus musculus	133-137
20971650-3	2010	Biological screening results demonstrated that luteolin derivatives 1d, 1e, and 4c carry great DAT agonistic potency (EC(50)=0.046, 0.869, and 1.375muM, respectively) compared with luteolin 8 (EC(50)=1.45+-0.29muM).	Luteolin	47-55	solute carrier family 6 member 3	Rattus norvegicus	95-98
20860968-0	2010	Effects of lycopene, indole-3-carbinol, and luteolin on nitric oxide production and iNOS expression are organ-specific in rats.	Luteolin	44-52	nitric oxide synthase 2	Rattus norvegicus	84-88
19954946-3	2010	Luteolin, a naturally occurring flavonoid, has been demonstrated to inhibit lipopolysaccharide-induced tumor necrosis factor-alpha (TNFalpha) release and activation of NF-kappaB pathway in macrophages.	Luteolin	0-8	tumor necrosis factor	Mus musculus	103-130
19954946-3	2010	Luteolin, a naturally occurring flavonoid, has been demonstrated to inhibit lipopolysaccharide-induced tumor necrosis factor-alpha (TNFalpha) release and activation of NF-kappaB pathway in macrophages.	Luteolin	0-8	tumor necrosis factor	Mus musculus	132-140
20571914-3	2010	Among the 20 flavonoids we examined, we found that isorhamnetin and luteolin had the best protective effects against H(2)O(2) or SIN-1-induced cytotoxicity in SH-SY5Y cells.	Luteolin	68-76	MAPK associated protein 1	Homo sapiens	129-134
21535545-6	2010	Otherwise, all tested flavonoids possessed the inhibitory activity to COX-2 reaction, and especially luteolin, kaempferol, hesperetin, and naringin showed relatively the potent inhibition on COX-2 reaction.	Luteolin	101-109	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	191-196
20403331-3	2010	Luteolin exposure decreased apical transport of B(a)P metabolites due to its interaction with the transporter breast cancer resistance protein.	Luteolin	0-8	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	110-142
20153296-6	2010	Interestingly, only a group of VEGF inhibitors, including apigenin, flavone and 4",7-dihydroxiflavone, reduced the expression of HIF-1alpha under these conditions, whereas others, such as fisetin, luteolin, galangin or quercetin, induced HIF-1alpha expression while reducing those of VEGF.	Luteolin	197-205	vascular endothelial growth factor A	Homo sapiens	31-35
20153296-6	2010	Interestingly, only a group of VEGF inhibitors, including apigenin, flavone and 4",7-dihydroxiflavone, reduced the expression of HIF-1alpha under these conditions, whereas others, such as fisetin, luteolin, galangin or quercetin, induced HIF-1alpha expression while reducing those of VEGF.	Luteolin	197-205	hypoxia inducible factor 1 subunit alpha	Homo sapiens	129-139
19766327-4	2009	The current study investigated the effects of luteolin, a citrus bioflavonoid, and its structural analog, diosmin, on IL-6 induced JAK2/STAT3 (Janus tyrosine kinase-2/signal transducer and activator of transcription-3) phosphorylation and signaling as well as behavioral phenotypes of MIA offspring.	Luteolin	46-54	interleukin 6	Homo sapiens	118-122
20930378-2	2010	Some flavonoids (apigenin, chrysin, flavone, flavanone, galangin, luteolin, and naringenin) by themselves induced CYP1A1 mRNA expression, especially flavone which was even more effective than beta-NF.	Luteolin	66-74	cytochrome P450, family 1, subfamily a, polypeptide 1	Mus musculus	114-120
19766327-4	2009	The current study investigated the effects of luteolin, a citrus bioflavonoid, and its structural analog, diosmin, on IL-6 induced JAK2/STAT3 (Janus tyrosine kinase-2/signal transducer and activator of transcription-3) phosphorylation and signaling as well as behavioral phenotypes of MIA offspring.	Luteolin	46-54	Janus kinase 2	Homo sapiens	131-135
19766327-4	2009	The current study investigated the effects of luteolin, a citrus bioflavonoid, and its structural analog, diosmin, on IL-6 induced JAK2/STAT3 (Janus tyrosine kinase-2/signal transducer and activator of transcription-3) phosphorylation and signaling as well as behavioral phenotypes of MIA offspring.	Luteolin	46-54	signal transducer and activator of transcription 3	Homo sapiens	136-141
19766327-4	2009	The current study investigated the effects of luteolin, a citrus bioflavonoid, and its structural analog, diosmin, on IL-6 induced JAK2/STAT3 (Janus tyrosine kinase-2/signal transducer and activator of transcription-3) phosphorylation and signaling as well as behavioral phenotypes of MIA offspring.	Luteolin	46-54	signal transducer and activator of transcription 3	Homo sapiens	143-217
19344998-0	2009	Luteolin, quercetin and ursolic acid are potent inhibitors of proliferation and inducers of apoptosis in both KRAS and BRAF mutated human colorectal cancer cells.	Luteolin	0-8	KRAS proto-oncogene, GTPase	Homo sapiens	110-114
19739098-3	2009	Based on our previous observations that the nutrient flavonoid luteolin potently blocks TNF-induced NF-kappaB activation in cancer cells, we investigated if the combination of SMC3 and luteolin would achieve a synergistic anticancer activity.	Luteolin	63-71	tumor necrosis factor	Homo sapiens	88-91
19442706-7	2009	Our results demonstrate that oral administration of luteolin for 8 days for those Abeta(25-35)-induced amnesic mice conferred robust neurovascular protection in Abeta(25-35)-induced amnesia, involving the improvement of the spatial learning and memory capabilities, the modulation of microvascular function, the increase of regional cerebral blood flow values, the clearance of reactive oxygen species, the improvement of cholinergic neuronal system, and the increase of brain-derived neurotrophic factor level and its receptor tyrosine kinase B expression in cerebral cortex.	Luteolin	52-60	brain derived neurotrophic factor	Mus musculus	471-504
20162352-3	2009	In the present study, we investigated the effects of luteolin, a flavonoid, on the regulation of receptor activator of nuclear factor-kappaB ligand (RANKL)-induced osteoclastogenesis, functions and signaling pathway.	Luteolin	53-61	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	97-147
20162352-3	2009	In the present study, we investigated the effects of luteolin, a flavonoid, on the regulation of receptor activator of nuclear factor-kappaB ligand (RANKL)-induced osteoclastogenesis, functions and signaling pathway.	Luteolin	53-61	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	149-154
19739098-3	2009	Based on our previous observations that the nutrient flavonoid luteolin potently blocks TNF-induced NF-kappaB activation in cancer cells, we investigated if the combination of SMC3 and luteolin would achieve a synergistic anticancer activity.	Luteolin	63-71	nuclear factor kappa B subunit 1	Homo sapiens	100-109
19344998-0	2009	Luteolin, quercetin and ursolic acid are potent inhibitors of proliferation and inducers of apoptosis in both KRAS and BRAF mutated human colorectal cancer cells.	Luteolin	0-8	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	119-123
18972039-1	2008	Studies on the sensitization, by novel alkynyl luteolin analogues, of TNF-alpha-induced apoptosis in HeLa and HepG2 cells revealed that LA-12 showed better sensitizing effects on TNF-alpha-induced cell death than luteolin, suggesting great potential for alkynyl luteolin analogues in cancer therapy.	Luteolin	47-55	tumor necrosis factor	Homo sapiens	70-79
19074529-1	2009	This article describes an in vitro investigation of the inhibition of cytochrome P450 (P450) 2C9 by a series of flavonoids made up of flavones (flavone, 6-hydroxyflavone, 7-hydroxyflavone, chrysin, baicalein, apigenin, luteolin, scutellarein, and wogonin) and flavonols (galangin, fisetin, kaempferol, morin, and quercetin).	Luteolin	219-227	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-96
18946510-5	2008	Results of enzyme kinetics revealed that curcumin, compared to the polyphenols quercetin, myricetin, kaempferol, luteolin and rutin, elicited a stronger competitive inhibitory effect on Glo1 (K(i) = 5.1+/-1.4 microM).	Luteolin	113-121	glyoxalase I	Homo sapiens	186-190
18831918-4	2008	We recently showed that the natural flavonoids quercetin and luteolin can eliminate "flush", as well as inhibit both niacin-induced plasma prostaglandin D2 (PGD2) and serotonin increase in an animal model.	Luteolin	61-69	prostaglandin D2 synthase	Homo sapiens	139-155
18191104-3	2008	Both diosmetin and luteolin decreased 1"-OH-MDZ formation by human recombinant CYP3A4, but not CYP3A5, whereas they decreased 4-OH-MDZ formation by both recombinant enzymes.	Luteolin	19-27	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	79-85
17982879-4	2007	Luteolin protects rat neural PC12 and glial C6 cells from N-methyl-4-phenyl-pyridinium (MPP+) induced toxicity in vitro and effectively activates Nrf2 as shown by ARE-reporter gene assays.	Luteolin	0-8	NFE2 like bZIP transcription factor 2	Rattus norvegicus	146-150
17630199-5	2007	Herein we characterize the effect of the flavonoids quercetin, genistein, luteolin, and quercetagetin on LPS-activated transduction mechanism regulation in human gingival fibroblasts (HGF).	Luteolin	74-82	hepatocyte growth factor	Homo sapiens	184-187
17384531-6	2007	Analyses of structure-activity relationships of 45 flavones, flavonols and their related compounds showed that luteolin, ayanin, apigenin and fisetin were the strongest inhibitors of IL-4 production with an IC(50) value of 2-5 microM and determined a fundamental structure for the inhibitory activity.	Luteolin	111-119	interleukin 4	Mus musculus	183-187
17296806-3	2007	Luteolin, a naturally occurring polyphenol flavonoid, has been reported to sensitize colorectal cancer cells to TNF-induced apoptosis through suppression of NF-kappaB; however, the mechanisms of this effect have not been well elucidated.	Luteolin	0-8	tumor necrosis factor	Homo sapiens	112-115
17296806-3	2007	Luteolin, a naturally occurring polyphenol flavonoid, has been reported to sensitize colorectal cancer cells to TNF-induced apoptosis through suppression of NF-kappaB; however, the mechanisms of this effect have not been well elucidated.	Luteolin	0-8	nuclear factor kappa B subunit 1	Homo sapiens	157-166
17337279-3	2007	Luteolin was not reversed by scopolamine N-methylbromide (M-SCOP) but blocked the impairment of learning acquisition induced by cholinergic neurotoxin (ethylcholine aziridinium, AF64A) and muscarinic (scopolamine hydrobromide, SCOP) and nicotinic (mecamylamine, MECA) receptor antagonists.	Luteolin	0-8	PH domain and leucine rich repeat protein phosphatase 1	Rattus norvegicus	60-64
17337279-3	2007	Luteolin was not reversed by scopolamine N-methylbromide (M-SCOP) but blocked the impairment of learning acquisition induced by cholinergic neurotoxin (ethylcholine aziridinium, AF64A) and muscarinic (scopolamine hydrobromide, SCOP) and nicotinic (mecamylamine, MECA) receptor antagonists.	Luteolin	0-8	PH domain and leucine rich repeat protein phosphatase 1	Rattus norvegicus	227-231
16850523-7	2007	On luteolin administration, colon cancer incidence, number of tumors per rat and the activities of beta-glucuronidase and mucinase, were significantly decreased both in the initiation and post-initiation stages of colon carcinogenesis dependent on the three different doses given.	Luteolin	3-11	glucuronidase, beta	Rattus norvegicus	99-117
16376383-9	2006	Among flavonoids tested, fisetin, apigenin, naringenin, luteolin, quercetin and kaempferol exhibited high inhibitory potencies for the 20alpha-HSD activity.	Luteolin	56-64	aldo-keto reductase family 1, member C18	Mus musculus	135-146
16756349-0	2006	Pyrrolidine dithiocarbamate inhibition of luteolin-induced apoptosis through up-regulated phosphorylation of Akt and caspase-9 in human leukemia HL-60 cells.	Luteolin	42-50	AKT serine/threonine kinase 1	Homo sapiens	109-112
16756349-0	2006	Pyrrolidine dithiocarbamate inhibition of luteolin-induced apoptosis through up-regulated phosphorylation of Akt and caspase-9 in human leukemia HL-60 cells.	Luteolin	42-50	caspase 9	Homo sapiens	117-126
16488130-9	2006	The addition of other AhR ligands, alpha-naphthoflavone (alpha-NF, 10 microM) and luteolin (10 microM), to the culture media resulted in a similar suppression in ER-alpha mRNA levels to that caused by 5 microM DIM.	Luteolin	82-90	estrogen receptor 1	Homo sapiens	162-170
16738032-5	2006	In the present study, three common flavonoids, quercetin, luteolin, and kaempferol, were used as substrates for glucuronidation by wild-type and variant UGT1A3s.	Luteolin	58-66	UDP glucuronosyltransferase family 1 member A3	Homo sapiens	153-159
16738032-9	2006	UGT1A3 variants have an altered glucuronidation activity toward quercetin, luteolin, and kaempferol and may alter human susceptibility to flavonoid exposure.	Luteolin	75-83	UDP glucuronosyltransferase family 1 member A3	Homo sapiens	0-6
16458870-4	2006	In our preliminary study, we investigated the effect of flavonoids including luteolin, quercetin, baicalein, genistein, taxifolin and catechin on HGF-mediated migration and invasion of HepG2 cells.	Luteolin	77-85	hepatocyte growth factor	Homo sapiens	146-149
16445590-9	2006	The cytotoxic effect of luteolin but not luteolin 5,3"-dimethylether was mediated via apoptosis (caspase-3 activation).	Luteolin	24-32	caspase 3	Rattus norvegicus	97-106
16116295-3	2005	In addition, the inhibition of ET-1 by a glycoside compound of luteolin (luteolin-6-C-glucoside) was weak.	Luteolin	63-71	endothelin 1	Homo sapiens	31-35
17100629-4	2006	Treatment with flavonoids such as luteolin, apigenin, quercetin, genistein, (-)-epigallocatechin gallate, and anthocyanidin resulted in significant downregulation of LPS-elicited TNF-alpha and nitric oxide (NO) production and diminished lethal shock.	Luteolin	34-42	tumor necrosis factor	Mus musculus	179-188
16470913-3	2006	RESULTS: In the dose-effect study, soybean isoflavone, luteolin and curcumin induced the CYP3A4 transcription via PXR in an evident dose-dependent manner, but isorhamnetin and rutin did not.	Luteolin	55-63	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	89-95
16470913-3	2006	RESULTS: In the dose-effect study, soybean isoflavone, luteolin and curcumin induced the CYP3A4 transcription via PXR in an evident dose-dependent manner, but isorhamnetin and rutin did not.	Luteolin	55-63	nuclear receptor subfamily 1 group I member 2	Homo sapiens	114-117
16470913-5	2006	In the time-effect study, 10 micromol/L and 50 micromol/L soybean isoflavone, luteolin and curcumin induced CYP3A4 transcription between 12 h and 48 h, the strongest induction appeared in 48 h. 48 h after induction, 50 micromol/L soybean isoflavone, luteolin and curcumin exhibited a 6.72-fold, 3.24-fold, and 2.13-fold increase respectively, compared with 0.1% DMSO treated cells.	Luteolin	78-86	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	108-114
16470913-5	2006	In the time-effect study, 10 micromol/L and 50 micromol/L soybean isoflavone, luteolin and curcumin induced CYP3A4 transcription between 12 h and 48 h, the strongest induction appeared in 48 h. 48 h after induction, 50 micromol/L soybean isoflavone, luteolin and curcumin exhibited a 6.72-fold, 3.24-fold, and 2.13-fold increase respectively, compared with 0.1% DMSO treated cells.	Luteolin	250-258	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	108-114
16470913-6	2006	CONCLUSION: Three phytochemicals, i.e. soybean isoflavone, luteolin and curcumin stimulate the PXR-mediated transcription of CYP3A4.	Luteolin	59-67	nuclear receptor subfamily 1 group I member 2	Homo sapiens	95-98
16470913-6	2006	CONCLUSION: Three phytochemicals, i.e. soybean isoflavone, luteolin and curcumin stimulate the PXR-mediated transcription of CYP3A4.	Luteolin	59-67	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	125-131
16688936-7	2005	Intragastric administration of luteolin (0.2mg/kg body weight) to DMH-treated rats significantly reduced the incidence and size of tumor in the colon, reduced lipid peroxidation levels and enhanced the plasma and hepatic activities of GSH, GPx, GST, GR, SOD, CAT, vitamin C, vitamin E and beta-carotene.	Luteolin	31-39	hematopoietic prostaglandin D synthase	Rattus norvegicus	245-248
16688936-7	2005	Intragastric administration of luteolin (0.2mg/kg body weight) to DMH-treated rats significantly reduced the incidence and size of tumor in the colon, reduced lipid peroxidation levels and enhanced the plasma and hepatic activities of GSH, GPx, GST, GR, SOD, CAT, vitamin C, vitamin E and beta-carotene.	Luteolin	31-39	glutathione-disulfide reductase	Rattus norvegicus	250-252
16688936-7	2005	Intragastric administration of luteolin (0.2mg/kg body weight) to DMH-treated rats significantly reduced the incidence and size of tumor in the colon, reduced lipid peroxidation levels and enhanced the plasma and hepatic activities of GSH, GPx, GST, GR, SOD, CAT, vitamin C, vitamin E and beta-carotene.	Luteolin	31-39	catalase	Rattus norvegicus	259-262
15946255-0	2005	The flavonoid luteolin prevents lipopolysaccharide-induced NF-kappaB signalling and gene expression by blocking IkappaB kinase activity in intestinal epithelial cells and bone-marrow derived dendritic cells.	Luteolin	14-22	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	59-68
15974445-6	2005	Furthermore, catechin, epigallocatechin gallate (EGCG), epicatechin (EC), luteolin, chrysin, quercetin, and galangin increased IL-2 secretion while EGC, apigenin, and fisetin inhibited the secretion.	Luteolin	74-82	interleukin 2	Homo sapiens	127-131
16158939-7	2005	Our results show that FAK functions as a key regulator of cell migration, and that FAK activity can be suppressed by specific FAK siRNA, and by luteolin and quercetin.	Luteolin	144-152	protein tyrosine kinase 2	Homo sapiens	22-25
16158939-7	2005	Our results show that FAK functions as a key regulator of cell migration, and that FAK activity can be suppressed by specific FAK siRNA, and by luteolin and quercetin.	Luteolin	144-152	protein tyrosine kinase 2	Homo sapiens	83-86
16158939-7	2005	Our results show that FAK functions as a key regulator of cell migration, and that FAK activity can be suppressed by specific FAK siRNA, and by luteolin and quercetin.	Luteolin	144-152	protein tyrosine kinase 2	Homo sapiens	83-86
15334063-2	2004	In this study, we found that pretreatment with luteolin, a plant flavonoid, greatly sensitized TNFalpha-induced apoptotic cell death in a number of human cancer cell lines; including colorectal cancer COLO205, HCT116 cells and cervical cancer HeLa cells.	Luteolin	47-55	tumor necrosis factor	Homo sapiens	95-103
15123766-9	2004	Interestingly, the flavonoids luteolin and cynaroside increased eNOS promoter activity and eNOS mRNA expression, whereas the caffeoylquinic acids cynarin and chlorogenic acid were without effect.	Luteolin	30-38	nitric oxide synthase 3	Homo sapiens	64-68
15123766-9	2004	Interestingly, the flavonoids luteolin and cynaroside increased eNOS promoter activity and eNOS mRNA expression, whereas the caffeoylquinic acids cynarin and chlorogenic acid were without effect.	Luteolin	30-38	nitric oxide synthase 3	Homo sapiens	91-95
14718582-7	2004	Antioxidant polyphenols (luteolin and resveratrol) mimicked the effects of DHPs and showed structural similarity to DHPs.	Luteolin	25-33	deoxyhypusine synthase	Homo sapiens	75-79
14718582-7	2004	Antioxidant polyphenols (luteolin and resveratrol) mimicked the effects of DHPs and showed structural similarity to DHPs.	Luteolin	25-33	deoxyhypusine synthase	Homo sapiens	116-120
14745173-3	2004	Lipopolysaccharide (LPS)-induced TNF-alpha production from macrophages was inhibited by treatment with flavone (luteolin, apigenin, and chrysin), flavonol (quercetin and myricetin), flavanonol (taxifolin), and anthocyanidin (cyanidin chloride) in vitro.	Luteolin	112-120	tumor necrosis factor	Mus musculus	33-42
15145447-13	2004	We report here, that luteolin and quercetin have a biphasic effect on the enol-keto conversion of phenylpyruvate mediated by MIF tautomerase.	Luteolin	21-29	macrophage migration inhibitory factor	Rattus norvegicus	125-128
14745173-5	2004	Serum TNF-alpha production was inhibited only by luteolin or apigenin, and only luteolin or quercetin inhibited 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced ear edema.	Luteolin	49-57	tumor necrosis factor	Mus musculus	6-15
12224631-2	2002	In the binding assay, pharmaceuticals had a stronger binding activity to hERbeta than that of some phytoestrogens (coumestrol, daidzein, genistein, luteolin, chrysin, flavone, and naringenin) or industrial chemicals, but phytoestrogens such as coumestrol had a binding activity as strong as pharmaceuticals such as 17alpha-ethynylestradiol (EE), tamoxifen (Tam), and mestranol.	Luteolin	148-156	estrogen receptor 2	Homo sapiens	73-80
12606047-2	2003	The oxidation of LDL was inhibited by micromolar concentrations of flavonoids such as (-)-epicatechin, quercetin, rutin, taxifolin and luteolin, presumably via scavenging of the MPO-derived NO(2) radical.	Luteolin	135-143	myeloperoxidase	Homo sapiens	178-181
2155715-4	1990	Four selected flavonoids (Taxifolin, Eriodictyol, Hesperetin and Luteolin), inhibited myeloperoxidase (MPO) release, while two of these (Taxifolin and Eriodictyol) strongly inhibited MPO activity.	Luteolin	65-73	myeloperoxidase	Homo sapiens	86-101
10718847-5	2000	RESULTS: Luteolin, baicalein and quercetin inhibited the release of histamine, leukotrienes (LTs), prostaglandin D2 (PGD2), and granulocyte macrophage-colony stimulating factor (GM-CSF) from HCMC in a concentration-dependent manner.	Luteolin	9-17	prostaglandin D2 synthase	Homo sapiens	99-115
10718847-5	2000	RESULTS: Luteolin, baicalein and quercetin inhibited the release of histamine, leukotrienes (LTs), prostaglandin D2 (PGD2), and granulocyte macrophage-colony stimulating factor (GM-CSF) from HCMC in a concentration-dependent manner.	Luteolin	9-17	colony stimulating factor 2	Homo sapiens	128-176
10718847-5	2000	RESULTS: Luteolin, baicalein and quercetin inhibited the release of histamine, leukotrienes (LTs), prostaglandin D2 (PGD2), and granulocyte macrophage-colony stimulating factor (GM-CSF) from HCMC in a concentration-dependent manner.	Luteolin	9-17	colony stimulating factor 2	Homo sapiens	178-184
11123379-3	2001	Pretreatment of RAW 264.7 with luteolin, luteolin-7-glucoside, quercetin, and the isoflavonoid genistein inhibited both the LPS-stimulated TNF-alpha and interleukin-6 release, whereas eriodictyol and hesperetin only inhibited TNF-alpha release.	Luteolin	31-39	toll-like receptor 4	Mus musculus	124-127
11123379-3	2001	Pretreatment of RAW 264.7 with luteolin, luteolin-7-glucoside, quercetin, and the isoflavonoid genistein inhibited both the LPS-stimulated TNF-alpha and interleukin-6 release, whereas eriodictyol and hesperetin only inhibited TNF-alpha release.	Luteolin	31-39	tumor necrosis factor	Mus musculus	139-148
11123379-3	2001	Pretreatment of RAW 264.7 with luteolin, luteolin-7-glucoside, quercetin, and the isoflavonoid genistein inhibited both the LPS-stimulated TNF-alpha and interleukin-6 release, whereas eriodictyol and hesperetin only inhibited TNF-alpha release.	Luteolin	31-39	tumor necrosis factor	Mus musculus	226-235
10556937-14	1999	The addition of EGF only marginally diminished the inhibitory effect of luteolin and quercetin on the growth rate of A431 cells, treatment of cellular proteins with EGF and luteolin or quercetin greatly reduced protein phosphorylation, indicating Lu and Qu may act effectively to inhibit a wide range of protein kinases, including EGFR tyrosine kinase.	Luteolin	72-80	epidermal growth factor	Homo sapiens	16-19
10556937-14	1999	The addition of EGF only marginally diminished the inhibitory effect of luteolin and quercetin on the growth rate of A431 cells, treatment of cellular proteins with EGF and luteolin or quercetin greatly reduced protein phosphorylation, indicating Lu and Qu may act effectively to inhibit a wide range of protein kinases, including EGFR tyrosine kinase.	Luteolin	72-80	epidermal growth factor	Homo sapiens	165-168
7493919-2	1995	Three purified aglycons of natural glucuronides, baicalein, luteolin and glycyrrhetic acid, inhibited UDP-GT activity towards SN-38 as a substrate.	Luteolin	60-68	UDP glucuronosyltransferase family 1 member A6	Homo sapiens	102-108
2155715-4	1990	Four selected flavonoids (Taxifolin, Eriodictyol, Hesperetin and Luteolin), inhibited myeloperoxidase (MPO) release, while two of these (Taxifolin and Eriodictyol) strongly inhibited MPO activity.	Luteolin	65-73	myeloperoxidase	Homo sapiens	103-106
2155715-4	1990	Four selected flavonoids (Taxifolin, Eriodictyol, Hesperetin and Luteolin), inhibited myeloperoxidase (MPO) release, while two of these (Taxifolin and Eriodictyol) strongly inhibited MPO activity.	Luteolin	65-73	myeloperoxidase	Homo sapiens	183-186
34889224-8	2021	The molecular docking results showed the components that docked well with key targets were quercetin, luteolin, kaempferol, and baicalein.The active components (quercetin, luteolin, kaempferol, and baicalein) of the RPR-FC and their targets act on proteins such as MAPK1, AKT1, VEGFA, and CASP3, which are closely related to IS.1 These targets are closely related to the NF-kappa B signaling pathway, the MAPK signaling pathway, the PI3K-Akt signaling pathway, the VEGF signaling pathway, and other signaling pathways.	Luteolin	172-180	mitogen-activated protein kinase 1	Homo sapiens	265-270
34460026-11	2022	Decreased apoptosis and inflammatory cytokines were also observed in H/R cells after Lut treatment.	Luteolin	85-88	HR, lysine demethylase and nuclear receptor corepressor	Rattus norvegicus	69-72
34460026-12	2022	Lut treatment downregulated SHP-1 expression and subsequently upregulated STAT3 phosphorylation in both I/R rat heart tissue and H9c2 cells.	Luteolin	0-3	protein tyrosine phosphatase, non-receptor type 6	Rattus norvegicus	28-33
34460026-12	2022	Lut treatment downregulated SHP-1 expression and subsequently upregulated STAT3 phosphorylation in both I/R rat heart tissue and H9c2 cells.	Luteolin	0-3	signal transducer and activator of transcription 3	Rattus norvegicus	74-79
34820015-6	2022	Inhibiting the tumor necrosis factor receptor-associated protein 1/phosphorylated-extracellular-regulated protein kinases1/2/cell division cycle 25 homolog C/cyclin-dependent kinase-1/cyclin B1 pathway was indispensable to the combined treatment with luteolin and oxaliplatin to induce G2/M cell cycle arrest.	Luteolin	251-259	cyclin B1	Mus musculus	184-193
34785108-12	2022	Metascape enrichment analysis showed that 25 genes were significantly enriched in the NF-kappaB pathway, which were mainly targets of luteolin, quercetin, and kaempferol as confirmed by MS analysis.	Luteolin	134-142	nuclear factor kappa B subunit 1	Homo sapiens	86-95
34889224-8	2021	The molecular docking results showed the components that docked well with key targets were quercetin, luteolin, kaempferol, and baicalein.The active components (quercetin, luteolin, kaempferol, and baicalein) of the RPR-FC and their targets act on proteins such as MAPK1, AKT1, VEGFA, and CASP3, which are closely related to IS.1 These targets are closely related to the NF-kappa B signaling pathway, the MAPK signaling pathway, the PI3K-Akt signaling pathway, the VEGF signaling pathway, and other signaling pathways.	Luteolin	172-180	AKT serine/threonine kinase 1	Homo sapiens	272-276
34889224-8	2021	The molecular docking results showed the components that docked well with key targets were quercetin, luteolin, kaempferol, and baicalein.The active components (quercetin, luteolin, kaempferol, and baicalein) of the RPR-FC and their targets act on proteins such as MAPK1, AKT1, VEGFA, and CASP3, which are closely related to IS.1 These targets are closely related to the NF-kappa B signaling pathway, the MAPK signaling pathway, the PI3K-Akt signaling pathway, the VEGF signaling pathway, and other signaling pathways.	Luteolin	172-180	vascular endothelial growth factor A	Homo sapiens	278-283
34889224-8	2021	The molecular docking results showed the components that docked well with key targets were quercetin, luteolin, kaempferol, and baicalein.The active components (quercetin, luteolin, kaempferol, and baicalein) of the RPR-FC and their targets act on proteins such as MAPK1, AKT1, VEGFA, and CASP3, which are closely related to IS.1 These targets are closely related to the NF-kappa B signaling pathway, the MAPK signaling pathway, the PI3K-Akt signaling pathway, the VEGF signaling pathway, and other signaling pathways.	Luteolin	172-180	caspase 3	Homo sapiens	289-294
34889224-8	2021	The molecular docking results showed the components that docked well with key targets were quercetin, luteolin, kaempferol, and baicalein.The active components (quercetin, luteolin, kaempferol, and baicalein) of the RPR-FC and their targets act on proteins such as MAPK1, AKT1, VEGFA, and CASP3, which are closely related to IS.1 These targets are closely related to the NF-kappa B signaling pathway, the MAPK signaling pathway, the PI3K-Akt signaling pathway, the VEGF signaling pathway, and other signaling pathways.	Luteolin	172-180	nuclear factor kappa B subunit 1	Homo sapiens	371-381
34889224-8	2021	The molecular docking results showed the components that docked well with key targets were quercetin, luteolin, kaempferol, and baicalein.The active components (quercetin, luteolin, kaempferol, and baicalein) of the RPR-FC and their targets act on proteins such as MAPK1, AKT1, VEGFA, and CASP3, which are closely related to IS.1 These targets are closely related to the NF-kappa B signaling pathway, the MAPK signaling pathway, the PI3K-Akt signaling pathway, the VEGF signaling pathway, and other signaling pathways.	Luteolin	172-180	mitogen-activated protein kinase 1	Homo sapiens	405-409
34889224-8	2021	The molecular docking results showed the components that docked well with key targets were quercetin, luteolin, kaempferol, and baicalein.The active components (quercetin, luteolin, kaempferol, and baicalein) of the RPR-FC and their targets act on proteins such as MAPK1, AKT1, VEGFA, and CASP3, which are closely related to IS.1 These targets are closely related to the NF-kappa B signaling pathway, the MAPK signaling pathway, the PI3K-Akt signaling pathway, the VEGF signaling pathway, and other signaling pathways.	Luteolin	172-180	AKT serine/threonine kinase 1	Homo sapiens	438-441
34889224-8	2021	The molecular docking results showed the components that docked well with key targets were quercetin, luteolin, kaempferol, and baicalein.The active components (quercetin, luteolin, kaempferol, and baicalein) of the RPR-FC and their targets act on proteins such as MAPK1, AKT1, VEGFA, and CASP3, which are closely related to IS.1 These targets are closely related to the NF-kappa B signaling pathway, the MAPK signaling pathway, the PI3K-Akt signaling pathway, the VEGF signaling pathway, and other signaling pathways.	Luteolin	172-180	vascular endothelial growth factor A	Homo sapiens	465-469
34885976-5	2021	We confirmed from previously reported literature that LT inhibits the production of nitric oxide and prostaglandin E2, as well as the expression of inducible NO synthetase and cyclooxygenase-2.	Luteolin	54-56	prostaglandin-endoperoxide synthase 2	Mus musculus	176-192
34643201-6	2021	In vitro insulin secretion assay revealed that myricetin, luteolin, and apigenin were able to induce insulin secretion by human pancreatic cells (insulin production = 20.9 +- 1.3, 13.74 +- 1.8, and 11.33 +- 1.1 ng mL-1, respectively).	Luteolin	58-66	insulin	Homo sapiens	9-16
34077310-4	2021	According to the "Drug-Ingredients-Targets-Disease" network built by STRING and Cytoscape, AKT1 was identified as the core target, and baicalein, luteolin, and quercetin were identified as the active ingredients of the Xuebijing injection in connection with AKT1.	Luteolin	146-154	AKT serine/threonine kinase 1	Homo sapiens	258-262
34704574-0	2021	Luteolin stimulates the NGF-induced neurite outgrowth in cultured PC12 cells through binding with NGF and potentiating its receptor signaling.	Luteolin	0-8	nerve growth factor	Rattus norvegicus	24-27
34643201-6	2021	In vitro insulin secretion assay revealed that myricetin, luteolin, and apigenin were able to induce insulin secretion by human pancreatic cells (insulin production = 20.9 +- 1.3, 13.74 +- 1.8, and 11.33 +- 1.1 ng mL-1, respectively).	Luteolin	58-66	insulin	Homo sapiens	101-108
34704574-0	2021	Luteolin stimulates the NGF-induced neurite outgrowth in cultured PC12 cells through binding with NGF and potentiating its receptor signaling.	Luteolin	0-8	nerve growth factor	Rattus norvegicus	98-101
34643201-6	2021	In vitro insulin secretion assay revealed that myricetin, luteolin, and apigenin were able to induce insulin secretion by human pancreatic cells (insulin production = 20.9 +- 1.3, 13.74 +- 1.8, and 11.33 +- 1.1 ng mL-1, respectively).	Luteolin	58-66	insulin	Homo sapiens	146-153
34804174-11	2021	We also found that caspase-3, caspase-8, and Bax were significantly upregulated and Bcl-2 was downregulated after LUT treatment.	Luteolin	114-117	caspase 3	Rattus norvegicus	19-28
34804174-11	2021	We also found that caspase-3, caspase-8, and Bax were significantly upregulated and Bcl-2 was downregulated after LUT treatment.	Luteolin	114-117	caspase 8	Rattus norvegicus	30-39
34804174-11	2021	We also found that caspase-3, caspase-8, and Bax were significantly upregulated and Bcl-2 was downregulated after LUT treatment.	Luteolin	114-117	BCL2 associated X, apoptosis regulator	Rattus norvegicus	45-48
34804174-11	2021	We also found that caspase-3, caspase-8, and Bax were significantly upregulated and Bcl-2 was downregulated after LUT treatment.	Luteolin	114-117	BCL2, apoptosis regulator	Rattus norvegicus	84-89
34804174-13	2021	LUT treatment can also reduce the NLRP3 inflammasome (NLRP3, ASC, and caspase-1) and TXNIP in the bladder.	Luteolin	0-3	NLR family, pyrin domain containing 3	Rattus norvegicus	34-39
34804174-13	2021	LUT treatment can also reduce the NLRP3 inflammasome (NLRP3, ASC, and caspase-1) and TXNIP in the bladder.	Luteolin	0-3	NLR family, pyrin domain containing 3	Rattus norvegicus	54-59
34804174-13	2021	LUT treatment can also reduce the NLRP3 inflammasome (NLRP3, ASC, and caspase-1) and TXNIP in the bladder.	Luteolin	0-3	PYD and CARD domain containing	Rattus norvegicus	61-64
34804174-13	2021	LUT treatment can also reduce the NLRP3 inflammasome (NLRP3, ASC, and caspase-1) and TXNIP in the bladder.	Luteolin	0-3	caspase 1	Rattus norvegicus	70-79
34804174-13	2021	LUT treatment can also reduce the NLRP3 inflammasome (NLRP3, ASC, and caspase-1) and TXNIP in the bladder.	Luteolin	0-3	thioredoxin interacting protein	Rattus norvegicus	85-90
34607339-5	2021	Hence, we investigated the effects of luteolin, a natural flavonoid mainly existing in vegetables and fruits, on liver injury, focusing on how luteolin participates in hepatitis based on the P2X7R-RAGE-TLR4 axis by regulating the release of HMGB1.	Luteolin	38-46	high mobility group box 1	Mus musculus	241-246
34777689-6	2021	Mechanistically, LUT treatment significantly enhanced the expression of nuclear factor-erythroid 2-related factor 2 (Nrf2), while it downregulated nod-like receptor pyrin domain-containing 3 (NLRP3) inflammasome activation.	Luteolin	17-20	NFE2 like bZIP transcription factor 2	Rattus norvegicus	72-115
34777689-6	2021	Mechanistically, LUT treatment significantly enhanced the expression of nuclear factor-erythroid 2-related factor 2 (Nrf2), while it downregulated nod-like receptor pyrin domain-containing 3 (NLRP3) inflammasome activation.	Luteolin	17-20	NFE2 like bZIP transcription factor 2	Rattus norvegicus	117-121
34777689-6	2021	Mechanistically, LUT treatment significantly enhanced the expression of nuclear factor-erythroid 2-related factor 2 (Nrf2), while it downregulated nod-like receptor pyrin domain-containing 3 (NLRP3) inflammasome activation.	Luteolin	17-20	NLR family, pyrin domain containing 3	Rattus norvegicus	147-190
34777689-6	2021	Mechanistically, LUT treatment significantly enhanced the expression of nuclear factor-erythroid 2-related factor 2 (Nrf2), while it downregulated nod-like receptor pyrin domain-containing 3 (NLRP3) inflammasome activation.	Luteolin	17-20	NLR family, pyrin domain containing 3	Rattus norvegicus	192-197
34607339-6	2021	The results demonstrated that the indicators of hepatic injury such as increased ALT, AST in the serum and infiltration of immune cells were attenuated after luteolin treatment in LPS-induced mice.	Luteolin	158-166	glutamic pyruvic transaminase, soluble	Mus musculus	81-84
34607339-6	2021	The results demonstrated that the indicators of hepatic injury such as increased ALT, AST in the serum and infiltration of immune cells were attenuated after luteolin treatment in LPS-induced mice.	Luteolin	158-166	transmembrane protease, serine 11d	Mus musculus	86-89
34790666-10	2021	We found that oral administration of luteolin (10 mg/Kg) for eight consecutive days could decrease the immobility time on tail suspension test, a mouse behavioral test measuring depression-like behavior, and attenuate LPS-induced inflammatory responses by significantly decreasing IL-6 production in mice brain-derived astrocytes and serum, and TNFalpha and corticosterone levels in serum.	Luteolin	37-45	interleukin 6	Mus musculus	281-285
34754315-10	2021	Molecular docking results showed that quercetin, luteolin, kaempferol, tanshinone IIa, wogonin, naringenin, nobiletin, dihydrotanshinlactone, beta-sitosterol, and salviolone have good affinity with core target proteins IL6, PTGS2, MAPK1, MAPK3, and CGRP1.	Luteolin	49-57	interleukin 6	Homo sapiens	219-222
34790666-10	2021	We found that oral administration of luteolin (10 mg/Kg) for eight consecutive days could decrease the immobility time on tail suspension test, a mouse behavioral test measuring depression-like behavior, and attenuate LPS-induced inflammatory responses by significantly decreasing IL-6 production in mice brain-derived astrocytes and serum, and TNFalpha and corticosterone levels in serum.	Luteolin	37-45	tumor necrosis factor	Mus musculus	345-353
34790666-11	2021	Luteolin treatment also significantly increased mature BDNF, dopamine, and noradrenaline levels in the hypothalamus of LPS-induced depression mice.	Luteolin	0-8	brain derived neurotrophic factor	Mus musculus	55-59
34754315-10	2021	Molecular docking results showed that quercetin, luteolin, kaempferol, tanshinone IIa, wogonin, naringenin, nobiletin, dihydrotanshinlactone, beta-sitosterol, and salviolone have good affinity with core target proteins IL6, PTGS2, MAPK1, MAPK3, and CGRP1.	Luteolin	49-57	prostaglandin-endoperoxide synthase 2	Homo sapiens	224-229
34754315-10	2021	Molecular docking results showed that quercetin, luteolin, kaempferol, tanshinone IIa, wogonin, naringenin, nobiletin, dihydrotanshinlactone, beta-sitosterol, and salviolone have good affinity with core target proteins IL6, PTGS2, MAPK1, MAPK3, and CGRP1.	Luteolin	49-57	mitogen-activated protein kinase 1	Homo sapiens	231-236
34754315-10	2021	Molecular docking results showed that quercetin, luteolin, kaempferol, tanshinone IIa, wogonin, naringenin, nobiletin, dihydrotanshinlactone, beta-sitosterol, and salviolone have good affinity with core target proteins IL6, PTGS2, MAPK1, MAPK3, and CGRP1.	Luteolin	49-57	mitogen-activated protein kinase 3	Homo sapiens	238-243
34754315-10	2021	Molecular docking results showed that quercetin, luteolin, kaempferol, tanshinone IIa, wogonin, naringenin, nobiletin, dihydrotanshinlactone, beta-sitosterol, and salviolone have good affinity with core target proteins IL6, PTGS2, MAPK1, MAPK3, and CGRP1.	Luteolin	49-57	calcitonin related polypeptide alpha	Homo sapiens	249-254
34733451-11	2021	Molecular docking showed that the active components of XJD (beta-sitosterol, kaempferol, formononetin, quercetin, and luteolin) showed good binding activities to five of the six hub gene targets.	Luteolin	118-126	ELAV like RNA binding protein 2	Homo sapiens	178-181
34733451-13	2021	The active ingredients of XJD (beta-sitosterol, kaempferol, formononetin, quercetin, and luteolin) may regulate the inflammatory and oxidative stress-related pathways of colon cells during the course of UC by binding to the hub gene targets.	Luteolin	89-97	ELAV like RNA binding protein 2	Homo sapiens	224-227
34605344-10	2021	CONCLUSION: According to the above results, it is suggested that SQW may play a role in the treatment of COVID-19 by directly or indirectly combining kaempferol, quercetin, and luteolin with ACE2, 3CLpro, PLpro, and PTGS2 to regulate multiple biological functions and signaling pathways.	Luteolin	177-185	angiotensin converting enzyme 2	Homo sapiens	191-195
34605344-10	2021	CONCLUSION: According to the above results, it is suggested that SQW may play a role in the treatment of COVID-19 by directly or indirectly combining kaempferol, quercetin, and luteolin with ACE2, 3CLpro, PLpro, and PTGS2 to regulate multiple biological functions and signaling pathways.	Luteolin	177-185	prostaglandin-endoperoxide synthase 2	Homo sapiens	216-221
34641514-3	2021	The alpha-glucosidase inhibitory assay screening resulted in the isolation of eight known compounds of quercetin, quercitrin, luteolin, 5-deoxyluteolin, 4-methyl ether isoliquiritigenin, 3,2",4"-trihydroxy-4-methoxychalcone, stigmasterol and beta-sitosterol.	Luteolin	126-134	sucrase-isomaltase	Homo sapiens	4-21
34671661-10	2021	Taken together, our study showed that the traditional Chinese medicine QJC, quercetin, luteolin, kaempferol, scutellarein, and stigmasterol alleviated the pathological condition of small intestine tissue and relieved stress-induced diarrhea by increasing the expression levels of PI3K and Akt and inhibiting the expression levels of PTEN.	Luteolin	87-95	thymoma viral proto-oncogene 1	Mus musculus	289-292
34671661-10	2021	Taken together, our study showed that the traditional Chinese medicine QJC, quercetin, luteolin, kaempferol, scutellarein, and stigmasterol alleviated the pathological condition of small intestine tissue and relieved stress-induced diarrhea by increasing the expression levels of PI3K and Akt and inhibiting the expression levels of PTEN.	Luteolin	87-95	phosphatase and tensin homolog	Mus musculus	333-337
34350508-5	2021	Docking results showed that rutin, puerarin, baicalin, luteolin and quercetin are the most potent TXNIP inhibitors, and among them, rutin as the most effective flavonoid.	Luteolin	55-63	thioredoxin interacting protein	Homo sapiens	98-103
34595237-7	2021	The results of molecular docking showed that AKT has the most binding activity, exhibiting certain binding activity with 10 compounds, including vanillic acid, protocatechuic acid, secologanic acid, quercetin, and luteolin; the results of qRT-PCR and WB confirmed that two key compounds, secologanic acid and luteolin, could significantly decrease the secretion of TNF-alpha and the AKT expression of RAW264.7 murine macrophages stimulated by LPS (lipopolysaccharide).	Luteolin	214-222	thymoma viral proto-oncogene 1	Mus musculus	45-48
34595237-7	2021	The results of molecular docking showed that AKT has the most binding activity, exhibiting certain binding activity with 10 compounds, including vanillic acid, protocatechuic acid, secologanic acid, quercetin, and luteolin; the results of qRT-PCR and WB confirmed that two key compounds, secologanic acid and luteolin, could significantly decrease the secretion of TNF-alpha and the AKT expression of RAW264.7 murine macrophages stimulated by LPS (lipopolysaccharide).	Luteolin	214-222	tumor necrosis factor	Mus musculus	365-374
34595237-7	2021	The results of molecular docking showed that AKT has the most binding activity, exhibiting certain binding activity with 10 compounds, including vanillic acid, protocatechuic acid, secologanic acid, quercetin, and luteolin; the results of qRT-PCR and WB confirmed that two key compounds, secologanic acid and luteolin, could significantly decrease the secretion of TNF-alpha and the AKT expression of RAW264.7 murine macrophages stimulated by LPS (lipopolysaccharide).	Luteolin	214-222	thymoma viral proto-oncogene 1	Mus musculus	383-386
34595237-7	2021	The results of molecular docking showed that AKT has the most binding activity, exhibiting certain binding activity with 10 compounds, including vanillic acid, protocatechuic acid, secologanic acid, quercetin, and luteolin; the results of qRT-PCR and WB confirmed that two key compounds, secologanic acid and luteolin, could significantly decrease the secretion of TNF-alpha and the AKT expression of RAW264.7 murine macrophages stimulated by LPS (lipopolysaccharide).	Luteolin	309-317	thymoma viral proto-oncogene 1	Mus musculus	45-48
34595237-7	2021	The results of molecular docking showed that AKT has the most binding activity, exhibiting certain binding activity with 10 compounds, including vanillic acid, protocatechuic acid, secologanic acid, quercetin, and luteolin; the results of qRT-PCR and WB confirmed that two key compounds, secologanic acid and luteolin, could significantly decrease the secretion of TNF-alpha and the AKT expression of RAW264.7 murine macrophages stimulated by LPS (lipopolysaccharide).	Luteolin	309-317	tumor necrosis factor	Mus musculus	365-374
34595237-7	2021	The results of molecular docking showed that AKT has the most binding activity, exhibiting certain binding activity with 10 compounds, including vanillic acid, protocatechuic acid, secologanic acid, quercetin, and luteolin; the results of qRT-PCR and WB confirmed that two key compounds, secologanic acid and luteolin, could significantly decrease the secretion of TNF-alpha and the AKT expression of RAW264.7 murine macrophages stimulated by LPS (lipopolysaccharide).	Luteolin	309-317	thymoma viral proto-oncogene 1	Mus musculus	383-386
34729134-8	2021	Results: Our findings showed that AGHE (200 and 400 mg/kg), AGME (400 and 800 mg/kg), and luteolin (10 and 20 mg/kg) were effective to reduce colonic ulcer score, area, and index as well as total colitis index, and MPO activity significantly in comparison with controls.	Luteolin	90-98	myeloperoxidase	Rattus norvegicus	215-218
34493195-7	2022	RESULTS: We filtered out 6 pivotal ingredients from QFPDD by using the bioinformatics method, namely quercetin, luteolin, berberine, hederagenin, shionone and kaempferol, which can inhibit the highly expressed genes (i.e. CXCR4, ICAM1, CXCL8, CXCL10, IL6, IL2, CCL2, IL1B, IL4, IFNG) in severe COVID-19 patients.	Luteolin	112-120	C-X-C motif chemokine receptor 4	Homo sapiens	222-227
34493195-7	2022	RESULTS: We filtered out 6 pivotal ingredients from QFPDD by using the bioinformatics method, namely quercetin, luteolin, berberine, hederagenin, shionone and kaempferol, which can inhibit the highly expressed genes (i.e. CXCR4, ICAM1, CXCL8, CXCL10, IL6, IL2, CCL2, IL1B, IL4, IFNG) in severe COVID-19 patients.	Luteolin	112-120	intercellular adhesion molecule 1	Homo sapiens	229-234
34493195-7	2022	RESULTS: We filtered out 6 pivotal ingredients from QFPDD by using the bioinformatics method, namely quercetin, luteolin, berberine, hederagenin, shionone and kaempferol, which can inhibit the highly expressed genes (i.e. CXCR4, ICAM1, CXCL8, CXCL10, IL6, IL2, CCL2, IL1B, IL4, IFNG) in severe COVID-19 patients.	Luteolin	112-120	C-X-C motif chemokine ligand 8	Homo sapiens	236-241
34493195-7	2022	RESULTS: We filtered out 6 pivotal ingredients from QFPDD by using the bioinformatics method, namely quercetin, luteolin, berberine, hederagenin, shionone and kaempferol, which can inhibit the highly expressed genes (i.e. CXCR4, ICAM1, CXCL8, CXCL10, IL6, IL2, CCL2, IL1B, IL4, IFNG) in severe COVID-19 patients.	Luteolin	112-120	C-X-C motif chemokine ligand 10	Homo sapiens	243-249
34493195-7	2022	RESULTS: We filtered out 6 pivotal ingredients from QFPDD by using the bioinformatics method, namely quercetin, luteolin, berberine, hederagenin, shionone and kaempferol, which can inhibit the highly expressed genes (i.e. CXCR4, ICAM1, CXCL8, CXCL10, IL6, IL2, CCL2, IL1B, IL4, IFNG) in severe COVID-19 patients.	Luteolin	112-120	interleukin 6	Homo sapiens	251-254
34493195-7	2022	RESULTS: We filtered out 6 pivotal ingredients from QFPDD by using the bioinformatics method, namely quercetin, luteolin, berberine, hederagenin, shionone and kaempferol, which can inhibit the highly expressed genes (i.e. CXCR4, ICAM1, CXCL8, CXCL10, IL6, IL2, CCL2, IL1B, IL4, IFNG) in severe COVID-19 patients.	Luteolin	112-120	interleukin 2	Homo sapiens	256-259
34493195-7	2022	RESULTS: We filtered out 6 pivotal ingredients from QFPDD by using the bioinformatics method, namely quercetin, luteolin, berberine, hederagenin, shionone and kaempferol, which can inhibit the highly expressed genes (i.e. CXCR4, ICAM1, CXCL8, CXCL10, IL6, IL2, CCL2, IL1B, IL4, IFNG) in severe COVID-19 patients.	Luteolin	112-120	C-C motif chemokine ligand 2	Homo sapiens	261-265
34493195-7	2022	RESULTS: We filtered out 6 pivotal ingredients from QFPDD by using the bioinformatics method, namely quercetin, luteolin, berberine, hederagenin, shionone and kaempferol, which can inhibit the highly expressed genes (i.e. CXCR4, ICAM1, CXCL8, CXCL10, IL6, IL2, CCL2, IL1B, IL4, IFNG) in severe COVID-19 patients.	Luteolin	112-120	interleukin 1 beta	Homo sapiens	267-271
34493195-7	2022	RESULTS: We filtered out 6 pivotal ingredients from QFPDD by using the bioinformatics method, namely quercetin, luteolin, berberine, hederagenin, shionone and kaempferol, which can inhibit the highly expressed genes (i.e. CXCR4, ICAM1, CXCL8, CXCL10, IL6, IL2, CCL2, IL1B, IL4, IFNG) in severe COVID-19 patients.	Luteolin	112-120	interleukin 4	Homo sapiens	273-276
34493195-7	2022	RESULTS: We filtered out 6 pivotal ingredients from QFPDD by using the bioinformatics method, namely quercetin, luteolin, berberine, hederagenin, shionone and kaempferol, which can inhibit the highly expressed genes (i.e. CXCR4, ICAM1, CXCL8, CXCL10, IL6, IL2, CCL2, IL1B, IL4, IFNG) in severe COVID-19 patients.	Luteolin	112-120	interferon gamma	Homo sapiens	278-282
34581093-7	2021	The results of network pharmacology showed that 15 potential active components such as EC, procyanidin B1, and luteolin presumedly functioned in the treatment of ALI through nuclear transcription factor-kappaB(NF-kappaB) signaling pathway, transforming growth factor-beta(TGF-beta) signaling pathway, and adenosine 5"-monophosphate(AMP)-activated protein kinase(AMPK) signaling pathway through key targets, such as RELA(P65).	Luteolin	111-119	transforming growth factor alpha	Mus musculus	272-280
34581093-7	2021	The results of network pharmacology showed that 15 potential active components such as EC, procyanidin B1, and luteolin presumedly functioned in the treatment of ALI through nuclear transcription factor-kappaB(NF-kappaB) signaling pathway, transforming growth factor-beta(TGF-beta) signaling pathway, and adenosine 5"-monophosphate(AMP)-activated protein kinase(AMPK) signaling pathway through key targets, such as RELA(P65).	Luteolin	111-119	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	415-423
34577802-12	2021	In addition, in A172 and U-373MG cells treated with luteolin at concentrations greater than 100 muM, nuclear fragmentation, which is a typical morphological change characterizing apoptosis, as well as fragmentation of caspase-3 and Poly (ADP-ribose) polymerase (PARP), which are apoptosis-related factors, were observed.	Luteolin	52-60	caspase 3	Homo sapiens	218-227
34577802-12	2021	In addition, in A172 and U-373MG cells treated with luteolin at concentrations greater than 100 muM, nuclear fragmentation, which is a typical morphological change characterizing apoptosis, as well as fragmentation of caspase-3 and Poly (ADP-ribose) polymerase (PARP), which are apoptosis-related factors, were observed.	Luteolin	52-60	poly(ADP-ribose) polymerase 1	Homo sapiens	232-260
34577802-12	2021	In addition, in A172 and U-373MG cells treated with luteolin at concentrations greater than 100 muM, nuclear fragmentation, which is a typical morphological change characterizing apoptosis, as well as fragmentation of caspase-3 and Poly (ADP-ribose) polymerase (PARP), which are apoptosis-related factors, were observed.	Luteolin	52-60	poly(ADP-ribose) polymerase 1	Homo sapiens	262-266
34439516-9	2021	Moreover, LUTN treatment considerably attenuates the AFB1-induced apoptosis in mouse liver, as demonstrated by declined apoptotic cells percentage, decreased Bax, Cyt-c, caspase-3 and caspase-9 transcription and protein with increased Bcl-2 expression.	Luteolin	10-14	BCL2-associated X protein	Mus musculus	158-161
34549702-10	2021	Molecular docking showed that quercetin, luteolin and kaempferol could bind to Akt1, PIK3R1 and MAPK1, respectively.	Luteolin	41-49	AKT serine/threonine kinase 1	Rattus norvegicus	79-83
34549702-10	2021	Molecular docking showed that quercetin, luteolin and kaempferol could bind to Akt1, PIK3R1 and MAPK1, respectively.	Luteolin	41-49	phosphoinositide-3-kinase regulatory subunit 1	Rattus norvegicus	85-91
34549702-10	2021	Molecular docking showed that quercetin, luteolin and kaempferol could bind to Akt1, PIK3R1 and MAPK1, respectively.	Luteolin	41-49	mitogen activated protein kinase 1	Rattus norvegicus	96-101
34439516-0	2021	Luteolin Alleviates AflatoxinB1-Induced Apoptosis and Oxidative Stress in the Liver of Mice through Activation of Nrf2 Signaling Pathway.	Luteolin	0-8	nuclear factor, erythroid derived 2, like 2	Mus musculus	114-118
34439516-7	2021	Our findings revealed that LUTN treatment significantly alleviated growth retardation and rescued liver injury by relieving the pathological and serum biochemical alterations (ALT, AST, ALP, and GGT) under AFB1 exposure.	Luteolin	27-31	transmembrane protease, serine 11d	Mus musculus	181-184
34439516-7	2021	Our findings revealed that LUTN treatment significantly alleviated growth retardation and rescued liver injury by relieving the pathological and serum biochemical alterations (ALT, AST, ALP, and GGT) under AFB1 exposure.	Luteolin	27-31	alopecia, recessive	Mus musculus	186-189
34439516-7	2021	Our findings revealed that LUTN treatment significantly alleviated growth retardation and rescued liver injury by relieving the pathological and serum biochemical alterations (ALT, AST, ALP, and GGT) under AFB1 exposure.	Luteolin	27-31	gamma-glutamyltransferase 1	Mus musculus	195-198
34439516-8	2021	LUTN ameliorated AFB1-induced oxidative stress by scavenging ROS and MDA accumulation and boosting the capacity of the antioxidant enzyme (CAT, T-SOD, GSH-Px and T-AOC).	Luteolin	0-4	catalase	Mus musculus	139-142
34439516-9	2021	Moreover, LUTN treatment considerably attenuates the AFB1-induced apoptosis in mouse liver, as demonstrated by declined apoptotic cells percentage, decreased Bax, Cyt-c, caspase-3 and caspase-9 transcription and protein with increased Bcl-2 expression.	Luteolin	10-14	caspase 3	Mus musculus	170-179
34439516-9	2021	Moreover, LUTN treatment considerably attenuates the AFB1-induced apoptosis in mouse liver, as demonstrated by declined apoptotic cells percentage, decreased Bax, Cyt-c, caspase-3 and caspase-9 transcription and protein with increased Bcl-2 expression.	Luteolin	10-14	caspase 9	Mus musculus	184-193
34439516-9	2021	Moreover, LUTN treatment considerably attenuates the AFB1-induced apoptosis in mouse liver, as demonstrated by declined apoptotic cells percentage, decreased Bax, Cyt-c, caspase-3 and caspase-9 transcription and protein with increased Bcl-2 expression.	Luteolin	10-14	B cell leukemia/lymphoma 2	Mus musculus	235-240
34439516-11	2021	Our results indicated that LUTN effectively alleviated AFB1-induced liver injury, and the underlying mechanisms were associated with the activation of the Nrf2 signaling pathway.	Luteolin	27-31	nuclear factor, erythroid derived 2, like 2	Mus musculus	155-159
34244900-4	2021	The results showed that treatment with luteolin and luteoloside reversed the reduction of organic anion transporter 1 (OAT1) levels, while apigenin attenuated the elevation of urate transporter 1 (URAT1) and glucose transporter 9 (GLUT9) levels in uric acid-treated HK-2 cells, which was consistent with the finding in the kidneys of potassium oxonate (PO)-induced mice.	Luteolin	39-47	solute carrier family 22 (organic anion transporter), member 6	Mus musculus	90-117
34244900-4	2021	The results showed that treatment with luteolin and luteoloside reversed the reduction of organic anion transporter 1 (OAT1) levels, while apigenin attenuated the elevation of urate transporter 1 (URAT1) and glucose transporter 9 (GLUT9) levels in uric acid-treated HK-2 cells, which was consistent with the finding in the kidneys of potassium oxonate (PO)-induced mice.	Luteolin	39-47	solute carrier family 22 (organic anion transporter), member 6	Mus musculus	119-123
34244900-4	2021	The results showed that treatment with luteolin and luteoloside reversed the reduction of organic anion transporter 1 (OAT1) levels, while apigenin attenuated the elevation of urate transporter 1 (URAT1) and glucose transporter 9 (GLUT9) levels in uric acid-treated HK-2 cells, which was consistent with the finding in the kidneys of potassium oxonate (PO)-induced mice.	Luteolin	39-47	solute carrier family 22 (organic anion/cation transporter), member 12	Mus musculus	197-202
34244900-4	2021	The results showed that treatment with luteolin and luteoloside reversed the reduction of organic anion transporter 1 (OAT1) levels, while apigenin attenuated the elevation of urate transporter 1 (URAT1) and glucose transporter 9 (GLUT9) levels in uric acid-treated HK-2 cells, which was consistent with the finding in the kidneys of potassium oxonate (PO)-induced mice.	Luteolin	39-47	solute carrier family 2 (facilitated glucose transporter), member 9	Mus musculus	208-229
34244900-4	2021	The results showed that treatment with luteolin and luteoloside reversed the reduction of organic anion transporter 1 (OAT1) levels, while apigenin attenuated the elevation of urate transporter 1 (URAT1) and glucose transporter 9 (GLUT9) levels in uric acid-treated HK-2 cells, which was consistent with the finding in the kidneys of potassium oxonate (PO)-induced mice.	Luteolin	39-47	solute carrier family 2 (facilitated glucose transporter), member 9	Mus musculus	231-236
34368345-13	2021	Lu exhibited therapeutical effects on D-GaI/LPS induced liver injury in mice which might be related to the regulation of the NLRP3/NF-kappaB pathway.	Luteolin	0-2	NLR family, pyrin domain containing 3	Mus musculus	125-130
34544532-7	2021	Collectively, these results suggest Her-2-modified nanospheres increases the efficiency of luteolin uptake and thus improves the treatment benefit of breast cancer.	Luteolin	91-99	erb-b2 receptor tyrosine kinase 2	Homo sapiens	36-41
34368345-13	2021	Lu exhibited therapeutical effects on D-GaI/LPS induced liver injury in mice which might be related to the regulation of the NLRP3/NF-kappaB pathway.	Luteolin	0-2	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	131-140
35372072-15	2022	Luteolin and quercetin may be the core active ingredients of QYSLS in the treatment of EGFRI-related adverse skin reactions, and their therapeutic effects are potentially mediated through PTGS2, CCL2, and MMP9 in the IL-17 and TNF signaling pathway.	Luteolin	0-8	prostaglandin-endoperoxide synthase 2	Homo sapiens	188-193
34238328-7	2021	Hippocampal neuron survival was determined by DCX, NeuN, and cleaved caspase-3 immunostaining in Cdkl5 KO mice treated with luteolin (10 mg/kg), a natural anti-inflammatory flavonoid.	Luteolin	124-132	cyclin-dependent kinase-like 5	Mus musculus	97-102
34729037-7	2021	Our analyses demonstrated that the combination treatment with galangin, luteolin, and DOX showed the greatest antineoplastic activity against HCC, which was observed by significant decreases in the levels of HCC markers, including serum alpha-fetoprotein-L3, and hepatic tissue expression of both glypican 3 and heat shock proteins.	Luteolin	72-80	glypican 3	Rattus norvegicus	297-307
35623848-6	2022	The bioactive compounds including luteolin, epicatechin, epigallocatechin gallate, lycopene, quercetin, vitamin A, vitamin C and vitamin E in FBV significantly lowered TNF-alpha production, CCL2 production, IL-1beta production, and reactive oxygen species production.	Luteolin	34-42	C-C motif chemokine ligand 2	Homo sapiens	190-194
35600955-8	2022	Results: The network pharmacology analysis showed that quercetin, luteolin, and kaempferol are the most significant active components in BHHD; STAT3, Jun, AKT1, MAPK3, MAPK1, and TP53 are the most critical drug targets; regulating hormones, reversing insulin (INS) resistance, exerting anti-inflammatory effects, and improving fertility might be the most important mechanisms of BHHD in the treatment of PCOS.	Luteolin	66-74	mitogen-activated protein kinase 3	Homo sapiens	161-166
35600955-8	2022	Results: The network pharmacology analysis showed that quercetin, luteolin, and kaempferol are the most significant active components in BHHD; STAT3, Jun, AKT1, MAPK3, MAPK1, and TP53 are the most critical drug targets; regulating hormones, reversing insulin (INS) resistance, exerting anti-inflammatory effects, and improving fertility might be the most important mechanisms of BHHD in the treatment of PCOS.	Luteolin	66-74	mitogen-activated protein kinase 1	Homo sapiens	168-173
35600955-8	2022	Results: The network pharmacology analysis showed that quercetin, luteolin, and kaempferol are the most significant active components in BHHD; STAT3, Jun, AKT1, MAPK3, MAPK1, and TP53 are the most critical drug targets; regulating hormones, reversing insulin (INS) resistance, exerting anti-inflammatory effects, and improving fertility might be the most important mechanisms of BHHD in the treatment of PCOS.	Luteolin	66-74	tumor protein p53	Homo sapiens	179-183
35600955-8	2022	Results: The network pharmacology analysis showed that quercetin, luteolin, and kaempferol are the most significant active components in BHHD; STAT3, Jun, AKT1, MAPK3, MAPK1, and TP53 are the most critical drug targets; regulating hormones, reversing insulin (INS) resistance, exerting anti-inflammatory effects, and improving fertility might be the most important mechanisms of BHHD in the treatment of PCOS.	Luteolin	66-74	insulin	Homo sapiens	251-258
35571739-12	2022	However, the miR-124-3p inhibitor significantly reversed the therapeutic effect of luteolin on COR-induced HT-22 cells.	Luteolin	83-91	microRNA 124a-3	Mus musculus	13-23
35571739-12	2022	However, the miR-124-3p inhibitor significantly reversed the therapeutic effect of luteolin on COR-induced HT-22 cells.	Luteolin	83-91	distribution of corticosterone in adrenal cortex cells	Mus musculus	95-98
35332561-7	2022	It could be concluded that luteolin was encapsulated in beta-casein micelles and exhibited higher antioxidant activity than luteolin alone.	Luteolin	27-35	casein beta	Homo sapiens	56-67
35310053-6	2022	RESULTS: Corneal fibroblasts exposed to polyI:C demonstrated decreased VCAM-1, ICAM-1, MCP-1, IL-6, and IL-8 expression levels upon exposure to LUT in a time-dependent and concentration-dependent manner.	Luteolin	144-147	vascular cell adhesion molecule 1	Homo sapiens	71-77
35310053-6	2022	RESULTS: Corneal fibroblasts exposed to polyI:C demonstrated decreased VCAM-1, ICAM-1, MCP-1, IL-6, and IL-8 expression levels upon exposure to LUT in a time-dependent and concentration-dependent manner.	Luteolin	144-147	intercellular adhesion molecule 1	Homo sapiens	79-85
35310053-6	2022	RESULTS: Corneal fibroblasts exposed to polyI:C demonstrated decreased VCAM-1, ICAM-1, MCP-1, IL-6, and IL-8 expression levels upon exposure to LUT in a time-dependent and concentration-dependent manner.	Luteolin	144-147	interleukin 6	Homo sapiens	94-98
35310053-6	2022	RESULTS: Corneal fibroblasts exposed to polyI:C demonstrated decreased VCAM-1, ICAM-1, MCP-1, IL-6, and IL-8 expression levels upon exposure to LUT in a time-dependent and concentration-dependent manner.	Luteolin	144-147	chemokine (C-X-C motif) ligand 15	Mus musculus	104-108
34106722-1	2021	The present study aims to investigate the structure of covalent conjugates of bovine beta-lactoglobulin (BLG) and flavonoids (luteolin, myricetin, and hyperoside), and their effect on the allergenicity and human intestinal microbiota.	Luteolin	126-134	beta-lactoglobulin	Bos taurus	85-103
34106722-1	2021	The present study aims to investigate the structure of covalent conjugates of bovine beta-lactoglobulin (BLG) and flavonoids (luteolin, myricetin, and hyperoside), and their effect on the allergenicity and human intestinal microbiota.	Luteolin	126-134	beta-lactoglobulin	Bos taurus	105-108
34497749-13	2021	Quercetin and Luteolin were verified to have good binding capability with the hub potential targets IL6, MAPK1, AKT1 through molecular docking.	Luteolin	14-22	interleukin 6	Homo sapiens	100-103
34497749-13	2021	Quercetin and Luteolin were verified to have good binding capability with the hub potential targets IL6, MAPK1, AKT1 through molecular docking.	Luteolin	14-22	mitogen-activated protein kinase 1	Homo sapiens	105-110
34497749-13	2021	Quercetin and Luteolin were verified to have good binding capability with the hub potential targets IL6, MAPK1, AKT1 through molecular docking.	Luteolin	14-22	AKT serine/threonine kinase 1	Homo sapiens	112-116
34143751-10	2021	Moreover, treatment with luteolin reduced the expression of NLRP1, NOX4, TXNIP, and NLRP3 proteins, and ameliorated the altered expression of apoptotic proteins in the retina of DR rats.	Luteolin	25-33	NLR family, pyrin domain containing 1A	Rattus norvegicus	60-65
34143751-10	2021	Moreover, treatment with luteolin reduced the expression of NLRP1, NOX4, TXNIP, and NLRP3 proteins, and ameliorated the altered expression of apoptotic proteins in the retina of DR rats.	Luteolin	25-33	NADPH oxidase 4	Rattus norvegicus	67-71
34143751-10	2021	Moreover, treatment with luteolin reduced the expression of NLRP1, NOX4, TXNIP, and NLRP3 proteins, and ameliorated the altered expression of apoptotic proteins in the retina of DR rats.	Luteolin	25-33	thioredoxin interacting protein	Rattus norvegicus	73-78
34143751-10	2021	Moreover, treatment with luteolin reduced the expression of NLRP1, NOX4, TXNIP, and NLRP3 proteins, and ameliorated the altered expression of apoptotic proteins in the retina of DR rats.	Luteolin	25-33	NLR family, pyrin domain containing 3	Rattus norvegicus	84-89
34211977-4	2021	Luteolin supplementation decreased intracellular reactive oxygen species levels and increased the expression levels of oxidative stress-related genes (SOD1, SOD2, and CAT).	Luteolin	0-8	superoxide dismutase 1	Homo sapiens	151-155
34211977-4	2021	Luteolin supplementation decreased intracellular reactive oxygen species levels and increased the expression levels of oxidative stress-related genes (SOD1, SOD2, and CAT).	Luteolin	0-8	superoxide dismutase 2	Homo sapiens	157-161
34211977-4	2021	Luteolin supplementation decreased intracellular reactive oxygen species levels and increased the expression levels of oxidative stress-related genes (SOD1, SOD2, and CAT).	Luteolin	0-8	catalase	Homo sapiens	167-170
34068281-5	2021	The pro-autophagic activity of seven flavonoid aglycons correlated perfectly with their ability to inhibit NQO2 activity, and flavones such as apigenin and luteolin showed the strongest activity in all assays.	Luteolin	156-164	N-ribosyldihydronicotinamide:quinone reductase 2	Homo sapiens	107-111
35571420-18	2022	The active compounds mainly included quercetin, kaempferol, formononetin, and luteolin, which had good docking scores and targeted the AKT protein.	Luteolin	78-86	AKT serine/threonine kinase 1	Rattus norvegicus	135-138
35442463-17	2022	CONCLUSIONS: (1) Icariin, quercetin and luteolin may act on target proteins, including IL-6, ESR1, EGFR, MAPK8, VEGFA and CASP8, to participate in the regulation of the human cytomegalovirus infection pathway, the PI3K-Akt signaling pathway, the TNF signaling pathway and other signaling pathways in order to effectively treat CAD.	Luteolin	40-48	interleukin 6	Homo sapiens	87-91
35442463-17	2022	CONCLUSIONS: (1) Icariin, quercetin and luteolin may act on target proteins, including IL-6, ESR1, EGFR, MAPK8, VEGFA and CASP8, to participate in the regulation of the human cytomegalovirus infection pathway, the PI3K-Akt signaling pathway, the TNF signaling pathway and other signaling pathways in order to effectively treat CAD.	Luteolin	40-48	estrogen receptor 1	Homo sapiens	93-97
35442463-17	2022	CONCLUSIONS: (1) Icariin, quercetin and luteolin may act on target proteins, including IL-6, ESR1, EGFR, MAPK8, VEGFA and CASP8, to participate in the regulation of the human cytomegalovirus infection pathway, the PI3K-Akt signaling pathway, the TNF signaling pathway and other signaling pathways in order to effectively treat CAD.	Luteolin	40-48	epidermal growth factor receptor	Homo sapiens	99-103
35442463-17	2022	CONCLUSIONS: (1) Icariin, quercetin and luteolin may act on target proteins, including IL-6, ESR1, EGFR, MAPK8, VEGFA and CASP8, to participate in the regulation of the human cytomegalovirus infection pathway, the PI3K-Akt signaling pathway, the TNF signaling pathway and other signaling pathways in order to effectively treat CAD.	Luteolin	40-48	mitogen-activated protein kinase 8	Homo sapiens	105-110
35442463-17	2022	CONCLUSIONS: (1) Icariin, quercetin and luteolin may act on target proteins, including IL-6, ESR1, EGFR, MAPK8, VEGFA and CASP8, to participate in the regulation of the human cytomegalovirus infection pathway, the PI3K-Akt signaling pathway, the TNF signaling pathway and other signaling pathways in order to effectively treat CAD.	Luteolin	40-48	vascular endothelial growth factor A	Homo sapiens	112-117
35442463-17	2022	CONCLUSIONS: (1) Icariin, quercetin and luteolin may act on target proteins, including IL-6, ESR1, EGFR, MAPK8, VEGFA and CASP8, to participate in the regulation of the human cytomegalovirus infection pathway, the PI3K-Akt signaling pathway, the TNF signaling pathway and other signaling pathways in order to effectively treat CAD.	Luteolin	40-48	caspase 8	Homo sapiens	122-127
35442463-17	2022	CONCLUSIONS: (1) Icariin, quercetin and luteolin may act on target proteins, including IL-6, ESR1, EGFR, MAPK8, VEGFA and CASP8, to participate in the regulation of the human cytomegalovirus infection pathway, the PI3K-Akt signaling pathway, the TNF signaling pathway and other signaling pathways in order to effectively treat CAD.	Luteolin	40-48	AKT serine/threonine kinase 1	Homo sapiens	219-222
35442463-17	2022	CONCLUSIONS: (1) Icariin, quercetin and luteolin may act on target proteins, including IL-6, ESR1, EGFR, MAPK8, VEGFA and CASP8, to participate in the regulation of the human cytomegalovirus infection pathway, the PI3K-Akt signaling pathway, the TNF signaling pathway and other signaling pathways in order to effectively treat CAD.	Luteolin	40-48	tumor necrosis factor	Homo sapiens	246-249
35372072-15	2022	Luteolin and quercetin may be the core active ingredients of QYSLS in the treatment of EGFRI-related adverse skin reactions, and their therapeutic effects are potentially mediated through PTGS2, CCL2, and MMP9 in the IL-17 and TNF signaling pathway.	Luteolin	0-8	C-C motif chemokine ligand 2	Homo sapiens	195-199
35372072-15	2022	Luteolin and quercetin may be the core active ingredients of QYSLS in the treatment of EGFRI-related adverse skin reactions, and their therapeutic effects are potentially mediated through PTGS2, CCL2, and MMP9 in the IL-17 and TNF signaling pathway.	Luteolin	0-8	matrix metallopeptidase 9	Homo sapiens	205-209
35372072-15	2022	Luteolin and quercetin may be the core active ingredients of QYSLS in the treatment of EGFRI-related adverse skin reactions, and their therapeutic effects are potentially mediated through PTGS2, CCL2, and MMP9 in the IL-17 and TNF signaling pathway.	Luteolin	0-8	interleukin 17A	Homo sapiens	217-222
35372072-15	2022	Luteolin and quercetin may be the core active ingredients of QYSLS in the treatment of EGFRI-related adverse skin reactions, and their therapeutic effects are potentially mediated through PTGS2, CCL2, and MMP9 in the IL-17 and TNF signaling pathway.	Luteolin	0-8	tumor necrosis factor	Homo sapiens	227-230
35355555-12	2022	In vitro cell experiments showed that the p-PI3K/PI3K and p-Akt/Akt expression ratios in BMSCs cultured with 0.5, 1 and 5 muM luteolin for 48 h were also significantly higher than those in the DMSO group (P<0.05).	Luteolin	126-134	AKT serine/threonine kinase 1	Rattus norvegicus	60-63
35355555-12	2022	In vitro cell experiments showed that the p-PI3K/PI3K and p-Akt/Akt expression ratios in BMSCs cultured with 0.5, 1 and 5 muM luteolin for 48 h were also significantly higher than those in the DMSO group (P<0.05).	Luteolin	126-134	AKT serine/threonine kinase 1	Rattus norvegicus	64-67
35215317-0	2022	Magnolol and Luteolin Inhibition of alpha-Glucosidase Activity: Kinetics and Type of Interaction Detected by In Vitro and In Silico Studies.	Luteolin	13-21	sucrase-isomaltase	Homo sapiens	36-53
35152837-4	2022	The effect of luteolin and glycyrrhizic acid on THP-1 derived macrophages polarization were evaluated using qRT-PCR, Western blotting, and ELISA assay.	Luteolin	14-22	GLI family zinc finger 2	Homo sapiens	48-53
35184424-0	2022	Luteolin Protects Cardiomyocytes Cells against Lipopolysaccharide-Induced Apoptosis and Inflammatory Damage by Modulating Nlrp3.	Luteolin	0-8	NLR family, pyrin domain containing 3	Rattus norvegicus	122-127
35215317-2	2022	This research aimed to determine the inhibitory activity of magnolol and luteolin on alpha-glucosidase activity.	Luteolin	73-81	sucrase-isomaltase	Homo sapiens	85-102
35111230-10	2022	DCX protein expression was increased in nonexercised groups compared to that of the exercised groups and those treated with PFE and Lu, while NeuN decreased.	Luteolin	132-134	doublecortin	Mus musculus	0-3
35280377-10	2022	Molecular docking confirmed that luteolin, coumarin, and quercetin could bind to the key target proteins (i.e., STAT3, PIK3R1, and MAPK1).	Luteolin	33-41	signal transducer and activator of transcription 3	Homo sapiens	112-117
35280377-10	2022	Molecular docking confirmed that luteolin, coumarin, and quercetin could bind to the key target proteins (i.e., STAT3, PIK3R1, and MAPK1).	Luteolin	33-41	phosphoinositide-3-kinase regulatory subunit 1	Homo sapiens	119-125
35280377-10	2022	Molecular docking confirmed that luteolin, coumarin, and quercetin could bind to the key target proteins (i.e., STAT3, PIK3R1, and MAPK1).	Luteolin	33-41	mitogen-activated protein kinase 1	Homo sapiens	131-136
35057010-7	2022	Luteolin and rutin inhibit NFkappaB activation, reducing IL-6 production.	Luteolin	0-8	interleukin 6	Homo sapiens	57-61
33727136-6	2021	Subsequently, we observed that luteolin-induced cytotoxicity and genotoxicity, measured by the high-throughput micronucleus assay, were significantly increased in TK6 cells transduced with CYP1A1 and 1A2.	Luteolin	31-39	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	189-195
33581257-10	2021	Through molecular docking, it was found that the four hub targets (TP53, IL6, VEGFA, and AKT1) binds luteolin and quercetin more tightly.	Luteolin	101-109	tumor protein p53	Rattus norvegicus	67-71
33581257-10	2021	Through molecular docking, it was found that the four hub targets (TP53, IL6, VEGFA, and AKT1) binds luteolin and quercetin more tightly.	Luteolin	101-109	interleukin 6	Rattus norvegicus	73-76
33581257-10	2021	Through molecular docking, it was found that the four hub targets (TP53, IL6, VEGFA, and AKT1) binds luteolin and quercetin more tightly.	Luteolin	101-109	vascular endothelial growth factor A	Rattus norvegicus	78-83
35212223-0	2022	Inhibition of HMGB1/TLR4 Signaling Pathway by Digitoflavone: A Potential Therapeutic Role in Alcohol-Associated Liver Disease.	Luteolin	46-59	high mobility group box 1	Mus musculus	14-19
35212223-0	2022	Inhibition of HMGB1/TLR4 Signaling Pathway by Digitoflavone: A Potential Therapeutic Role in Alcohol-Associated Liver Disease.	Luteolin	46-59	toll-like receptor 4	Mus musculus	20-24
34052328-5	2021	Luteolin and apigenin significantly inhibited lung cancer cell growth, induced cell apoptosis, and down-regulated the IFN-gamma-induced PD-L1 expression by suppressing the phosphorylation of STAT3.	Luteolin	0-8	interferon gamma	Mus musculus	118-127
33581257-10	2021	Through molecular docking, it was found that the four hub targets (TP53, IL6, VEGFA, and AKT1) binds luteolin and quercetin more tightly.	Luteolin	101-109	AKT serine/threonine kinase 1	Rattus norvegicus	89-93
34052328-5	2021	Luteolin and apigenin significantly inhibited lung cancer cell growth, induced cell apoptosis, and down-regulated the IFN-gamma-induced PD-L1 expression by suppressing the phosphorylation of STAT3.	Luteolin	0-8	CD274 antigen	Mus musculus	136-141
34052328-5	2021	Luteolin and apigenin significantly inhibited lung cancer cell growth, induced cell apoptosis, and down-regulated the IFN-gamma-induced PD-L1 expression by suppressing the phosphorylation of STAT3.	Luteolin	0-8	signal transducer and activator of transcription 3	Mus musculus	191-196
34052328-6	2021	Both luteolin and apigenin showed potent anti-cancer activities in the H358 xenograft and Lewis lung carcinoma model in vivo, and the treatment with monoclonal PD1 antibody enhanced the infiltration of T cells into tumor tissues.	Luteolin	5-13	programmed cell death 1	Mus musculus	160-163
34055010-11	2021	Further verification based on molecular docking results showed that NOS3 had the good binding ability with quercetin and luteolin.	Luteolin	121-129	nitric oxide synthase 3	Rattus norvegicus	68-72
34025416-10	2021	By recognizing the five compounds related to the ESR1 and IGF1, which are Quercetin, kaempferol, Luteolin, Apigenin, and Emodin.	Luteolin	97-105	estrogen receptor 1	Homo sapiens	49-53
34025416-10	2021	By recognizing the five compounds related to the ESR1 and IGF1, which are Quercetin, kaempferol, Luteolin, Apigenin, and Emodin.	Luteolin	97-105	insulin like growth factor 1	Homo sapiens	58-62
33968984-9	2021	Molecular docking results suggest that each bioactive compounds (quercetin, wogonin, luteolin, naringenin, and kaempferol) is capable to bind with STAT3, PTGS2, JUN, VEGFA, EGFR, and ALOX5.	Luteolin	85-93	signal transducer and activator of transcription 3	Homo sapiens	147-152
33925607-0	2021	Combined Luteolin and Indole-3-Carbinol Synergistically Constrains ERalpha-Positive Breast Cancer by Dual Inhibiting Estrogen Receptor Alpha and Cyclin-Dependent Kinase 4/6 Pathway in Cultured Cells and Xenograft Mice.	Luteolin	9-17	estrogen receptor 1 (alpha)	Mus musculus	117-140
33925607-0	2021	Combined Luteolin and Indole-3-Carbinol Synergistically Constrains ERalpha-Positive Breast Cancer by Dual Inhibiting Estrogen Receptor Alpha and Cyclin-Dependent Kinase 4/6 Pathway in Cultured Cells and Xenograft Mice.	Luteolin	9-17	cyclin-dependent kinase 4	Mus musculus	145-172
33968984-9	2021	Molecular docking results suggest that each bioactive compounds (quercetin, wogonin, luteolin, naringenin, and kaempferol) is capable to bind with STAT3, PTGS2, JUN, VEGFA, EGFR, and ALOX5.	Luteolin	85-93	prostaglandin-endoperoxide synthase 2	Homo sapiens	154-159
33968984-9	2021	Molecular docking results suggest that each bioactive compounds (quercetin, wogonin, luteolin, naringenin, and kaempferol) is capable to bind with STAT3, PTGS2, JUN, VEGFA, EGFR, and ALOX5.	Luteolin	85-93	vascular endothelial growth factor A	Homo sapiens	166-171
33968984-9	2021	Molecular docking results suggest that each bioactive compounds (quercetin, wogonin, luteolin, naringenin, and kaempferol) is capable to bind with STAT3, PTGS2, JUN, VEGFA, EGFR, and ALOX5.	Luteolin	85-93	epidermal growth factor receptor	Homo sapiens	173-177
33968984-9	2021	Molecular docking results suggest that each bioactive compounds (quercetin, wogonin, luteolin, naringenin, and kaempferol) is capable to bind with STAT3, PTGS2, JUN, VEGFA, EGFR, and ALOX5.	Luteolin	85-93	arachidonate 5-lipoxygenase	Homo sapiens	183-188
33015735-13	2021	qPCR and immunohistochemistry results showed that Lu significantly reduced HMGB1 mRNA level and protein level.	Luteolin	50-52	high mobility group box 1	Mus musculus	75-80
33900303-13	2021	These data suggest that sestrin2 and Nrf2 positively interact to promote antioxidative actions and attenuate mitochondrial damage, by which luteolin relieves diabetic myocardial I/R injury.	Luteolin	140-148	sestrin 2	Rattus norvegicus	24-32
33900303-13	2021	These data suggest that sestrin2 and Nrf2 positively interact to promote antioxidative actions and attenuate mitochondrial damage, by which luteolin relieves diabetic myocardial I/R injury.	Luteolin	140-148	NFE2 like bZIP transcription factor 2	Rattus norvegicus	37-41
33920726-10	2021	Natural products such as isoquercetin, luteolin, and cyanidin act as SIRT6 activators, whereas vitexin, catechin, scutellarin, fucoidan, etc.	Luteolin	39-47	sirtuin 6	Homo sapiens	69-74
33015735-14	2021	In addition, Lu significantly reduced the expression of HMGB1-TLR-NF-kappaB signaling pathway protein of intestine in mice.	Luteolin	13-15	high mobility group box 1	Mus musculus	56-61
33015735-14	2021	In addition, Lu significantly reduced the expression of HMGB1-TLR-NF-kappaB signaling pathway protein of intestine in mice.	Luteolin	13-15	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	66-75
33015735-15	2021	In conclusion, Lu significantly reduced and alleviated DSS-induced colitis in mice, and the mechanism was related to the regulation of intestinal HMGB1-TLR-NF-kappaB signaling pathway in mice.	Luteolin	15-17	high mobility group box 1	Mus musculus	146-151
33015735-15	2021	In conclusion, Lu significantly reduced and alleviated DSS-induced colitis in mice, and the mechanism was related to the regulation of intestinal HMGB1-TLR-NF-kappaB signaling pathway in mice.	Luteolin	15-17	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	156-165
33967604-2	2021	The results revealed that FLJWE and luteolin, but not chlorogenic acid, inhibited the production of inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), and inflammatory cytokines in PRV-infected RAW 264.7 cells.	Luteolin	36-44	nitric oxide synthase 2	Homo sapiens	133-137
33967604-2	2021	The results revealed that FLJWE and luteolin, but not chlorogenic acid, inhibited the production of inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), and inflammatory cytokines in PRV-infected RAW 264.7 cells.	Luteolin	36-44	prostaglandin-endoperoxide synthase 2	Homo sapiens	140-156
33967604-2	2021	The results revealed that FLJWE and luteolin, but not chlorogenic acid, inhibited the production of inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), and inflammatory cytokines in PRV-infected RAW 264.7 cells.	Luteolin	36-44	prostaglandin-endoperoxide synthase 2	Homo sapiens	158-163
33757400-0	2022	Luteolin Induces Apoptosis and Autophagy in HCT116 Colon Cancer Cells via p53-Dependent Pathway.	Luteolin	0-8	tumor protein p53	Homo sapiens	74-77
33757400-5	2022	Luteolin at 10 - 20 muM induced cytotoxicity in p53 wild-type HCT116 colon cancer cells but not in p53 mutant HT-29 cells and normal colon cells.	Luteolin	0-8	tumor protein p53	Homo sapiens	48-51
33757400-7	2022	We identified that luteolin can induce autophagy in p53 wild-type cells but not in p53 mutant cells, suggesting that luteolin-induced autophagy is p53-dependent; however, chloroquine-mediated inhibition of autophagy did not alter cytotoxicity and apoptosis of cells treated with luteolin.	Luteolin	19-27	tumor protein p53	Homo sapiens	52-55
33434535-5	2021	We found that luteolin treatment significantly reduced colonic damage, and inhibited colonic inflammation in UC rats, evidenced by the decreased levels of NF-kappaB, IL-17 and IL-23 in UC rats and the increased level of PPAR-gamma.	Luteolin	14-22	interleukin 17A	Rattus norvegicus	166-171
33434535-5	2021	We found that luteolin treatment significantly reduced colonic damage, and inhibited colonic inflammation in UC rats, evidenced by the decreased levels of NF-kappaB, IL-17 and IL-23 in UC rats and the increased level of PPAR-gamma.	Luteolin	14-22	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	220-230
33739882-3	2021	In our current study, we examined the contributions of the NF-E2-related factor 2 (Nrf2)/glutamate-cysteine ligase (GCL) pathway to LU-mediated neuroprotection in the transient abdominal aorta occlusion rat model of SCII.	Luteolin	132-134	NFE2 like bZIP transcription factor 2	Rattus norvegicus	83-87
33739882-8	2021	Furthermore, LU effectively enhanced the antioxidative activity, alleviated mitochondrial swelling, decreased the expression levels of several proinflammatory cytokines after SCII, and significantly upregulated Nrf2, GCLc, and GCLm expression levels.	Luteolin	13-15	NFE2 like bZIP transcription factor 2	Rattus norvegicus	211-215
33739882-8	2021	Furthermore, LU effectively enhanced the antioxidative activity, alleviated mitochondrial swelling, decreased the expression levels of several proinflammatory cytokines after SCII, and significantly upregulated Nrf2, GCLc, and GCLm expression levels.	Luteolin	13-15	glutamate-cysteine ligase, catalytic subunit	Rattus norvegicus	217-221
33739882-8	2021	Furthermore, LU effectively enhanced the antioxidative activity, alleviated mitochondrial swelling, decreased the expression levels of several proinflammatory cytokines after SCII, and significantly upregulated Nrf2, GCLc, and GCLm expression levels.	Luteolin	13-15	glutamate cysteine ligase, modifier subunit	Rattus norvegicus	227-231
33739882-10	2021	Collectively, these findings indicate that the neuroprotective efficacy of LU depends on suppression of oxidative stress and preservation of mitochondrial function through signaling pathways involving Nrf2 activation and downstream gene expression.	Luteolin	75-77	NFE2 like bZIP transcription factor 2	Rattus norvegicus	201-205
33640964-7	2021	Multi-blot and microarray assays revealed decreased phosphorylated STAT3 (pSTAT3) and dihydropyrimidine dehydrogenase (DPYD) on Lut exposure.	Luteolin	128-131	signal transducer and activator of transcription 3	Homo sapiens	67-72
33640964-7	2021	Multi-blot and microarray assays revealed decreased phosphorylated STAT3 (pSTAT3) and dihydropyrimidine dehydrogenase (DPYD) on Lut exposure.	Luteolin	128-131	dihydropyrimidine dehydrogenase	Homo sapiens	119-123
33146673-7	2021	RESULTS: The network pharmacology research showed that TCM could decrease IL-6 using several compounds, such as quercetin, ursolic acid, luteolin, and rutin.	Luteolin	137-145	interleukin 6	Homo sapiens	74-78
33654432-3	2021	Objective: We aim to explore the regulatory mechanism of terminal differentiation-induced non-coding RNA (TINCR)-miR-761 molecular module in early TNBC, as well as its influence on anti-tumor activity of LU.	Luteolin	204-206	TINCR ubiquitin domain containing	Homo sapiens	106-111
33654432-3	2021	Objective: We aim to explore the regulatory mechanism of terminal differentiation-induced non-coding RNA (TINCR)-miR-761 molecular module in early TNBC, as well as its influence on anti-tumor activity of LU.	Luteolin	204-206	microRNA 761	Homo sapiens	113-120
33654432-9	2021	Besides, LU can significantly down-regulate TINCR and miR-761, and partially offset the anti-TNBC activity of LU when they were abnormally up-regulated, which was mainly reflected in the decrease of anti-proliferation and pro-apoptotic ability of LU against TNBC.	Luteolin	9-11	TINCR ubiquitin domain containing	Homo sapiens	44-49
33654432-9	2021	Besides, LU can significantly down-regulate TINCR and miR-761, and partially offset the anti-TNBC activity of LU when they were abnormally up-regulated, which was mainly reflected in the decrease of anti-proliferation and pro-apoptotic ability of LU against TNBC.	Luteolin	9-11	microRNA 761	Homo sapiens	54-61
33146673-11	2021	Quercetin, ursolic acid, luteolin, and rutin could inhibit COVID-19 by downregulating IL-6.	Luteolin	25-33	interleukin 6	Homo sapiens	86-90
33335556-9	2020	Moreover, luteolin treatment upregulated the expression of ERbeta and p-ERK1/2, whereas fulvestrant blocked the expression of p-ERK1/2.	Luteolin	10-18	estrogen receptor 2	Rattus norvegicus	59-65
33140889-12	2020	Six active compounds of LQC can enter the active pocket of Akt1, namely beta-carotene, kaempferol, luteolin, naringenin, quercetin and wogonin, thereby exerting potential therapeutic effects in COVID-19.	Luteolin	99-107	AKT serine/threonine kinase 1	Homo sapiens	59-63
33520015-11	2020	Finally, 6 key proteins of TNF, IL-10, IL-2, IL-6, STAT1 and CCL2 were selected and successfully docked with 4 active ingredients of quercetin, luteolin, wogonin and kaempferol.	Luteolin	144-152	tumor necrosis factor	Homo sapiens	27-30
33520015-11	2020	Finally, 6 key proteins of TNF, IL-10, IL-2, IL-6, STAT1 and CCL2 were selected and successfully docked with 4 active ingredients of quercetin, luteolin, wogonin and kaempferol.	Luteolin	144-152	interleukin 10	Homo sapiens	32-37
33520015-11	2020	Finally, 6 key proteins of TNF, IL-10, IL-2, IL-6, STAT1 and CCL2 were selected and successfully docked with 4 active ingredients of quercetin, luteolin, wogonin and kaempferol.	Luteolin	144-152	interleukin 2	Homo sapiens	39-43
33520015-11	2020	Finally, 6 key proteins of TNF, IL-10, IL-2, IL-6, STAT1 and CCL2 were selected and successfully docked with 4 active ingredients of quercetin, luteolin, wogonin and kaempferol.	Luteolin	144-152	interleukin 6	Homo sapiens	45-49
33520015-11	2020	Finally, 6 key proteins of TNF, IL-10, IL-2, IL-6, STAT1 and CCL2 were selected and successfully docked with 4 active ingredients of quercetin, luteolin, wogonin and kaempferol.	Luteolin	144-152	signal transducer and activator of transcription 1	Homo sapiens	51-56
33520015-11	2020	Finally, 6 key proteins of TNF, IL-10, IL-2, IL-6, STAT1 and CCL2 were selected and successfully docked with 4 active ingredients of quercetin, luteolin, wogonin and kaempferol.	Luteolin	144-152	C-C motif chemokine ligand 2	Homo sapiens	61-65
33335556-8	2020	In addition, luteolin treatment significantly upregulated the expression of Bcl-2 and downregulated the expression of Bax and caspase-3, whereas fulvestrant and U0126 partially reversed the effects of luteolin.	Luteolin	13-21	BCL2, apoptosis regulator	Rattus norvegicus	76-81
33335556-8	2020	In addition, luteolin treatment significantly upregulated the expression of Bcl-2 and downregulated the expression of Bax and caspase-3, whereas fulvestrant and U0126 partially reversed the effects of luteolin.	Luteolin	13-21	BCL2 associated X, apoptosis regulator	Rattus norvegicus	118-121
33335556-8	2020	In addition, luteolin treatment significantly upregulated the expression of Bcl-2 and downregulated the expression of Bax and caspase-3, whereas fulvestrant and U0126 partially reversed the effects of luteolin.	Luteolin	13-21	caspase 3	Rattus norvegicus	126-135
33459225-7	2021	Of the compounds addressed in this review, 7 phenolic compounds, including quercetin, curcumin, naringenin, luteolin, hesperidin, mangiferin, and gallic acid showed binding affinity with molecular ACE-2 target in silico, and 1, esculetin, decreased ACE-2 expression in vivo.	Luteolin	108-116	angiotensin converting enzyme 2	Homo sapiens	197-202
33459225-7	2021	Of the compounds addressed in this review, 7 phenolic compounds, including quercetin, curcumin, naringenin, luteolin, hesperidin, mangiferin, and gallic acid showed binding affinity with molecular ACE-2 target in silico, and 1, esculetin, decreased ACE-2 expression in vivo.	Luteolin	108-116	angiotensin converting enzyme 2	Homo sapiens	249-254
33335556-9	2020	Moreover, luteolin treatment upregulated the expression of ERbeta and p-ERK1/2, whereas fulvestrant blocked the expression of p-ERK1/2.	Luteolin	10-18	mitogen activated protein kinase 3	Rattus norvegicus	72-78
33296106-8	2020	Rupatadine could be repurposed for COVID-19 prophylaxis alone or together with other PAF-inhibitors of natural origin such as the flavonoids quercetin and luteolin, which have antiviral, anti-inflammatory, and anti-PAF actions.	Luteolin	155-163	PCNA clamp associated factor	Homo sapiens	215-218
33176504-6	2021	LUT administration also reduced TNF-alpha and IL-10 mRNA expression in lung tissue.	Luteolin	0-3	tumor necrosis factor	Rattus norvegicus	32-41
33176504-6	2021	LUT administration also reduced TNF-alpha and IL-10 mRNA expression in lung tissue.	Luteolin	0-3	interleukin 10	Rattus norvegicus	46-51
33000272-3	2020	Luteolin, a non-toxic naturally occurring plant flavonoid with diverse biological activities, has been demonstrated to be effective against certain types of cancer, and has also been described as a ligand of AhR.	Luteolin	0-8	aryl hydrocarbon receptor	Homo sapiens	208-211
32898663-0	2020	Luteolin supplementation ameliorates cobalt-induced oxidative stress and inflammation by suppressing NF-kB/Kim-1 signaling in the heart and kidney of rats.	Luteolin	0-8	nuclear factor kappa B subunit 1	Rattus norvegicus	101-106
32898663-0	2020	Luteolin supplementation ameliorates cobalt-induced oxidative stress and inflammation by suppressing NF-kB/Kim-1 signaling in the heart and kidney of rats.	Luteolin	0-8	hepatitis A virus cellular receptor 1	Rattus norvegicus	107-112
32783997-9	2020	The results provide new mechanistic details underlying the anti-inflammatory, anti-apoptotic and anti-autophagic effects of Lut through the activation of the ERK signaling pathway.	Luteolin	124-127	mitogen-activated protein kinase 1	Mus musculus	158-161
33050842-3	2022	Hesperidin and luteolin reduced cell viability in a dose and time-dependent manner, caused a significant accumulation of apoptotic cells into the G0/G1 and sub-G1 cell cycle phases, induced apoptosis through the intrinsic and extrinsic pathways, down-regulated anti-apoptotic, Bcl-2, and upregulated pro-apoptotic, Bax.	Luteolin	15-23	BCL2 apoptosis regulator	Homo sapiens	277-282
33026809-5	2020	Three flavonoids, apigenin, hispidulin, and luteolin, showed MNK2 inhibitory activity with IC50 values of 308, 252, and 579 nM, respectively.	Luteolin	44-52	MAPK interacting serine/threonine kinase 2	Homo sapiens	61-65
32777260-0	2020	Luteolin enhances TRAIL sensitivity in non-small cell lung cancer cells through increasing DR5 expression and Drp1-mediated mitochondrial fission.	Luteolin	0-8	TNF superfamily member 10	Homo sapiens	18-23
32777260-0	2020	Luteolin enhances TRAIL sensitivity in non-small cell lung cancer cells through increasing DR5 expression and Drp1-mediated mitochondrial fission.	Luteolin	0-8	TNF receptor superfamily member 10b	Homo sapiens	91-94
32777260-0	2020	Luteolin enhances TRAIL sensitivity in non-small cell lung cancer cells through increasing DR5 expression and Drp1-mediated mitochondrial fission.	Luteolin	0-8	dynamin 1 like	Homo sapiens	110-114
32777260-8	2020	Moreover, luteolin treatment alone or in combination with TRAIL increased the phosphorylation of c-Jun N-terminal kinase (JNK), while SP600125 (the JNK inhibitor) significantly abolished the synergistic effect on DR5 expression and Drp1 translocation, indicating that JNK signaling activation was greatly associated with the synergistic effect exerted by luteolin in NSCLC cells.	Luteolin	10-18	mitogen-activated protein kinase 8	Homo sapiens	97-120
32777260-8	2020	Moreover, luteolin treatment alone or in combination with TRAIL increased the phosphorylation of c-Jun N-terminal kinase (JNK), while SP600125 (the JNK inhibitor) significantly abolished the synergistic effect on DR5 expression and Drp1 translocation, indicating that JNK signaling activation was greatly associated with the synergistic effect exerted by luteolin in NSCLC cells.	Luteolin	10-18	mitogen-activated protein kinase 8	Homo sapiens	122-125
32777260-8	2020	Moreover, luteolin treatment alone or in combination with TRAIL increased the phosphorylation of c-Jun N-terminal kinase (JNK), while SP600125 (the JNK inhibitor) significantly abolished the synergistic effect on DR5 expression and Drp1 translocation, indicating that JNK signaling activation was greatly associated with the synergistic effect exerted by luteolin in NSCLC cells.	Luteolin	10-18	mitogen-activated protein kinase 8	Homo sapiens	148-151
32777260-8	2020	Moreover, luteolin treatment alone or in combination with TRAIL increased the phosphorylation of c-Jun N-terminal kinase (JNK), while SP600125 (the JNK inhibitor) significantly abolished the synergistic effect on DR5 expression and Drp1 translocation, indicating that JNK signaling activation was greatly associated with the synergistic effect exerted by luteolin in NSCLC cells.	Luteolin	10-18	TNF receptor superfamily member 10b	Homo sapiens	213-216
32777260-8	2020	Moreover, luteolin treatment alone or in combination with TRAIL increased the phosphorylation of c-Jun N-terminal kinase (JNK), while SP600125 (the JNK inhibitor) significantly abolished the synergistic effect on DR5 expression and Drp1 translocation, indicating that JNK signaling activation was greatly associated with the synergistic effect exerted by luteolin in NSCLC cells.	Luteolin	10-18	dynamin 1 like	Homo sapiens	232-236
32777260-8	2020	Moreover, luteolin treatment alone or in combination with TRAIL increased the phosphorylation of c-Jun N-terminal kinase (JNK), while SP600125 (the JNK inhibitor) significantly abolished the synergistic effect on DR5 expression and Drp1 translocation, indicating that JNK signaling activation was greatly associated with the synergistic effect exerted by luteolin in NSCLC cells.	Luteolin	10-18	mitogen-activated protein kinase 8	Homo sapiens	148-151
33050842-3	2022	Hesperidin and luteolin reduced cell viability in a dose and time-dependent manner, caused a significant accumulation of apoptotic cells into the G0/G1 and sub-G1 cell cycle phases, induced apoptosis through the intrinsic and extrinsic pathways, down-regulated anti-apoptotic, Bcl-2, and upregulated pro-apoptotic, Bax.	Luteolin	15-23	BCL2 associated X, apoptosis regulator	Homo sapiens	315-318
32768952-6	2020	Luteolin treatment leads to a decrease of mesenchymal markers and an increase of epithelial markers in both TNBC cells and TAZ-induced mesenchymal cells.	Luteolin	0-8	tafazzin, phospholipid-lysophospholipid transacylase	Mus musculus	123-126
33050575-4	2020	Luteolin, apigenin, quercetin, myricetin, rutin, naringenin, epicatechin, and genistein activate the Nrf2/ARE pathway in both normal and cancer cells.	Luteolin	0-8	NFE2 like bZIP transcription factor 2	Homo sapiens	101-105
33050575-8	2020	Paradoxically, some flavonoids, including luteolin, apigenin, and chrysin, inhibit the Nrf2/ARE pathway in vitro.	Luteolin	42-50	NFE2 like bZIP transcription factor 2	Homo sapiens	87-91
32462548-2	2020	The present study investigated the effects of two flavonoids (apigenin and luteolin) on the production of IL-31 and IL-33 in lipopolysaccharide (LPS)-activated astrocytes.	Luteolin	75-83	interleukin 31	Homo sapiens	106-111
32462548-2	2020	The present study investigated the effects of two flavonoids (apigenin and luteolin) on the production of IL-31 and IL-33 in lipopolysaccharide (LPS)-activated astrocytes.	Luteolin	75-83	interleukin 33	Homo sapiens	116-121
32869630-0	2020	Luteolin, a potent human monoamine oxidase-A inhibitor and dopamine D4 and vasopressin V1A receptor antagonist.	Luteolin	0-8	monoamine oxidase A	Homo sapiens	25-44
32869630-3	2020	Here, luteolin exhibited selective inhibition of hMAO-A (IC50 = 8.57 +- 0.47 microM) over hMAO-B (IC50 > 100 microM).	Luteolin	6-14	monoamine oxidase A	Homo sapiens	49-55
32869630-3	2020	Here, luteolin exhibited selective inhibition of hMAO-A (IC50 = 8.57 +- 0.47 microM) over hMAO-B (IC50 > 100 microM).	Luteolin	6-14	monoamine oxidase B	Homo sapiens	90-96
32958799-5	2020	We used serum LDH release, serum cardiac troponin I level, hemodynamic data, myocardial infarction size and apoptosis-related indices to measure SERCA2a cardio-protective effects of luteolin pretreatment.	Luteolin	182-190	ATPase, Ca++ transporting, cardiac muscle, slow twitch 2	Mus musculus	145-152
32938255-0	2021	Luteolin Attenuates Glycerol-Induced Acute Renal Failure and Cardiac Complications Through Modulation of Kim-1/NF-kappaB/Nrf2 Signaling Pathways.	Luteolin	0-8	hepatitis A virus cellular receptor 1	Rattus norvegicus	105-110
32938255-0	2021	Luteolin Attenuates Glycerol-Induced Acute Renal Failure and Cardiac Complications Through Modulation of Kim-1/NF-kappaB/Nrf2 Signaling Pathways.	Luteolin	0-8	NFE2 like bZIP transcription factor 2	Rattus norvegicus	121-125
32898663-6	2020	Treatment with Luteolin or Gallic acid produced significant reversal of the oxidative stress parameters with reductions in NF-kappaB and Kim-1 expressions, leading to suppression of histopathological lesions observed in the tissues.	Luteolin	15-23	hepatitis A virus cellular receptor 1	Rattus norvegicus	137-142
32768952-9	2020	Collectively, our results support luteolin as a novel YAP/TAZ inhibitor for development as a new agent for the treatment of TNBC.	Luteolin	34-42	yes-associated protein 1	Mus musculus	54-57
32768952-9	2020	Collectively, our results support luteolin as a novel YAP/TAZ inhibitor for development as a new agent for the treatment of TNBC.	Luteolin	34-42	tafazzin, phospholipid-lysophospholipid transacylase	Mus musculus	58-61
32598492-5	2020	Luteolin administration also upregulated the expression of ABCG1, and SRB1 as well as cholesterol 7 alpha-hydroxylase (Cyp7alpha1) in the liver of diet-induced obese mice.	Luteolin	0-8	ATP binding cassette subfamily G member 1	Mus musculus	59-64
32598492-5	2020	Luteolin administration also upregulated the expression of ABCG1, and SRB1 as well as cholesterol 7 alpha-hydroxylase (Cyp7alpha1) in the liver of diet-induced obese mice.	Luteolin	0-8	scavenger receptor class B, member 1	Mus musculus	70-74
32598492-5	2020	Luteolin administration also upregulated the expression of ABCG1, and SRB1 as well as cholesterol 7 alpha-hydroxylase (Cyp7alpha1) in the liver of diet-induced obese mice.	Luteolin	0-8	cytochrome P450, family 7, subfamily a, polypeptide 1	Mus musculus	86-117
32598492-5	2020	Luteolin administration also upregulated the expression of ABCG1, and SRB1 as well as cholesterol 7 alpha-hydroxylase (Cyp7alpha1) in the liver of diet-induced obese mice.	Luteolin	0-8	cytochrome P450, family 7, subfamily a, polypeptide 1	Mus musculus	119-129
32574665-0	2020	Combination of luteolin and lycopene effectively protect against the "two-hit" in NAFLD through Sirt1/AMPK signal pathway.	Luteolin	15-23	sirtuin 1	Homo sapiens	96-101
32574665-0	2020	Combination of luteolin and lycopene effectively protect against the "two-hit" in NAFLD through Sirt1/AMPK signal pathway.	Luteolin	15-23	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	102-106
32574665-8	2020	SIGNIFICANCE: Thus, luteolin and lycopene in combination can effectively ameliorate "two-hit" in NAFLD through activation of the Sirt1/AMPK pathway.	Luteolin	20-28	sirtuin 1	Homo sapiens	129-134
32574665-8	2020	SIGNIFICANCE: Thus, luteolin and lycopene in combination can effectively ameliorate "two-hit" in NAFLD through activation of the Sirt1/AMPK pathway.	Luteolin	20-28	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	135-139
31805186-0	2020	Recruitment of miR-8080 by luteolin inhibits androgen receptor splice variant 7 expression in castration-resistant prostate cancer.	Luteolin	27-35	microRNA 8080	Homo sapiens	15-23
32526242-4	2020	Here we show that the flavonoid luteolin exerts a significant cytotoxic effect on the colon cancer cell line HCT116 and the breast adenocarcinoma cell line MDA-MB231, by inducing both apoptotic and necrotic cell death, and that this effect is not impaired by HIF-1 activation.	Luteolin	32-40	hypoxia inducible factor 1 subunit alpha	Homo sapiens	259-264
31805186-8	2020	Microarray analysis identified MiR-8080, which contains a possible target sequence for AR-V7 3"-UTR, as a gene upregulated by luteolin.	Luteolin	126-134	microRNA 8080	Homo sapiens	31-39
31805186-10	2020	Furthermore, miR-8080 knockdown canceled luteolin decreasing AR-V7 and the cell growth of 22Rv1.	Luteolin	41-49	microRNA 8080	Homo sapiens	13-21
31805186-11	2020	MiR-8080 induced by luteolin intake enhanced the therapeutic effect of enzalutamide on 22Rv1 xenografts under castration conditions.	Luteolin	20-28	microRNA 8080	Homo sapiens	0-8
31805186-12	2020	These results indicate luteolin inhibits CRPC by AR-V7 suppression through miR-8080, highlighting luteolin and miR-8080 as promising therapeutic agents for this disease.	Luteolin	23-31	microRNA 8080	Homo sapiens	75-83
31805186-12	2020	These results indicate luteolin inhibits CRPC by AR-V7 suppression through miR-8080, highlighting luteolin and miR-8080 as promising therapeutic agents for this disease.	Luteolin	23-31	microRNA 8080	Homo sapiens	111-119
32439592-0	2020	Luteolin alleviates ochratoxin A induced oxidative stress by regulating Nrf2 and HIF-1alpha pathways in NRK-52E rat kidney cells.	Luteolin	0-8	NFE2 like bZIP transcription factor 2	Rattus norvegicus	72-76
32903480-7	2020	In addition, Lut inhibited Dex-induced expression of Bax and cytochrome c and increased the expression of B cell lymphoma-2(Bcl-2).	Luteolin	13-16	BCL2 associated X, apoptosis regulator	Rattus norvegicus	53-56
32903480-7	2020	In addition, Lut inhibited Dex-induced expression of Bax and cytochrome c and increased the expression of B cell lymphoma-2(Bcl-2).	Luteolin	13-16	BCL2, apoptosis regulator	Rattus norvegicus	124-129
32439592-0	2020	Luteolin alleviates ochratoxin A induced oxidative stress by regulating Nrf2 and HIF-1alpha pathways in NRK-52E rat kidney cells.	Luteolin	0-8	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	81-91
32587127-7	2020	Luteolin, one of the major chemical constituents in SPEtOH, significantly inhibited hANO1 activity in hANO1-HEK293T cells.	Luteolin	0-8	anoctamin 1	Homo sapiens	84-89
32587127-7	2020	Luteolin, one of the major chemical constituents in SPEtOH, significantly inhibited hANO1 activity in hANO1-HEK293T cells.	Luteolin	0-8	anoctamin 1	Homo sapiens	102-107
32895125-7	2020	Luteolin dose-dependently induced the expression of OPCML mRNA and protein in MDA-MB-231 cells (P < 0.05), down-regulated the methylation status in the promoter region of OPCML gene, up-regulated the level of non-methylated OPCML, and reduced the activity of methylase in the cells (P < 0.05).	Luteolin	0-8	opioid binding protein/cell adhesion molecule like	Homo sapiens	52-57
32570112-12	2020	RESULTS: 10 muM DA and 20 muM LU treatments inhibited 3T3-L1 adipogenesis through down-regulating the expression of C/ebpalpha, C/ebpbeta, and Ppargamma, which are the critical adipogenic transcription factors.	Luteolin	30-32	CCAAT/enhancer binding protein (C/EBP), alpha	Mus musculus	116-126
32570112-12	2020	RESULTS: 10 muM DA and 20 muM LU treatments inhibited 3T3-L1 adipogenesis through down-regulating the expression of C/ebpalpha, C/ebpbeta, and Ppargamma, which are the critical adipogenic transcription factors.	Luteolin	30-32	CCAAT/enhancer binding protein (C/EBP), alpha	Mus musculus	128-137
32570112-12	2020	RESULTS: 10 muM DA and 20 muM LU treatments inhibited 3T3-L1 adipogenesis through down-regulating the expression of C/ebpalpha, C/ebpbeta, and Ppargamma, which are the critical adipogenic transcription factors.	Luteolin	30-32	peroxisome proliferator activated receptor gamma	Mus musculus	143-152
32570112-15	2020	Mechanistic studies showed that DA and LU promoted adipocyte lipolysis in mice through activating the AMPK signaling and SIRT1-FOXO1 pathway.	Luteolin	39-41	sirtuin 1	Mus musculus	121-126
32570112-15	2020	Mechanistic studies showed that DA and LU promoted adipocyte lipolysis in mice through activating the AMPK signaling and SIRT1-FOXO1 pathway.	Luteolin	39-41	forkhead box O1	Mus musculus	127-132
32656311-11	2020	However, few other natural products like resveratrol, quercetin, luteolin, naringenin, zingiberene, and gallic acid has the significant binding affinity towards ACE2 receptor only and therefore may be used for ACE2-mediated attachment inhibition of SARS-CoV-2.	Luteolin	65-73	angiotensin converting enzyme 2	Homo sapiens	161-165
32656311-11	2020	However, few other natural products like resveratrol, quercetin, luteolin, naringenin, zingiberene, and gallic acid has the significant binding affinity towards ACE2 receptor only and therefore may be used for ACE2-mediated attachment inhibition of SARS-CoV-2.	Luteolin	65-73	angiotensin converting enzyme 2	Homo sapiens	210-214
32017949-13	2020	Moreover, luteolin and kaempferol, the main activity compounds in MHF, significantly inhibited TNF-alpha-induced HPMVEC apoptosis, and downregulated NF-kappaB/MLCK pathway by targeting NOX4.	Luteolin	10-18	tumor necrosis factor	Homo sapiens	95-104
32017949-13	2020	Moreover, luteolin and kaempferol, the main activity compounds in MHF, significantly inhibited TNF-alpha-induced HPMVEC apoptosis, and downregulated NF-kappaB/MLCK pathway by targeting NOX4.	Luteolin	10-18	nuclear factor kappa B subunit 1	Homo sapiens	149-158
32017949-13	2020	Moreover, luteolin and kaempferol, the main activity compounds in MHF, significantly inhibited TNF-alpha-induced HPMVEC apoptosis, and downregulated NF-kappaB/MLCK pathway by targeting NOX4.	Luteolin	10-18	myosin light chain kinase 3	Homo sapiens	159-163
32017949-13	2020	Moreover, luteolin and kaempferol, the main activity compounds in MHF, significantly inhibited TNF-alpha-induced HPMVEC apoptosis, and downregulated NF-kappaB/MLCK pathway by targeting NOX4.	Luteolin	10-18	NADPH oxidase 4	Homo sapiens	185-189
31976547-10	2020	Moreover, luteolin treatment mitigated irinotecan-induced oxidative stress (i.e. by reducing the levels of ROS and LOOH, and augmenting endogenous antioxidants) and inflammation (i.e. through the decrease of MPO enzyme activity, TNF, IL-1beta, and IL-6 levels; and increasing IL-4 and IL-10).	Luteolin	10-18	myeloperoxidase	Mus musculus	208-211
31976547-10	2020	Moreover, luteolin treatment mitigated irinotecan-induced oxidative stress (i.e. by reducing the levels of ROS and LOOH, and augmenting endogenous antioxidants) and inflammation (i.e. through the decrease of MPO enzyme activity, TNF, IL-1beta, and IL-6 levels; and increasing IL-4 and IL-10).	Luteolin	10-18	tumor necrosis factor	Mus musculus	229-232
31976547-10	2020	Moreover, luteolin treatment mitigated irinotecan-induced oxidative stress (i.e. by reducing the levels of ROS and LOOH, and augmenting endogenous antioxidants) and inflammation (i.e. through the decrease of MPO enzyme activity, TNF, IL-1beta, and IL-6 levels; and increasing IL-4 and IL-10).	Luteolin	10-18	interleukin 1 alpha	Mus musculus	234-242
31976547-10	2020	Moreover, luteolin treatment mitigated irinotecan-induced oxidative stress (i.e. by reducing the levels of ROS and LOOH, and augmenting endogenous antioxidants) and inflammation (i.e. through the decrease of MPO enzyme activity, TNF, IL-1beta, and IL-6 levels; and increasing IL-4 and IL-10).	Luteolin	10-18	interleukin 6	Mus musculus	248-252
31976547-10	2020	Moreover, luteolin treatment mitigated irinotecan-induced oxidative stress (i.e. by reducing the levels of ROS and LOOH, and augmenting endogenous antioxidants) and inflammation (i.e. through the decrease of MPO enzyme activity, TNF, IL-1beta, and IL-6 levels; and increasing IL-4 and IL-10).	Luteolin	10-18	interleukin 4	Mus musculus	276-280
31976547-10	2020	Moreover, luteolin treatment mitigated irinotecan-induced oxidative stress (i.e. by reducing the levels of ROS and LOOH, and augmenting endogenous antioxidants) and inflammation (i.e. through the decrease of MPO enzyme activity, TNF, IL-1beta, and IL-6 levels; and increasing IL-4 and IL-10).	Luteolin	10-18	interleukin 10	Mus musculus	285-290
32271832-0	2020	Low dose of luteolin activates Nrf2 in the liver of mice at start of the active phase but not that of the inactive phase.	Luteolin	12-20	nuclear factor, erythroid derived 2, like 2	Mus musculus	31-35
32271832-2	2020	Several studies reported that high dose of luteolin activates the Nrf2/ARE pathway in the liver.	Luteolin	43-51	nuclear factor, erythroid derived 2, like 2	Mus musculus	66-70
32435528-14	2020	LUT inhibited the activity of phlpp1 leading to positive regulation of the AKT/Bcl-2 pathway, which attenuated doxorubicin-induced cardiotoxicity.	Luteolin	0-3	PH domain and leucine rich repeat protein phosphatase 1	Rattus norvegicus	30-36
32435528-14	2020	LUT inhibited the activity of phlpp1 leading to positive regulation of the AKT/Bcl-2 pathway, which attenuated doxorubicin-induced cardiotoxicity.	Luteolin	0-3	AKT serine/threonine kinase 1	Rattus norvegicus	75-78
32435528-14	2020	LUT inhibited the activity of phlpp1 leading to positive regulation of the AKT/Bcl-2 pathway, which attenuated doxorubicin-induced cardiotoxicity.	Luteolin	0-3	BCL2, apoptosis regulator	Rattus norvegicus	79-84
31976547-11	2020	Besides, the disruption of the tight junctions ZO-1 and occludin were also prevented by luteolin treatment.	Luteolin	88-96	occludin	Mus musculus	56-64
32895125-7	2020	Luteolin dose-dependently induced the expression of OPCML mRNA and protein in MDA-MB-231 cells (P < 0.05), down-regulated the methylation status in the promoter region of OPCML gene, up-regulated the level of non-methylated OPCML, and reduced the activity of methylase in the cells (P < 0.05).	Luteolin	0-8	opioid binding protein/cell adhesion molecule like	Homo sapiens	171-176
32895125-7	2020	Luteolin dose-dependently induced the expression of OPCML mRNA and protein in MDA-MB-231 cells (P < 0.05), down-regulated the methylation status in the promoter region of OPCML gene, up-regulated the level of non-methylated OPCML, and reduced the activity of methylase in the cells (P < 0.05).	Luteolin	0-8	opioid binding protein/cell adhesion molecule like	Homo sapiens	171-176
32014914-0	2020	Luteolin-regulated MicroRNA-301-3p Targets Caspase-8 and Modulates TRAIL Sensitivity in PANC-1 Cells.	Luteolin	0-8	caspase 8	Homo sapiens	43-52
32633238-10	2020	The pretreatment with AuCM, CM extract and LT diminished oxidative stress and reduced NOS2 activity.	Luteolin	43-45	nitric oxide synthase 2	Homo sapiens	86-90
32489059-7	2020	Molecular docking prediction showed that luteolin, quercetin and catalpol had a strong binding activity with Akt1; luteolin had strong binding activity but quercetin and catalpol had a certain binding activity with TNFalpha.	Luteolin	41-49	AKT serine/threonine kinase 1	Homo sapiens	109-113
32489059-7	2020	Molecular docking prediction showed that luteolin, quercetin and catalpol had a strong binding activity with Akt1; luteolin had strong binding activity but quercetin and catalpol had a certain binding activity with TNFalpha.	Luteolin	41-49	tumor necrosis factor	Homo sapiens	215-223
32204450-0	2020	Effect of Luteolin and Apigenin on the Production of Il-31 and Il-33 in Lipopolysaccharides-Activated Microglia Cells and Their Mechanism of Action.	Luteolin	10-18	interleukin 31	Mus musculus	53-58
32204450-0	2020	Effect of Luteolin and Apigenin on the Production of Il-31 and Il-33 in Lipopolysaccharides-Activated Microglia Cells and Their Mechanism of Action.	Luteolin	10-18	interleukin 33	Mus musculus	63-68
32035215-0	2020	Luteolin alleviates methamphetamine-induced neurotoxicity by suppressing PI3K/Akt pathway-modulated apoptosis and autophagy in rats.	Luteolin	0-8	AKT serine/threonine kinase 1	Rattus norvegicus	78-81
32035215-7	2020	Seventy-five of the 347 DEGs were modulated in luteolin-pretreated rats, which were enriched into 12 pathways, containing the PI3K/Akt.	Luteolin	47-55	AKT serine/threonine kinase 1	Rattus norvegicus	131-134
32035215-8	2020	Results further showed that luteolin pretreatment significantly repressed the METH-induced increases of PI3K, Akt, p-Akt, p53, Bax, caspase 3, normalized the ratio of p-Akt/Akt, and autophagy-related proteins (Beclin1, Atg5 and LC3-II) expression.	Luteolin	28-36	AKT serine/threonine kinase 1	Rattus norvegicus	110-113
32035215-8	2020	Results further showed that luteolin pretreatment significantly repressed the METH-induced increases of PI3K, Akt, p-Akt, p53, Bax, caspase 3, normalized the ratio of p-Akt/Akt, and autophagy-related proteins (Beclin1, Atg5 and LC3-II) expression.	Luteolin	28-36	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	122-125
32035215-8	2020	Results further showed that luteolin pretreatment significantly repressed the METH-induced increases of PI3K, Akt, p-Akt, p53, Bax, caspase 3, normalized the ratio of p-Akt/Akt, and autophagy-related proteins (Beclin1, Atg5 and LC3-II) expression.	Luteolin	28-36	BCL2 associated X, apoptosis regulator	Rattus norvegicus	127-130
32035215-8	2020	Results further showed that luteolin pretreatment significantly repressed the METH-induced increases of PI3K, Akt, p-Akt, p53, Bax, caspase 3, normalized the ratio of p-Akt/Akt, and autophagy-related proteins (Beclin1, Atg5 and LC3-II) expression.	Luteolin	28-36	caspase 3	Rattus norvegicus	132-141
32035215-8	2020	Results further showed that luteolin pretreatment significantly repressed the METH-induced increases of PI3K, Akt, p-Akt, p53, Bax, caspase 3, normalized the ratio of p-Akt/Akt, and autophagy-related proteins (Beclin1, Atg5 and LC3-II) expression.	Luteolin	28-36	AKT serine/threonine kinase 1	Rattus norvegicus	117-120
32035215-8	2020	Results further showed that luteolin pretreatment significantly repressed the METH-induced increases of PI3K, Akt, p-Akt, p53, Bax, caspase 3, normalized the ratio of p-Akt/Akt, and autophagy-related proteins (Beclin1, Atg5 and LC3-II) expression.	Luteolin	28-36	beclin 1	Rattus norvegicus	210-217
32035215-8	2020	Results further showed that luteolin pretreatment significantly repressed the METH-induced increases of PI3K, Akt, p-Akt, p53, Bax, caspase 3, normalized the ratio of p-Akt/Akt, and autophagy-related proteins (Beclin1, Atg5 and LC3-II) expression.	Luteolin	28-36	autophagy related 5	Rattus norvegicus	219-223
32035215-9	2020	Taken together, these findings indicate that luteolin attenuates METH-induced apoptosis and autophagy by suppressing the PI3K/Akt pathway.	Luteolin	45-53	AKT serine/threonine kinase 1	Rattus norvegicus	126-129
32117796-7	2020	Linarin, sinensetin, cedar acid, isoliquiritigenin, sinigrin, luteolin, chlorogenic acid, orientin, epigoitrin, and rupestonic acid exhibited significant effects on TNF-alpha expression, which is almost consistent with predicted results.	Luteolin	62-70	tumor necrosis factor	Homo sapiens	165-174
31994822-3	2020	Luteolin inhibited cell survival and induced G2/M cell-cycle arrest, p21 upregulation and downregulation of phospho(p)-S6, which is downstream of mTOR signaling.	Luteolin	0-8	H3 histone pseudogene 16	Homo sapiens	69-72
31994822-3	2020	Luteolin inhibited cell survival and induced G2/M cell-cycle arrest, p21 upregulation and downregulation of phospho(p)-S6, which is downstream of mTOR signaling.	Luteolin	0-8	mechanistic target of rapamycin kinase	Homo sapiens	146-150
31917965-0	2020	Luteolin retards CXCL12-induced Jurkat cells migration by disrupting transcription of CXCR4.	Luteolin	0-8	C-X-C motif chemokine ligand 12	Homo sapiens	17-23
31917965-0	2020	Luteolin retards CXCL12-induced Jurkat cells migration by disrupting transcription of CXCR4.	Luteolin	0-8	C-X-C motif chemokine receptor 4	Homo sapiens	86-91
31917965-2	2020	However, it"s still unexplored whether luteolin represses the metastasis progression of leukemia cells via regulating the expression of C-X-C motif chemokine receptor 4 (CXCR4).	Luteolin	39-47	C-X-C motif chemokine receptor 4	Homo sapiens	136-168
31917965-2	2020	However, it"s still unexplored whether luteolin represses the metastasis progression of leukemia cells via regulating the expression of C-X-C motif chemokine receptor 4 (CXCR4).	Luteolin	39-47	C-X-C motif chemokine receptor 4	Homo sapiens	170-175
31917965-4	2020	C-X-C motif chemokine ligand 12 (CXCL12) was applied to induce migration of Jurkat cells after the cells were pre-incubated with luteolin (50, 100, 150, and 200 muM).	Luteolin	129-137	C-X-C motif chemokine ligand 12	Homo sapiens	0-31
31917965-4	2020	C-X-C motif chemokine ligand 12 (CXCL12) was applied to induce migration of Jurkat cells after the cells were pre-incubated with luteolin (50, 100, 150, and 200 muM).	Luteolin	129-137	C-X-C motif chemokine ligand 12	Homo sapiens	33-39
31917965-9	2020	We found that luteolin repressed CXCR4 expression at mRNA levels and restrained CXCL12-induced proliferation as well as migration.	Luteolin	14-22	C-X-C motif chemokine receptor 4	Homo sapiens	33-38
31917965-9	2020	We found that luteolin repressed CXCR4 expression at mRNA levels and restrained CXCL12-induced proliferation as well as migration.	Luteolin	14-22	C-X-C motif chemokine ligand 12	Homo sapiens	80-86
31917965-11	2020	Additionally, luteolin impeded the phosphorylated expression of PI3K, AKT, and ERK1 which was enhanced by CXCL12.	Luteolin	14-22	AKT serine/threonine kinase 1	Homo sapiens	70-73
31917965-11	2020	Additionally, luteolin impeded the phosphorylated expression of PI3K, AKT, and ERK1 which was enhanced by CXCL12.	Luteolin	14-22	mitogen-activated protein kinase 3	Homo sapiens	79-83
31917965-11	2020	Additionally, luteolin impeded the phosphorylated expression of PI3K, AKT, and ERK1 which was enhanced by CXCL12.	Luteolin	14-22	C-X-C motif chemokine ligand 12	Homo sapiens	106-112
31917965-12	2020	In conclusion, luteolin exhibited anti-proliferation and anti-metastasis functions in CXCL12-treated Jurkat cells and inactivated PI3K/AKT and ERK signaling pathways via repressing the transcription of CXCR4.	Luteolin	15-23	C-X-C motif chemokine ligand 12	Homo sapiens	86-92
31917965-12	2020	In conclusion, luteolin exhibited anti-proliferation and anti-metastasis functions in CXCL12-treated Jurkat cells and inactivated PI3K/AKT and ERK signaling pathways via repressing the transcription of CXCR4.	Luteolin	15-23	AKT serine/threonine kinase 1	Homo sapiens	135-138
31917965-12	2020	In conclusion, luteolin exhibited anti-proliferation and anti-metastasis functions in CXCL12-treated Jurkat cells and inactivated PI3K/AKT and ERK signaling pathways via repressing the transcription of CXCR4.	Luteolin	15-23	mitogen-activated protein kinase 1	Homo sapiens	143-146
31917965-12	2020	In conclusion, luteolin exhibited anti-proliferation and anti-metastasis functions in CXCL12-treated Jurkat cells and inactivated PI3K/AKT and ERK signaling pathways via repressing the transcription of CXCR4.	Luteolin	15-23	C-X-C motif chemokine receptor 4	Homo sapiens	202-207
32587817-4	2020	Optimization results of Technetium-99m-luteolin labeling obtained optimum pH conditions 8, the amount of SnCl2.2H2O as a reducing agent 60 muL, the optimum amount of luteolin 6 mg/ml, and the optimum incubation time is 30 min.	Luteolin	39-47	tripartite motif containing 37	Homo sapiens	139-142
32009392-5	2020	Further study demonstrated that UGT1A9 played a predominately role in the glucuronidation of luteolin.	Luteolin	93-101	UDP glucuronosyltransferase 1 family, polypeptide A9	Mus musculus	32-38
32014914-0	2020	Luteolin-regulated MicroRNA-301-3p Targets Caspase-8 and Modulates TRAIL Sensitivity in PANC-1 Cells.	Luteolin	0-8	TNF superfamily member 10	Homo sapiens	67-72
32014914-5	2020	RESULTS: The levels of miR-301-3p were down-regulated in PANC-1 cells exposed to luteolin, which inhibits the growth of PANC-1 cells and sensitizes cells to TRAIL.	Luteolin	81-89	TNF superfamily member 10	Homo sapiens	157-162
31888099-1	2019	BACE1 inhibitory conjugates derived from two natural products, luteolin (1) and p-hydroxy-cinnamic acid (2), were subjected to systematic structure modifications, including various positions in luteolin segment for conjugation, different linkers (length, bond variation), as well as various substitutions in cinnamic acid segment (various substituents on benzene, and replacement of benzene by heteroaromatics and cycloalkane).	Luteolin	63-71	beta-secretase 1	Homo sapiens	0-5
31912839-7	2020	Furthermore, the mutation of tph-1, which encodes the conserved rate-limiting enzyme of serotonin synthesis, fully abolished luteolin-induced fat loss but did not affect fat reduction by the other five flavonoids.	Luteolin	125-133	BH4_AAA_HYDROXYL_2 domain-containing protein	Caenorhabditis elegans	29-34
31912839-8	2020	In wild-type N2 worms, luteolin treatment not only elevated the expression of tph-1, but also enhanced the mRNA levels of mod-1 and ser-6, which are two serotonin-related receptors and play specific roles in serotonin-mediated fat reduction.	Luteolin	23-31	BH4_AAA_HYDROXYL_2 domain-containing protein	Caenorhabditis elegans	78-83
31912839-8	2020	In wild-type N2 worms, luteolin treatment not only elevated the expression of tph-1, but also enhanced the mRNA levels of mod-1 and ser-6, which are two serotonin-related receptors and play specific roles in serotonin-mediated fat reduction.	Luteolin	23-31	Uncharacterized protein	Caenorhabditis elegans	122-127
31912839-8	2020	In wild-type N2 worms, luteolin treatment not only elevated the expression of tph-1, but also enhanced the mRNA levels of mod-1 and ser-6, which are two serotonin-related receptors and play specific roles in serotonin-mediated fat reduction.	Luteolin	23-31	G_PROTEIN_RECEP_F1_2 domain-containing protein	Caenorhabditis elegans	132-137
31912839-9	2020	The mutation of either mod-1 or ser-6 also fully abolished luteolin-induced fat loss.	Luteolin	59-67	Uncharacterized protein	Caenorhabditis elegans	23-28
31912839-9	2020	The mutation of either mod-1 or ser-6 also fully abolished luteolin-induced fat loss.	Luteolin	59-67	G_PROTEIN_RECEP_F1_2 domain-containing protein	Caenorhabditis elegans	32-37
31896157-0	2021	Luteolin Attenuates Diabetic Nephropathy through Suppressing Inflammatory Response and Oxidative Stress by Inhibiting STAT3 Pathway.	Luteolin	0-8	signal transducer and activator of transcription 3	Mus musculus	118-123
32668964-0	2020	MLL3 Induced by Luteolin Causes Apoptosis in Tamoxifen-Resistant Breast Cancer Cells through H3K4 Monomethylation and Suppression of the PI3K/AKT/mTOR Pathway.	Luteolin	16-24	lysine methyltransferase 2C	Homo sapiens	0-4
32668964-0	2020	MLL3 Induced by Luteolin Causes Apoptosis in Tamoxifen-Resistant Breast Cancer Cells through H3K4 Monomethylation and Suppression of the PI3K/AKT/mTOR Pathway.	Luteolin	16-24	AKT serine/threonine kinase 1	Homo sapiens	142-145
32474511-2	2020	Aims and Objectives: This study was conducted to determine the targeted inhibitory effects of luteolin-loaded Her-2-poly (lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) on gastric cancer cells and to delineate the mechanism underlying the inhibition of tumors by luteolin.	Luteolin	94-102	erb-b2 receptor tyrosine kinase 2	Homo sapiens	110-115
31778952-8	2020	By contrast, high ROS levels, obtained when Nrf2 is inhibited by a small molecule (luteolin), favour apoptosis by upregulating proapoptotic RKIP and downregulating prosurvival Snail.	Luteolin	83-91	NFE2 like bZIP transcription factor 2	Homo sapiens	44-48
31778952-8	2020	By contrast, high ROS levels, obtained when Nrf2 is inhibited by a small molecule (luteolin), favour apoptosis by upregulating proapoptotic RKIP and downregulating prosurvival Snail.	Luteolin	83-91	phosphatidylethanolamine binding protein 1	Homo sapiens	140-144
31778952-8	2020	By contrast, high ROS levels, obtained when Nrf2 is inhibited by a small molecule (luteolin), favour apoptosis by upregulating proapoptotic RKIP and downregulating prosurvival Snail.	Luteolin	83-91	snail family transcriptional repressor 1	Homo sapiens	176-181
31778952-11	2020	To test this hypothesis, we used luteolin (3",4",5,7-tetrahydroflavone) as Nrf2 inhibitor, since it reduces the expression of Nrf2 and increases intracellular ROS.	Luteolin	33-41	NFE2 like bZIP transcription factor 2	Homo sapiens	75-79
31778952-11	2020	To test this hypothesis, we used luteolin (3",4",5,7-tetrahydroflavone) as Nrf2 inhibitor, since it reduces the expression of Nrf2 and increases intracellular ROS.	Luteolin	33-41	NFE2 like bZIP transcription factor 2	Homo sapiens	126-130
31827551-8	2019	The active compounds of acacetin, kaempferol, luteolin, and quercetin showed a good binding affinity towards TNF (C-score >= 4).	Luteolin	46-54	tumor necrosis factor-like	Rattus norvegicus	109-112
31646844-9	2019	On the other hand, the hypnotic effect of 3 mg/kg of luteolin was almost completely blocked by caffeine, an antagonist for both adenosine A1 and A2A receptor (A1R and A2AR), 8-Cyclopentyl-1,3-dipropylxanthine (DPCPX), an A1R antagonist, and SCH-58261, an A2AR antagonist.	Luteolin	53-61	adenosine A1 receptor	Mus musculus	145-162
31731716-4	2019	In this study, we found that S100A7 was highly expressed in cancer cells and could be reduced by luteolin (Lu) and quercetin (Qu) through Src/Stat3 signaling.	Luteolin	97-105	v-src avian sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog	Danio rerio	138-141
31731716-4	2019	In this study, we found that S100A7 was highly expressed in cancer cells and could be reduced by luteolin (Lu) and quercetin (Qu) through Src/Stat3 signaling.	Luteolin	97-105	signal transducer and activator of transcription 3 (acute-phase response factor)	Danio rerio	142-147
31731716-4	2019	In this study, we found that S100A7 was highly expressed in cancer cells and could be reduced by luteolin (Lu) and quercetin (Qu) through Src/Stat3 signaling.	Luteolin	107-109	v-src avian sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog	Danio rerio	138-141
31731716-4	2019	In this study, we found that S100A7 was highly expressed in cancer cells and could be reduced by luteolin (Lu) and quercetin (Qu) through Src/Stat3 signaling.	Luteolin	107-109	signal transducer and activator of transcription 3 (acute-phase response factor)	Danio rerio	142-147
31731716-6	2019	Flavonoids Lu and Qu reduce protein levels of p-Src, p-Stat3 and S100A7 in A431-III cells.	Luteolin	11-13	v-src avian sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog	Danio rerio	48-51
31731716-6	2019	Flavonoids Lu and Qu reduce protein levels of p-Src, p-Stat3 and S100A7 in A431-III cells.	Luteolin	11-13	signal transducer and activator of transcription 3 (acute-phase response factor)	Danio rerio	55-60
31731716-13	2019	These results suggest that Lu and Qu may inhibit Src/Stat3/S100A7 signaling to reduce tumorigenesis of cancer cells.	Luteolin	27-29	v-src avian sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog	Danio rerio	49-52
31731716-13	2019	These results suggest that Lu and Qu may inhibit Src/Stat3/S100A7 signaling to reduce tumorigenesis of cancer cells.	Luteolin	27-29	signal transducer and activator of transcription 3 (acute-phase response factor)	Danio rerio	53-58
31646844-9	2019	On the other hand, the hypnotic effect of 3 mg/kg of luteolin was almost completely blocked by caffeine, an antagonist for both adenosine A1 and A2A receptor (A1R and A2AR), 8-Cyclopentyl-1,3-dipropylxanthine (DPCPX), an A1R antagonist, and SCH-58261, an A2AR antagonist.	Luteolin	53-61	adenosine A2a receptor	Mus musculus	255-259
31646844-10	2019	From the binding affinity assay, we have found that luteolin significantly binds to not only A1R but also A2AR with IC50 of 1.19, 0.84 mug/kg, respectively.	Luteolin	52-60	adenosine A1 receptor	Mus musculus	93-96
31646844-10	2019	From the binding affinity assay, we have found that luteolin significantly binds to not only A1R but also A2AR with IC50 of 1.19, 0.84 mug/kg, respectively.	Luteolin	52-60	adenosine A2a receptor	Mus musculus	106-110
31646844-12	2019	From these results, it has been suggested that luteolin has hypnotic efficacy through A1R and A2AR binding.	Luteolin	47-55	adenosine A1 receptor	Mus musculus	86-89
31646844-12	2019	From these results, it has been suggested that luteolin has hypnotic efficacy through A1R and A2AR binding.	Luteolin	47-55	adenosine A2a receptor	Mus musculus	94-98
31646844-9	2019	On the other hand, the hypnotic effect of 3 mg/kg of luteolin was almost completely blocked by caffeine, an antagonist for both adenosine A1 and A2A receptor (A1R and A2AR), 8-Cyclopentyl-1,3-dipropylxanthine (DPCPX), an A1R antagonist, and SCH-58261, an A2AR antagonist.	Luteolin	53-61	adenosine A2a receptor	Mus musculus	167-171
31646844-9	2019	On the other hand, the hypnotic effect of 3 mg/kg of luteolin was almost completely blocked by caffeine, an antagonist for both adenosine A1 and A2A receptor (A1R and A2AR), 8-Cyclopentyl-1,3-dipropylxanthine (DPCPX), an A1R antagonist, and SCH-58261, an A2AR antagonist.	Luteolin	53-61	adenosine A1 receptor	Mus musculus	159-162
31665675-0	2019	Combination of curcumin and luteolin synergistically inhibits TNF-alpha-induced vascular inflammation in human vascular cells and mice.	Luteolin	28-36	tumor necrosis factor	Homo sapiens	62-71
31720444-7	2019	Six phytochemicals (Geranin, Apigenin, Fisetin, Luteolin, Phthalic acid and Gallic acid) were predicted to be inhibitors of CYP3A4 and, may slowdown elimination of PIs thereby maintain optimal PIs concentrations.	Luteolin	48-56	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	124-130
31665675-3	2019	The aims of this study were to investigate whether and how combined curcumin and luteolin synergistically inhibit tumor necrosis factor-alpha (TNF-alpha)-induced monocytes adhesion endothelium, a crucial step of the development of endothelial dysfunction, both in human vascular cells and mouse aortic endothelium.	Luteolin	81-89	tumor necrosis factor	Homo sapiens	114-141
31665675-5	2019	We also found that TNF-alpha-enhanced protein expressions of vascular cell adhesion molecule 1 (VCAM-1), monocyte chemotactic protein-1 (MCP-1) and nuclear factor (NF)-kappaB translocation were synergistically reduced by the combined curcumin and luteolin in EA.hy 926 cells while the individual chemical did not have this inhibitory effect.	Luteolin	247-255	tumor necrosis factor	Homo sapiens	19-28
31665675-5	2019	We also found that TNF-alpha-enhanced protein expressions of vascular cell adhesion molecule 1 (VCAM-1), monocyte chemotactic protein-1 (MCP-1) and nuclear factor (NF)-kappaB translocation were synergistically reduced by the combined curcumin and luteolin in EA.hy 926 cells while the individual chemical did not have this inhibitory effect.	Luteolin	247-255	vascular cell adhesion molecule 1	Homo sapiens	61-94
31665675-5	2019	We also found that TNF-alpha-enhanced protein expressions of vascular cell adhesion molecule 1 (VCAM-1), monocyte chemotactic protein-1 (MCP-1) and nuclear factor (NF)-kappaB translocation were synergistically reduced by the combined curcumin and luteolin in EA.hy 926 cells while the individual chemical did not have this inhibitory effect.	Luteolin	247-255	nuclear factor kappa B subunit 1	Homo sapiens	148-174
31665675-6	2019	Consistently, 2 weeks dietary intake of combined curcumin (500 mg/kg) and luteolin (500 mg/kg) in C57BL/6 mice synergistically prevented TNF-alpha-stimulated adhesion of mouse monocytes to aortic endothelium ex vivo as well as the TNF-alpha-increased aortic protein expression of MCP-1 and VCAM-1.	Luteolin	74-82	tumor necrosis factor	Mus musculus	137-146
31665675-6	2019	Consistently, 2 weeks dietary intake of combined curcumin (500 mg/kg) and luteolin (500 mg/kg) in C57BL/6 mice synergistically prevented TNF-alpha-stimulated adhesion of mouse monocytes to aortic endothelium ex vivo as well as the TNF-alpha-increased aortic protein expression of MCP-1 and VCAM-1.	Luteolin	74-82	tumor necrosis factor	Mus musculus	231-240
31665675-6	2019	Consistently, 2 weeks dietary intake of combined curcumin (500 mg/kg) and luteolin (500 mg/kg) in C57BL/6 mice synergistically prevented TNF-alpha-stimulated adhesion of mouse monocytes to aortic endothelium ex vivo as well as the TNF-alpha-increased aortic protein expression of MCP-1 and VCAM-1.	Luteolin	74-82	chemokine (C-C motif) ligand 2	Mus musculus	280-285
31665675-6	2019	Consistently, 2 weeks dietary intake of combined curcumin (500 mg/kg) and luteolin (500 mg/kg) in C57BL/6 mice synergistically prevented TNF-alpha-stimulated adhesion of mouse monocytes to aortic endothelium ex vivo as well as the TNF-alpha-increased aortic protein expression of MCP-1 and VCAM-1.	Luteolin	74-82	vascular cell adhesion molecule 1	Mus musculus	290-296
31665675-7	2019	Therefore, combined curcumin and luteolin at physiological concentrations synergistically inhibits TNF-alpha-induced monocytes adhesion to endothelial cells and expressions of MCP-1 and VCAM-1 via suppressing NF-kappaB translocation into the nucleus.	Luteolin	33-41	tumor necrosis factor	Homo sapiens	99-108
31665675-7	2019	Therefore, combined curcumin and luteolin at physiological concentrations synergistically inhibits TNF-alpha-induced monocytes adhesion to endothelial cells and expressions of MCP-1 and VCAM-1 via suppressing NF-kappaB translocation into the nucleus.	Luteolin	33-41	C-C motif chemokine ligand 2	Homo sapiens	176-181
31665675-7	2019	Therefore, combined curcumin and luteolin at physiological concentrations synergistically inhibits TNF-alpha-induced monocytes adhesion to endothelial cells and expressions of MCP-1 and VCAM-1 via suppressing NF-kappaB translocation into the nucleus.	Luteolin	33-41	vascular cell adhesion molecule 1	Homo sapiens	186-192
31665675-3	2019	The aims of this study were to investigate whether and how combined curcumin and luteolin synergistically inhibit tumor necrosis factor-alpha (TNF-alpha)-induced monocytes adhesion endothelium, a crucial step of the development of endothelial dysfunction, both in human vascular cells and mouse aortic endothelium.	Luteolin	81-89	tumor necrosis factor	Homo sapiens	143-152
31665675-4	2019	Our results show that combined curcumin (1 muM) and luteolin (0.5 muM) synergistically (combination index is 0.60) inhibited TNF-alpha-induced monocytes adhesion to human EA.hy926 endothelial cells while the individual chemicals did not have such effect at the selected concentrations.	Luteolin	52-60	latexin	Homo sapiens	66-69
31665675-4	2019	Our results show that combined curcumin (1 muM) and luteolin (0.5 muM) synergistically (combination index is 0.60) inhibited TNF-alpha-induced monocytes adhesion to human EA.hy926 endothelial cells while the individual chemicals did not have such effect at the selected concentrations.	Luteolin	52-60	tumor necrosis factor	Homo sapiens	125-134
31590417-10	2019	Luteolin reduced the binding of Sterol-regulatory element-binding protein 2 (SREBP2) in the promoter region of the NPC1L1 gene and decreased mRNA levels of SREBP2 and hepatocyte nuclear factor 4alpha.	Luteolin	0-8	sterol regulatory element binding transcription factor 2	Homo sapiens	156-162
31671543-9	2019	As previously shown for other types of cancer-associated fibroblasts, treatment by luteolin could reverse this fibroblast phenotype and decrease TIMP3 secretion.	Luteolin	83-91	TIMP metallopeptidase inhibitor 3	Homo sapiens	145-150
31590417-10	2019	Luteolin reduced the binding of Sterol-regulatory element-binding protein 2 (SREBP2) in the promoter region of the NPC1L1 gene and decreased mRNA levels of SREBP2 and hepatocyte nuclear factor 4alpha.	Luteolin	0-8	hepatocyte nuclear factor 4 alpha	Homo sapiens	167-199
31590417-6	2019	Some polyphenols, particularly luteolin, have been reported as NPC1L1-mediated anti-dyslipidemia constituents.	Luteolin	31-39	NPC1 like intracellular cholesterol transporter 1	Homo sapiens	63-69
31590417-7	2019	Luteolin affects NPC1L1 through two mechanisms.	Luteolin	0-8	NPC1 like intracellular cholesterol transporter 1	Homo sapiens	17-23
31590417-8	2019	Luteolin directly inhibits NPC1L1 by binding to it, which occurs in a short timeframe similar to that for ezetimibe.	Luteolin	0-8	NPC1 like intracellular cholesterol transporter 1	Homo sapiens	27-33
31590417-10	2019	Luteolin reduced the binding of Sterol-regulatory element-binding protein 2 (SREBP2) in the promoter region of the NPC1L1 gene and decreased mRNA levels of SREBP2 and hepatocyte nuclear factor 4alpha.	Luteolin	0-8	sterol regulatory element binding transcription factor 2	Homo sapiens	32-75
31590417-11	2019	These data suggest that luteolin decreases the expression of NPC1L1 through regulation of transcription factors.	Luteolin	24-32	NPC1 like intracellular cholesterol transporter 1	Homo sapiens	61-67
31590417-10	2019	Luteolin reduced the binding of Sterol-regulatory element-binding protein 2 (SREBP2) in the promoter region of the NPC1L1 gene and decreased mRNA levels of SREBP2 and hepatocyte nuclear factor 4alpha.	Luteolin	0-8	sterol regulatory element binding transcription factor 2	Homo sapiens	77-83
31288002-0	2019	Luteolin and 5-flurouracil act synergistically to induce cellular weapons in experimentally induced Solid Ehrlich Carcinoma: Realistic role of P53; a guardian fights in a cellular battle.	Luteolin	0-8	transformation related protein 53, pseudogene	Mus musculus	143-146
31590417-10	2019	Luteolin reduced the binding of Sterol-regulatory element-binding protein 2 (SREBP2) in the promoter region of the NPC1L1 gene and decreased mRNA levels of SREBP2 and hepatocyte nuclear factor 4alpha.	Luteolin	0-8	NPC1 like intracellular cholesterol transporter 1	Homo sapiens	115-121
31383362-9	2019	Also, luteolin induced oxidative stress and ER stress in p53-null Hep3B cells.	Luteolin	6-14	tumor protein p53	Homo sapiens	57-60
31611756-4	2019	Luteolin suppressed the expression of matrix metalloproteinase-9 and inhibited migration and invasion in MDA-MB-231 cells treated with the tumor promotor 12-O-tetradecanoylphorbol-13-acetate at non-cytotoxic concentrations (0, 5, and 10 muM).	Luteolin	0-8	matrix metallopeptidase 9	Homo sapiens	38-64
31611756-4	2019	Luteolin suppressed the expression of matrix metalloproteinase-9 and inhibited migration and invasion in MDA-MB-231 cells treated with the tumor promotor 12-O-tetradecanoylphorbol-13-acetate at non-cytotoxic concentrations (0, 5, and 10 muM).	Luteolin	0-8	latexin	Homo sapiens	237-240
31611756-5	2019	Furthermore, at cytotoxic concentrations (20 and 40 muM), luteolin induced apoptosis via extrinsic and intrinsic pathways in MDA-MB-231 cells.	Luteolin	58-66	latexin	Homo sapiens	52-55
31302373-5	2019	However, luteolin supplementation resulted in lower CD11c+ macrophages in gonadal adipose tissue, as well as a trend toward lower macrophage infiltration.	Luteolin	9-17	integrin alpha X	Mus musculus	52-57
31302373-6	2019	Luteolin supplementation also significantly lowered mRNA expression of inflammatory and M1 markers MCP-1, CD11c, TNF-alpha and IL-6, while maintaining expression of M2 marker MGL1.	Luteolin	0-8	mast cell protease 1	Mus musculus	99-104
31302373-6	2019	Luteolin supplementation also significantly lowered mRNA expression of inflammatory and M1 markers MCP-1, CD11c, TNF-alpha and IL-6, while maintaining expression of M2 marker MGL1.	Luteolin	0-8	integrin alpha X	Mus musculus	106-111
31302373-6	2019	Luteolin supplementation also significantly lowered mRNA expression of inflammatory and M1 markers MCP-1, CD11c, TNF-alpha and IL-6, while maintaining expression of M2 marker MGL1.	Luteolin	0-8	tumor necrosis factor	Mus musculus	113-122
31302373-6	2019	Luteolin supplementation also significantly lowered mRNA expression of inflammatory and M1 markers MCP-1, CD11c, TNF-alpha and IL-6, while maintaining expression of M2 marker MGL1.	Luteolin	0-8	interleukin 6	Mus musculus	127-131
31302373-6	2019	Luteolin supplementation also significantly lowered mRNA expression of inflammatory and M1 markers MCP-1, CD11c, TNF-alpha and IL-6, while maintaining expression of M2 marker MGL1.	Luteolin	0-8	C-type lectin domain family 10, member A	Mus musculus	175-179
31302373-8	2019	We further found that luteolin supplementation protected mice from insulin resistance induced by HFD consumption; this improved insulin resistance was correlated with reductions in CD11c+ adipose tissue macrophages.	Luteolin	22-30	integrin alpha X	Mus musculus	181-186
31362009-5	2019	Moreover, Lut and GA prevented CoCl2-induced increases in hydrogen peroxide (H2O2), malondialdehyde (MDA) and nitric oxide (NO) in the brain, while also restoring the activities of acetylcholinesterase, glutathione S-transferase (GST) and superoxide dismutase (SOD).	Luteolin	10-13	acetylcholinesterase	Rattus norvegicus	181-201
31362009-5	2019	Moreover, Lut and GA prevented CoCl2-induced increases in hydrogen peroxide (H2O2), malondialdehyde (MDA) and nitric oxide (NO) in the brain, while also restoring the activities of acetylcholinesterase, glutathione S-transferase (GST) and superoxide dismutase (SOD).	Luteolin	10-13	hematopoietic prostaglandin D synthase	Rattus norvegicus	203-228
31362009-5	2019	Moreover, Lut and GA prevented CoCl2-induced increases in hydrogen peroxide (H2O2), malondialdehyde (MDA) and nitric oxide (NO) in the brain, while also restoring the activities of acetylcholinesterase, glutathione S-transferase (GST) and superoxide dismutase (SOD).	Luteolin	10-13	hematopoietic prostaglandin D synthase	Rattus norvegicus	230-233
31362009-6	2019	In addition, Lut and GA produced significant reversal of CoCl2-induced elevation in levels of serum Interleukin 1 beta (IL-1beta) and Tumor necrosis factor (TNFalpha).	Luteolin	13-16	interleukin 1 beta	Rattus norvegicus	100-118
31362009-6	2019	In addition, Lut and GA produced significant reversal of CoCl2-induced elevation in levels of serum Interleukin 1 beta (IL-1beta) and Tumor necrosis factor (TNFalpha).	Luteolin	13-16	interleukin 1 alpha	Rattus norvegicus	120-128
31362009-6	2019	In addition, Lut and GA produced significant reversal of CoCl2-induced elevation in levels of serum Interleukin 1 beta (IL-1beta) and Tumor necrosis factor (TNFalpha).	Luteolin	13-16	tumor necrosis factor-like	Rattus norvegicus	134-155
31362009-6	2019	In addition, Lut and GA produced significant reversal of CoCl2-induced elevation in levels of serum Interleukin 1 beta (IL-1beta) and Tumor necrosis factor (TNFalpha).	Luteolin	13-16	tumor necrosis factor	Rattus norvegicus	157-165
31207429-10	2019	Finally, a significant (p <  0.05) decrease in IFN-gamma, TNF-alpha, IL-1alpha and IL-18 levels was observed most notably in groups that received high doses of luteolin (50 and 100 mg/kg).	Luteolin	160-168	interleukin 18	Rattus norvegicus	47-56
31207429-10	2019	Finally, a significant (p <  0.05) decrease in IFN-gamma, TNF-alpha, IL-1alpha and IL-18 levels was observed most notably in groups that received high doses of luteolin (50 and 100 mg/kg).	Luteolin	160-168	tumor necrosis factor	Rattus norvegicus	58-67
31207429-10	2019	Finally, a significant (p <  0.05) decrease in IFN-gamma, TNF-alpha, IL-1alpha and IL-18 levels was observed most notably in groups that received high doses of luteolin (50 and 100 mg/kg).	Luteolin	160-168	interleukin 1 alpha	Rattus norvegicus	69-78
31207429-10	2019	Finally, a significant (p <  0.05) decrease in IFN-gamma, TNF-alpha, IL-1alpha and IL-18 levels was observed most notably in groups that received high doses of luteolin (50 and 100 mg/kg).	Luteolin	160-168	interleukin 18	Rattus norvegicus	83-88
31092862-4	2019	During the molecular modelling studies of some naturally occurring flavonoids such as quercetin, luteolin, myricetin, kaempferol, naringin, hesperidin, galangin, baicalein and epicatechin with human ERalpha (3ERT and 1GWR), we observed that most of the ligands bound to the active site pocket of both 3ERT and 1GWR.	Luteolin	97-105	estrogen receptor 1	Homo sapiens	199-206
31336028-0	2019	Combination of metformin and luteolin synergistically protects carbon tetrachloride-induced hepatotoxicity: Mechanism involves antioxidant, anti-inflammatory, antiapoptotic, and Nrf2/HO-1 signaling pathway.	Luteolin	29-37	NFE2 like bZIP transcription factor 2	Rattus norvegicus	178-182
31336028-0	2019	Combination of metformin and luteolin synergistically protects carbon tetrachloride-induced hepatotoxicity: Mechanism involves antioxidant, anti-inflammatory, antiapoptotic, and Nrf2/HO-1 signaling pathway.	Luteolin	29-37	heme oxygenase 1	Rattus norvegicus	183-187
31336028-8	2019	The protective roles of Met and Lut separately or in combination were observed in hepatotoxicity induced by CCl4 .	Luteolin	32-35	C-C motif chemokine ligand 4	Rattus norvegicus	108-112
30977402-7	2019	Furthermore, tert-butylhydroquinone triggered the overexpression of Nrf2 to reduce ER stress, but luteolin inhibited Nrf2 nuclear localization to elevate ER stress.	Luteolin	98-106	nuclear factor, erythroid derived 2, like 2	Mus musculus	117-121
32269953-0	2020	Adaptive immunoregulation of luteolin and chlorogenic acid in lipopolysaccharide-induced interleukin-10 expression.	Luteolin	29-37	interleukin 10	Mus musculus	89-103
32269953-1	2020	Objective: To investigate the mechanism of the adaptive effect of two compounds in Lonicerae japonica flos (LJF), luteolin (LUT) and chlorogenic acid (CGA), on the expression of interleukin (IL) IL-10 and IL-6.	Luteolin	114-122	interleukin 6	Mus musculus	205-209
31006528-7	2019	The results showed that luteoline ameliorated neuronal apoptosis as evidenced by decrease of apoptotic cells, downregulation of the cleavage levels of caspase-3 and PRAP, and inactivation of caspase-3.	Luteolin	24-33	caspase 3	Mus musculus	151-160
31006528-7	2019	The results showed that luteoline ameliorated neuronal apoptosis as evidenced by decrease of apoptotic cells, downregulation of the cleavage levels of caspase-3 and PRAP, and inactivation of caspase-3.	Luteolin	24-33	caspase 3	Mus musculus	191-200
30954346-0	2019	Luteolin improves myocardial cell glucolipid metabolism by inhibiting hypoxia inducible factor-1alpha expression in angiotensin II/hypoxia-induced hypertrophic H9c2 cells.	Luteolin	0-8	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	70-101
30954346-0	2019	Luteolin improves myocardial cell glucolipid metabolism by inhibiting hypoxia inducible factor-1alpha expression in angiotensin II/hypoxia-induced hypertrophic H9c2 cells.	Luteolin	0-8	angiotensinogen	Rattus norvegicus	116-130
30129150-9	2018	Additionally, quantitative real-time polymerase chain reaction and Western blot analysis were performed to determine the mRNA and protein expression of Nrf2 and its downstream genes after LUT treatment.	Luteolin	188-191	NFE2 like bZIP transcription factor 2	Homo sapiens	152-156
30641047-0	2019	A physiological concentration of luteolin induces phase II drug-metabolizing enzymes through the ERK1/2 signaling pathway in HepG2 cells.	Luteolin	33-41	mitogen-activated protein kinase 3	Homo sapiens	97-103
30641047-8	2019	Luteolin increased phosphorylation of Nrf2 at Ser40, and MEK inhibitors (U0126 and PD98059) canceled luteolin-induced phosphorylation of Nrf2.	Luteolin	0-8	NFE2 like bZIP transcription factor 2	Homo sapiens	38-42
30641047-8	2019	Luteolin increased phosphorylation of Nrf2 at Ser40, and MEK inhibitors (U0126 and PD98059) canceled luteolin-induced phosphorylation of Nrf2.	Luteolin	0-8	NFE2 like bZIP transcription factor 2	Homo sapiens	137-141
30641047-10	2019	In conclusion, a physiological concentration of luteolin induces the expression of phase II drug-metabolizing enzymes by enhancement of Nrf2 nuclear accumulation through MEK1/2-ERK1/2-mediated phosphorylation of Nrf2, increasing Nrf2 stability and inducing a conformational change of Keap1.	Luteolin	48-56	NFE2 like bZIP transcription factor 2	Homo sapiens	136-140
30641047-10	2019	In conclusion, a physiological concentration of luteolin induces the expression of phase II drug-metabolizing enzymes by enhancement of Nrf2 nuclear accumulation through MEK1/2-ERK1/2-mediated phosphorylation of Nrf2, increasing Nrf2 stability and inducing a conformational change of Keap1.	Luteolin	48-56	mitogen-activated protein kinase kinase 1	Homo sapiens	170-176
30641047-10	2019	In conclusion, a physiological concentration of luteolin induces the expression of phase II drug-metabolizing enzymes by enhancement of Nrf2 nuclear accumulation through MEK1/2-ERK1/2-mediated phosphorylation of Nrf2, increasing Nrf2 stability and inducing a conformational change of Keap1.	Luteolin	48-56	mitogen-activated protein kinase 3	Homo sapiens	177-183
30641047-10	2019	In conclusion, a physiological concentration of luteolin induces the expression of phase II drug-metabolizing enzymes by enhancement of Nrf2 nuclear accumulation through MEK1/2-ERK1/2-mediated phosphorylation of Nrf2, increasing Nrf2 stability and inducing a conformational change of Keap1.	Luteolin	48-56	NFE2 like bZIP transcription factor 2	Homo sapiens	212-216
30641047-10	2019	In conclusion, a physiological concentration of luteolin induces the expression of phase II drug-metabolizing enzymes by enhancement of Nrf2 nuclear accumulation through MEK1/2-ERK1/2-mediated phosphorylation of Nrf2, increasing Nrf2 stability and inducing a conformational change of Keap1.	Luteolin	48-56	NFE2 like bZIP transcription factor 2	Homo sapiens	212-216
30641047-10	2019	In conclusion, a physiological concentration of luteolin induces the expression of phase II drug-metabolizing enzymes by enhancement of Nrf2 nuclear accumulation through MEK1/2-ERK1/2-mediated phosphorylation of Nrf2, increasing Nrf2 stability and inducing a conformational change of Keap1.	Luteolin	48-56	kelch like ECH associated protein 1	Homo sapiens	284-289
31057098-4	2019	Out of all, the most potent DPP-IV inhibitor were found to be resveratrol, luteolin, apigenin and flavone having activity in nanomolar range.	Luteolin	75-83	dipeptidyl peptidase 4	Homo sapiens	28-34
30469543-3	2018	This study aimed to evaluate the effects of the natural flavonoid taxifolin, luteolin, (-)-gallocatechin, and (-)-catechin on human P-gp activity.	Luteolin	77-85	ATP binding cassette subfamily B member 1	Homo sapiens	132-136
31956559-7	2020	Luteolin (50 mg/kg) was showed significant decrease in serum level of oxidative and lysosomal enzymes, proinflammatory cytokines i.e. tumor necrosis factor (TNF)-alpha (39.28 +- 3.17), interleukin (IL)-1beta (12.07 +- 1.24), and IL-6 (24.72 +- 2.52) in MSU crystal-induced rats.	Luteolin	0-8	tumor necrosis factor	Rattus norvegicus	134-167
31956559-7	2020	Luteolin (50 mg/kg) was showed significant decrease in serum level of oxidative and lysosomal enzymes, proinflammatory cytokines i.e. tumor necrosis factor (TNF)-alpha (39.28 +- 3.17), interleukin (IL)-1beta (12.07 +- 1.24), and IL-6 (24.72 +- 2.52) in MSU crystal-induced rats.	Luteolin	0-8	interleukin 1 alpha	Rattus norvegicus	185-207
31956559-7	2020	Luteolin (50 mg/kg) was showed significant decrease in serum level of oxidative and lysosomal enzymes, proinflammatory cytokines i.e. tumor necrosis factor (TNF)-alpha (39.28 +- 3.17), interleukin (IL)-1beta (12.07 +- 1.24), and IL-6 (24.72 +- 2.52) in MSU crystal-induced rats.	Luteolin	0-8	interleukin 6	Rattus norvegicus	229-233
30514689-0	2018	[Combined treatment with myo-inositol and luteolin selectively suppresses growth of human lung cancer A549 cells possibly by suppressing activation of PDK1 and Akt].	Luteolin	42-50	pyruvate dehydrogenase kinase 1	Homo sapiens	151-155
30514689-0	2018	[Combined treatment with myo-inositol and luteolin selectively suppresses growth of human lung cancer A549 cells possibly by suppressing activation of PDK1 and Akt].	Luteolin	42-50	AKT serine/threonine kinase 1	Homo sapiens	160-163
30295262-3	2018	The effects of luteolin and chloroquine on expression of cleaved-caspase 3 and LC3 in RPMI8826 cells was detected by Western blot.	Luteolin	15-23	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	79-82